Annual Report 2017
Collaborating Organisations
Partner Organisations
Feature photography of CBNS staff, students and laboratories throughout this report by Joe Vittorio. Other photographs and images courtesy of CBNS members and organisations, unless otherwise attributed. Content compiled and edited by Anne Meyer. Graphic design by Sophie Campbell, SCDesign.
ab o ut CBNS About the CBNS
2
Director’s Report
4
CBNS at a Glance
6
Research
9
Research Overview
11
Signature Projects
12
Cross-Centre Activities
22
Strategic Projects
26
R e s ear c h
Contents
Engagement 31 Collaborations and Partnerships
32 36
Events
38
Education Committee
40
Mentoring Program
41
Outreach Sub-Committee
42
CBNS Awards
44
Media Coverage
45
Governance
47
Governance and Management
48
Governance Board
48
Scientific Advisory Board
50
Performance
53
Mid-term Review
55
Performance and KPIs
56
Financial Report 2017
58
g ove r nan c e
CBNS Experience
e n gag e m e nt
Spin-Offs 35
CBNS Personnel
62
Visitors to the CBNS
68
Publications 70
CBNS Annual Report 2017 1
p e r fo r man c e
Awards, Memberships and Grant Success 59
About the CBNS The Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology or, as we prefer to be known, ARC Centre for Bio-Nano Science (CBNS) was established in mid-2014 as a national innovator in bio-nano sciences. We bring together a diverse team of Australia’s leading scientists with the aim of developing next generation bio-responsive nano-structured materials. The key scientific aim that underpins all the activities of the Centre is to fully understand, and then exploit, the interface between nano-engineered materials and biological systems. The CBNS research program is structured around the applications of understanding this interface: drug and gene delivery; vaccines; bio-imaging (both cellular and whole body imaging); and sensors and diagnostics. CBNS research is integrated by overarching research activities to understand the social dimensions of bio-nanotechnology, to visualise bio-nano interactions and by using a systems biology
Health and biomedical sector engagement
approach to fully describe the complex interactions that dictate success or failure of nanotechnology for therapeutic applications. In delivering the promise of bio-nano science, CBNS has brought together Australia’s leading scientists and engineers with expertise in nanotechnology, polymer science, cell biology, cancer biology, systems biology, chemical engineering, 3D CGI, immunology, chemistry and social science. The Centre consists of five primary nodes: Monash University (Monash); the University of Melbourne (Melbourne), the University of
Centre for Bio-Nano Science
Queensland (UQ), the University of New South Wales (UNSW) and the University of South Australia (UniSA). In addition, there are nine overseas partners plus the Australian Nuclear Science and Technology Organisation (ANSTO). The CBNS is a seven-year program of research and is funded by the ARC ($26M) and the Australian collaborating universities ($9M) over this period. The universities also contribute in-kind, as do the partner organisations. In total the in-kind support for the CBNS is valued at more than $23M over the life of the program and we thank all of the contributors for this support.
Education and training
Delivery (delivery systems, vaccines)
Computational biology
Understanding and exploiting the bio-nano interface
Social dimensions
Detection (sensors and diagnostics, imaging technologies)
Community outreach
2 CBNS Annual Report 2017
Visualisation
Industry and commercial engagement
ab o ut CBNS CBNS Annual Report 2017 3
Director’s Report Welcome to the fourth annual report of the ARC Centre for Bio-Nano Science (CBNS) which covers our activities in 2017. The CBNS can look back at a sustained growth and positive outcomes in 2017 and will continue this work for 2018. The Centre has built on producing high-calibre research outputs, which have been strengthened by a refined research direction through the formation of our ‘Signature Projects’. We continue engaging with our communities through the successful delivery of events, outreach activities, industry collaboration and interaction with the media. Building on last year’s recognition, our members have been acknowledged through an array of awards and honours. Highlights are captured in this welcome message, while a comprehensive listing is provided within the pages of this report.
Our international approach to collaboration also continues to yield exciting research. For instance, CBNS researchers at the University of New South Wales, the University of Nottingham in the UK, the Memorial Sloan Kettering Cancer Center in the USA, the St Vincent’s Clinic, the University of Queensland and Monash University are collaborating on a project with the goal to use virtual reality (VR) to explore the surface of a cancer cell. The ground-breaking VR technology allows multiple scientists to see inside a human cell at the same time. This technology gives researchers a three-dimensional tool to improve doctor interaction and help analyse how cancer drugs work.
Signature Projects
Engagement
In 2017, we have collaboratively formed ten signature projects while our CBNS themes continue underpinning our research program. These projects have been developed to address significant, unanswered questions that cannot be solved by small groups over short periods of time with comparatively narrow expertise. A detailed overview of these projects can be found in this report.
In 2017 CBNS members organised, contributed to and supported events that engaged expert and general audiences alike. These included the International Nanomedicine Conference at Coogee, co-organised and chaired by CBNS researchers, an ARC joint workshop for Early Career Researchers (ECRs) run by CBNS and the ARC Centre of Excellence for Electromaterials Science (ACES) at St. Vincent’s Hospital in Melbourne and a jointly run biomedical applications workshop organised by the ARC Training Centre for Biopharmaceutical Innovation and the CBNS at the University of Queensland.
The CBNS has grown to be a collaborative and truly international centre. We are now home to over 300 researchers from 31 countries.
Growth The CBNS has grown to be a collaborative and truly international centre. We are now home to over 300 researchers from 31 countries. These researchers make an important contribution to the CBNS and add depth and breadth to our profile.
4 CBNS Annual Report 2017
Our Education Committee continued its work in organising and delivering programs and events that build the capabilities of CBNS members as well as working together with our new Outreach Sub-Committee. These activities included cell and animal imaging workshops, as well as a workshop on IP, patents, copyright and trademark.
This year, CBNS implemented the Outreach Sub-Committee. Its aim is to identify opportunities for members of CBNS to contribute to outreach, through community or industry-related activities, events and media liaison. This involved a highly successful National Science Week movie screening of the film Jabbed – Love, Fear and Vaccines, followed by a lively discussion panel and a Q&A session with experts in the fields of immunology and public health as well as presentations to high school students at the University of South Australia. In July, CBNS members Matthew Kearnes, Declan Kuch and Georgia Miller from the University of New South Wales brought together policy experts, clinicians, laboratory scientists and social sciences researchers for the Biomedical Future Symposium – Medicine and Beyond. This symposium preceded a public lecture with Professor Jenny Reardon (University of California, Santa Cruz (UCSC)) titled “Just Biomedical Research?” which was broadcasted on ABC’s Radio National Big Ideas program in November. As part of the CBNS Visiting Professor Program, we welcomed Professor Wolfgang Parak from the Philipps University in Marburg, Germany to the Centre in June. During his stay in Australia, Professor Parak gave a plenary talk at the 8th International Nanomedicine Conference in Sydney. More details of his visit will be covered on page 39 of this report. A number of significant international exchanges were also instigated to our international collaborators including the visit of UNSW’s Manish Sriram to Burghausen, Germany or the lab visits of CBNS students Emily Pilkington (Monash) to Warwick University, UK and Ibrahim Javed (Monash) visiting Tongji University in Shanghai, China.
ab o ut CBNS
Funding
Awards
New staff
In November, CBNS Deputy Director Professor Frank Caruso, CBNS Director Professor Tom Davis and CBNS CIs Professor Stephen Kent, Professor Chris Porter, Dr Angus Johnston, Professor Edmund Crampin and Professor Ben Boyd received the ARC Linkage Infrastructure, Equipment and Facilities (LIEF) funding worth $639,369 for their project Nano-bioscience imaging facility.
The year saw Centre members continuing to be recognised for their contribution to science. A distinct highlight was Professor Maria Kavallaris, CBNS CI from UNSW, winning the 2017 NSW Premier’s Prize for Science and Engineering. The Prize was presented by the NSW Premier with the Governor of NSW, His Excellency General David Hurley AC DSC (Ret’d) at Government House in Sydney.
While some of our staff have moved on to other projects and we thank them for their contribution, we have been fortunate to welcome some new outstanding staff to the Centre. These include our new UniSA node Chief Investigators Professor Clive Prestidge and Professor Benjamin Thierry as well as Centre Administrator Dr Charlotte Hurry and Senior Events and Communications Coordinator Anne Meyer.
The LIEF scheme provides funding for research infrastructure, equipment and facilities to eligible organisations. It enables higher education researchers to participate in cooperative initiatives so that expensive infrastructure, equipment and facilities can be shared between higher education organisations and also with industry. CBNS CI Professor Rob Parton (UQ) was awarded a NHMRC Program Grant for his collaborative project “Translating membrane proteins into therapeutics; from bedside to bench” worth $9,466,000. Our research was also recognised by a number of different NHMRC fellowships namely to Professor Frank Caruso, Professor Stephen Kent, Dr Angus Johnston, Dr Jacob Coffey and Associate Professor Kris Thurecht. Moreover, Dr John Quinn has been awarded a 2017 ARC Future Fellowship and Dr Nghia Truong Phuoc has been granted the ARC Discovery Early Career Researcher Award (DECRA). More details can be found on page 60 in the awards section.
A distinct highlight was Professor Maria Kavallaris, CBNS CI from UNSW, winning the 2017 NSW Premier’s Prize for Science and Engineering. Additionally, Professor Mark Kendall, CBNS CI and Node Leader from UQ, has been elected a Fellow of The Australian Academy of Technological Sciences and Engineering (ATSE). We are also very proud to announce that Professor Justin Gooding, CBNS CI from UNSW was presented with the 2017 University of Technology Sydney Eureka Prize for Outstanding Mentor of Young Researchers during the Australian Museum Eureka Prizes 2017 in Sydney. More awards have been documented on page 60.
Mid-term Review We are delighted to announce that the Centre has satisfactorily met the objectives of the ARC Centres of Excellence scheme. After the ARC conducted a site visit to Monash Institute of Pharmaceutical Sciences (MIPS) for the Centre’s mid-term review on 30 August, we can proudly announce that we have met the Centre’s agreed objectives and aims. Therefore, Monash University and the Centre will receive the remaining current allocation of ARC Centre funding to 30 December 2020. We look forward to more successful research, engagement and collaboration in the upcoming three years.
Professor Tom Davis Centre Director
CBNS Annual Report 2017 5
CBNS at a Glance Timeline 42 months into 84 month program 2014 2015 2016 2017 2018 2019 2020 2021
Funding $9M in University funding
Partners and collaborators
$35M
5
over 7 years
$26M in ARC funding
10
Australian universities
partner organisations
Key data
24 publications in journals with impact factors >10
88
Our people
Chief Investigators
talks given
13
new fellowships awarded
19 Senior research fellows undertaking CBNS research
Post-doctoral researchers
344 people
115
Honours and Masters students
10
10
14
8 Management, administration and operational staff
6 CBNS Annual Report 2017
18
Diverse disciplines: bioimaging, cell biology, chemistry, engineering, immunology, pharmacology, sociology, systems biology, visual arts
Partner Investigators
150
Research assistants and technical staff
PhD students
US Partner Organisations: Columbia University Medical Center Memorial Sloan Kettering Cancer Center (New York) University of California, Santa Barbara University of Wisconsin-Madison
European Partner Organisations: University of Nottingham University of Warwick Imperial College London University College Dublin
Asian Partner Organisation: Sungkyunkwan University, Korea
Australian Partner Organisation: ANSTO (Sydney)
Collaborating Organisations
University of Queensland
University of New South Wales University of South Australia Monash University (Administering Organisation) University of Melbourne
CBNS Annual Report 2017 7
ab o ut CBNS
Partner Organisations
8 CBNS Annual Report 2017
R e s ear c h
Research CBNS Annual Report 2017 9
10 CBNS Annual Report 2017
Research Overview CBNS research focuses on four elements: the engineering of nanomaterials, the study of the interaction between these materials and the biological systems, the stimulation on immune responses as well as the reporting of biological events.
• JTCC : Visualising bio-imaging and data in 3D Virtual Reality (VR) (see page 12) • Predicting bio-nano interactions (see page 13) • Isolating, interrogating and bioengineering single circulating cells (see page 14) • A material scientist’s guide to the cell (see page 15) • Overcoming challenges of in vivo targeting (see page 16) • Development of complex multicellular systems for the evaluation and characterisation of bio-nano interactions (see page 17) • Social dimensions of bio-nano interactions (see page 18) • Mediating protein interactions (see page 19) • Sensors and diagnostic for managing bloodstream infections (see page 20) • Improved molecular imaging agents (see page 21) The research program, and expertise within the CBNS, is presented in more detail in the following pages.
CBNS Annual Report 2017 11
R e s ear c h
The CBNS research program is structured around ten signature projects. These signature projects capture the ultimate application of collaboration within the Centre’s research: every CBNS researcher engages in at least one of these signature projects embracing the collaborative spirit of the Centre:
Signature Projects JTCC: VISUALISING BIO-IMAGING AND DATA IN 3D VIRTUAL REALITY (VR) Leaders: Associate Professor John McGhee, Professor Tom Davis Co-Leaders: Dr Andrew Lilja, Mr John Bailey, Mr Campbell Strong Collaborating Organisations/Groups: Professor Cameron Alexander (University of Nottingham), Professor Jason Lewis (Memorial Sloan Kettering Cancer Center), Associate Professor Steven Faux (St Vincent’s Clinic), Professor Maria Kavallaris (UNSW), Professor Rob Parton and Associate Professor Kris Thurecht (UQ), Dr Angus Johnston (Monash)
The project This ARC Centre of Excellence project will explore how design-led 3D VR immersive techniques can be used to visualise the dynamic processes within a cancer cell. The research also intends to conduct user testing of the VR content with students and scientific communities. The goal of this research is to establish whether VR immersive data interaction provides benefits as an educational tool. We also intend to investigate whether 3D VR visualisations of laboratory data can facilitate and enhance the scientific discovery process. As part of this evaluation, we will be developing a VR platform to ‘share’ content. The goal is to connect VR 3D cellular data between multiple users and sites across the CBNS nodes simultaneously on a collaborative VR platform, to be termed the ‘VR Cell Arena System’.
The big questions
?
Can the use of data-driven 3D computer visualisation provide greater insight into the mechanisms of internalisation of a drug delivery system?
?
Can design-led VR through the use of Head Mounted Displays (HMDs), provide improved modes of interaction and education of the scientific data?
Sub-projects: 1. 3D Visualisation of Cancer Cell Data – UNSW, UQ and Monash 2. 3D VR of High Resolution 3D Cell Dynamics Data – UNSW and Children’s Cancer Institute (CCIA) 3. 3D VR in vivo Nanoparticles Dynamics Data – UNSW and UQ
Visualisation of a nanoparticle binding to receptors on the surface of a cancer cell. Image: John McGhee, Andrew Lilja, John Bailey, 3D Visualisation Aesthetics Lab, UNSW (@3DVAL).
The benefit of this research • The core benefit of this research is to enhance data visualisation through design-led approaches to VR immersion and experience design.
Our goals • Establish new computer graphics pipeline tools for enhanced forms of VR 3D visualisation on HMDs. • Develop an education and scientific discovery VR platform for improved interaction with Nanoscience laboratory data. • Design and build meaningful and embodied interfaces that allow multi-user immersive 3D VR data interaction.
Immersive visualisation of the internal structures of a cancer cell. Image: John McGhee, John Bailey, 3D Visualisation Aesthetics Lab, UNSW (@3DVAL).
12 CBNS Annual Report 2017
Visualisation of vesicle transport within a cancer cell. Image: John McGhee, John Bailey, Andrew Lilja, 3D Visualisation Aesthetics Lab, UNSW (@3DVAL).
PREDICTING BIO-NANO INTERACTIONS Leaders: Professor Stephen Kent, Professor Edmund Crampin Co-Leaders: Dr Mattias Björnmalm, Dr Adam Wheatley, Mr Matt Faria Collaborating Organisations/Groups: Professor Molly Stevens (Imperial College London), Professor Rob Parton and Associate Professor Kris Thurecht (UQ), Dr Angus Johnston and Dr Simon Corrie (Monash), Professor Frank Caruso (Melbourne)
Understanding how materials and cells interact will be key to the future development of improved nanomedicines and vaccines. We aim to understand the rules by which immune cells interact with a range of nanoengineered particle systems with tailored physical properties. The combined effects of size, charge, surface chemistry and other physicochemical characteristics will be studied for their effect on particle interactions with a wide range of immune cells.
The big questions
?
How does simultaneously varying 2, 3 or more physicochemical characteristics of nanoparticles influence their interactions with immune cells in vitro and in vivo?
?
Are there trends in how nanoparticle characteristics affect immune cell interactions, that can be generalised across multiple particle technologies?
?
Can we standardise the way in which nanoparticle-cell interactions are studied, such that we can generate predictive algorithms for these interactions?
The benefits of this research • The experimental and theoretical techniques we develop will provide a roadmap for biological analysis of newly developed nanomaterials for the global research community. • Our fundamental understanding of the relative importance of nanoparticle physicochemical properties will be advanced, leading to more rational design of these materials. • By developing our ability to predict bio-nano interactions prior to clinical evaluation, we will vastly accelerate our ability to evaluate and design nanoparticles for diagnostic and therapeutic purposes.
Our goals
HeLa cells incubated with PMA hydrogel particles. “Reprinted with permisson from 10.1021/acs.lang muir.6b01634. Copyright © 2016, American Chemical Society”.
• To develop novel experimental assays and theoretical models that can predict the biological fate of engineered nanomaterials. • To use our techniques, to assess panels of nanomaterials created by experts across the CBNS, advancing our fundamental understanding of how these complex materials interact with biological systems.
Single particle simulation of sedimentation and diffusion for two particle systems.
CBNS Annual Report 2017 13
R e s ear c h
The project
ISOLATING, INTERROGATING AND BIOENGINEERING SINGLE CIRCULATING CELLS Leaders: Professor Justin Gooding, Professor Benjamin Thierry Co-Leaders: Dr Stephen Parker, Dr Marnie Winter Collaborating Organisations/Groups: Associate Professor Therese Becker (Ingham Institute for Applied Medical Research), Professor Katharina Gaus (EMBL Australia Node in Single Molecule Science), Professor Maria Kavallaris (Children’s Cancer Institute, UNSW), Dr Dan Inglis (Bionomics Ltd), Professor Wayne Tilley and Dr Luke Selth (University of Adelaide), Professor Tim Price, Dr Jenny Hardingham (Adelaide Oncology and Haematology, The Queen Elizabeth Hospital)
The project The isolation of rare single circulating cells from biological samples, including blood, presents tremendous opportunities to not only advance the understanding of the molecular bases of diseases such as cancer, but also to develop novel diagnostic modalities. We are developing a range of technologies able to isolate, interrogate and bioengineer circulating cells, with a focus on: • Circulating tumour cells • Circulating fetal cells • Immune cells that can be harnessed for anti-cancer immunotherapy
The big questions
?
How can we understand the heterogeneity in cell populations and in particular rare cells such as circulating tumour cells?
?
This program aims to provide new tools for biomedical researchers to specifically capture rare cells and then be able to release individual cells of interest for further analysis such as genomic/transcriptomic/proteomic screening, cloning or single cell bioassays including the ability to form metastatic tumours. Such a technology will have implications for both fundamental research in understanding cell heterogeneity and in precision medicine where therapeutic strategies can be designed for the heterogeneity in the cells of a given patient.
?
Can genomic and transcriptomic testing of circulating fetal cells isolated from maternal blood provide a non-invasive prenatal diagnostic modality able to detect the full range of chromosomal abnormalities and single gene disorders that are the major reason for referral to fetal medicine units?
The benefit of this research • Efficient technologies able to isolate rare circulating cells from biological fluids such as blood will lead to novel diagnostic and prognostics approaches as well as provide new and significant insights into the molecular bases on diseases, including metastatic cancer and pregnancy complications such as preeclampsia, thereby guiding the development of more effective treatments.
Circulating Fetal Cells Isolated from Maternal Blood: (A) Cytotrophoblast and (B) Syncytial Nuclear Aggregate. (C) Scanning electron microscope images of a trophoblastic cell isolated on a microfabricated honeycomb filter.
Our goals • We will develop a technology able to select unique rare cells from other background cells before isolating and cloning it such that its relative contribution to the progression of diseases can be determined. We will use this unique capability to determine the molecular profile and processes that are responsible for a circulating tumour cell forming a metastatic tumour. • We will perform genetic and transcriptomic analysis of circulating fetal cells from pregnant women’s blood to identify biomarkers of pregnancy complications including preeclampsia for improved diagnosis and treatment. In close collaboration with obstetricians, geneticists and ethicists, we will translate our technological development into a clinically relevant non-invasive prenatal diagnostic technology.
14 CBNS Annual Report 2017
The many faces of cancer: Disseminated tumor cells isolated from cancer patients’ blood and lymph nodes.
R e s ear c h
A semiconductor (such as silicon) surface is modified with antibodies that bind specifically to surface proteins that are known to be upregulated in rare cells. These antibodies are conjugated to the semiconductor surface via an electrochemically-cleavable linker molecule. This surface can capture the rare cells out of a sample such as whole human blood. Once captured, the rare cells can be interrogated both fluorescently and electrochemically (left panel) before selecting a unique rare cell. Illuminating that unique cell results in accumulation of electrons within the illuminated region, leading to that region becoming conductive when compared to neighbouring nonilluminated regions. Applying a negative bias will initiate the electrochemical cleaving reaction in the illuminated region only and subsequent release of the cell.
A MATERIAL SCIENTIST’S GUIDE TO THE CELL Leaders: Dr Angus Johnston, Professor Rob Parton Co-Leaders: Dr Nik Veldhuis, Mrs Laura Selby Collaborating Organisations/Groups: Professor Justin Gooding (UNSW), Professor Nigel Bunnett (Columbia University), Professor Cameron Alexander (University of Nottingham), Professor Marino Zerial (Max Planck Institute Dresden), Professor Satyajit Mayor (National Centre for Biological Science Bangalore), Dr Georgina Such (Melbourne)
The project Effective drug delivery depends on delivering drugs to the sites in the cell where they are therapeutically active – and nanoparticles are seen as an effective strategy for the future. The aim of this signature project is to gain a fundamental understanding of how nanoparticles are trafficked in cells. In particular, we are focusing on understanding how nanoparticles and their cargo are internalised, trafficked in the endosomes and trafficked from the endosome into the cytoplasm (i.e. endosomal escape). These fundamental interactions are poorly understood and by understanding these interactions, we aim to engineer the next generation of nanoparticles that can respond intelligently to the cellular environment.
Nanoparticles delivering their cargo into lysosomes.
The big question
?
Can we improve the effectiveness of drugs by controlling where they are trafficked in cells?
The benefit of this research • Improved therapeutic efficiency and lower side effects from drugs
Our goals • Engineer nanoparticles to target subcellular locations • Develop techniques to quantify cellular localisation in live cells • Translate our fundamental understanding of cellular processing to virtual reality visualisations
Electron microscopy image of endosomes.
CBNS Annual Report 2017 15
OVERCOMING CHALLENGES OF IN VIVO TARGETING Leaders: Associate Professor Kris Thurecht, Professor Frank Caruso Co-Leaders: Dr Zach Houston, Mr Matt Faria Collaborating Organisations/Groups: Professor Cameron Alexander (University of Nottingham), Professor Maria Kavallaris (UNSW), Professor Stephen Kent and Dr Georgina Such (Melbourne), Professor Chris Porter and Dr Angus Johnston (Monash), Professor Steve Mahler (UQ), Dr Brad Walsh (Minomic International)
The project To develop an in-depth understanding of the role that the physicochemical properties of nanomaterials have on overcoming the different biological barriers that can impede nanoparticle accumulation in tissue.
The big questions
?
Can we directly assess the contribution that targeting cellular proteins has on the degree of accumulation of nanomedicines within disease tissue? Is it really beneficial to use active targeting? This includes assessment of how active targeting influences immune response accumulation in disease tissue.
?
How do targeting ligands affect intra-tissue distribution and ultimate efficacy of imaging agent/therapeutic? Does the targeting ligand affect how the drug or therapeutic is distributed throughout the disease site and consequently its efficacy?
The benefits of this research • By developing a better understanding of factors that influence effective in vivo targeting, we will be able to design better targeted materials, assisting both our clinical and commercial partners with advancing the field of nanomedicine. • By obtaining high-quality investigative data into the mechanisms and dynamics of in vivo nanoparticle trafficking, we will be able to build a solid foundation for researchers inside and outside of the Centre.
Our goals • To combine and exploit the knowledge in the CBNS across biology, materials science and advanced imaging to investigate the roles of particle physical properties on active targeting and in vivo localisation.
Schematic representation of the different biological barriers encountered by nanomaterials following administration into the bloodstream.
16 CBNS Annual Report 2017
Schematic representation of the different biological barriers encountered by nanomaterials following administration into the bloodstream.
Biodistribution of different nanoparticles in mice determined by PET-CT showing the effect of nanomaterial properties on organ accumulation.
DEVELOPMENT OF COMPLEX MULTICELLULAR SYSTEMS FOR THE EVALUATION AND CHARACTERISATION OF BIO-NANO INTERACTIONS Leaders: Professor Maria Kavallaris, Professor Benjamin Thierry Co-Leaders: Dr Frieda Mansfeld, Dr Fran Ercole Collaborating Organisations/Groups: Professor Jason Lewis (Memorial Sloan Kettering Cancer Center), Professor Cameron Alexander (University of Nottingham), Professor Richard Lock (Children’s Cancer Institute)
A major challenge in the development and implementation of effective nanomedicine, is the lack of preclinical models that recapitulate the complexity of the complex cellular systems and microenvironments. Towards accelerating the development of nanotechnology strategies that target specific organ and cellular systems, we are developing the next generation of in vitro models designed to replicate physiological and biological systems relevant to the characterisation and evaluation of bio-nano interactions. Ultimately, these advanced models will guide the development of nano-based therapeutic and diagnostic strategies better tailored to specific diseases.
The big questions
?
How do we model multicellular systems in vitro and in vivo to use in the development of effective nano-based delivery and targeting of specific cell types?
?
How do we design in vitro models that recapitulate the complex microenvironment of both healthy and pathological tissues so that we can better model and predict the design and bioactivity of nanomaterials?
?
How do we determine the key requirements for in vitro and in vivo models that replicate multicellular systems and environments that will form the basis of testing platforms for novel nanoparticles for detection and delivery to target organs, tissues and cells?
Childhood brain cancer cell showing star-polymer nanoparticles (green) in the cell cytoplasm. Nucleus is blue and cell membrane is orange. (Image: Helen Forgham)
The benefit of this research • Advanced models that recapitulate the key biological and physiological features of tissues will provide important understanding into the cellular complexity of tissues and their interactions with nanomaterials and consequently will improve the predictive power of in vitro models with regards to ultimate clinical translation of novel therapeutics and diagnostic nanomaterials and devices.
Our goal • We will develop multicellular models using advanced technologies that represent the complex tissue microenvironments in order to accurately develop diagnostic devices and effective and versatile nanoparticle-based delivery systems. An “intestinal epithelium on a chip” in vitro model to study the uptake of nanoparticulate carriers (green in the image) and prodrugs in the small intestine: Exposed to microfluidic fluid shear, intestinal cells (nuclei in yellow) undergo rapid differentiation and spontaneously produce a protective layer of mucus (magenta). 3D cell spheroids embedded in matrix. 3D cell spheroids are valuable models to investigate nanoparticle uptake and interactions in a controlled biological relevant environment.
Drug delivery into 3D cell spheroids.
CBNS Annual Report 2017 17
R e s ear c h
The project
SOCIAL DIMENSIONS OF BIO-NANO INTERACTIONS Leader: Professor Matthew Kearnes Co-Leader: Dr Declan Kuch Collaborating Organisations/Groups: Professor Stephen Kent, Dr Stephen Parker and Mr Josh Glass (Melbourne), Professor Justin Gooding and Professor Maria Kavallaris (UNSW), Associate Professor Kris Thurecht and Professor Rob Parton (UQ), Dr Angus Johnston (Monash)
The project Bio-nano technologies, together with advances in precision and personalised medicine, are likely to profoundly change health care practices. By exploring the social dimensions of research across this area of work, in collaboration with key CBNS research initiatives, this program will provide insights into the societal dimensions of predictive bio-nanotechnologies. This project seeks to address key questions related to the intersection between big data, healthcare, personalised and precision as well as regulation. The proposed program of work will entail the use of the following social science methodologies, and will be facilitated by a range of cross-node collaborations. These methods include: 1. Social Media Monitoring and analysis tools (using tools such as NodeXL) will enable tissue mapping of the institutional and discursive shaping of research agendas in precision and personalised medicine 2. Ethnographic Observation: close analysis of science-in-practice will serve to document the imagined social worlds that underpin developments in bio-nanotechnology, focusing specially on CBNS research projects 3. Interdisciplinary Exchange Workshops will bring CBNS researchers into conversations with researchers working in the social sciences, humanities and law to explore the broader social dimensions of their work 4. Targeted Public Engagement Initiatives will also form part of the work plan of the program, enabling CoE researchers to address the societal dimensions of their research in appropriately designed and facilitated public forums
The big question
?
How can we understand the social dimensions of personalised and precision medicine, at the interface between bio- and nano-technology? Social science methodologies have often struggled to keep pace with new and emerging technologies – and have largely separated social questions from processes of technology development. This program is designed to document the ‘imagined social worlds’ that underpin research in precision and personalised medicine, particularly in areas such as bio-nano sensor technologies, targeted cancer therapies and vaccines. We will also explore how advances in precision medicine rely upon advances in computational models and tools, development of large-scale health databases and patient characterisation methodologies. We seek to uncover how research across these fields may precipitate new social practices.
Visiting Professor Barbara Prainsack from the King’s College London (KCL) gives a public lecture on Precision Medicine to an audience of policy-makers at UNSW.
The benefits of this research • This program will provide insights into the social and regulatory responses to ‘precision medicine’ in Australia and other advanced industrialised countries. This program will also benefit public engagement with science through a parallel outreach capacity building program in partnership with all nodes in the Centre.
Associate Professor Matthew Kearnes discussing nano-particle regulation in Australia and the United States with Associate Professor Diana Bowman from the Arizona State University (ASU) at a public seminar at UNSW.
Our goal • The core objective of this project is to explore, in realtime, how the novel configuration of material and human relations in bio-nanotechnology may bring about profound transformations in contemporary healthcare practice. We will also develop new theories of public outreach and engagement relevant to the novel challenges posed by bio-nano science and technology in the context of biomedical innovation posed by precision medicine.
18 CBNS Annual Report 2017
Dr Declan Kuch and Dr Zach Houston discussing social dimensions of animal imaging at the Centre for Advanced Imaging (CAI), UQ.
MEDIATING PROTEIN INTERACTIONS Leaders: Dr Pu-Chun Ke, Professor Frank Caruso, Professor Pall Thordarson Co-Leaders: Dr Yi (David) Ju, Ms Emily Pilkington, Dr Adam Martin
The project We aim to develop strategies for controlling protein and peptide structure and aggregation and understand which biological signals are important to sustain and promote cell growth in biomaterials based on peptides and proteins. Central to these aims is to better understand the mechanism that underpins protein and peptide self-assembly, folding and misfolding. The knowledge obtained from this work will be essential for developing more effective strategies against amyloid diseases and protein fouling which will be the primary focus of this project.
The big questions
?
How to modulate protein binding on particle surfaces through material engineering for improved delivery of nanomedicines?
?
How does the toxicity of amyloid proteins evolve with their changing physicochemical properties and environments through fibrillation and corona formation?
?
How to exploit the chirality of toxic amyloid proteins for their in vivo clearance and chiral nanoparticles?
?
What are the mechanisms and implications of amyloid protein cross-talk (e.g. amyloid beta and amylin)?
The benefits of this research • To provide key guidance to the design of stealth nanoparticles for nanomedicine • To develop theranostics against amyloid diseases
Our goals • To establish a synergetic, world-class team at CBNS, investigating the implications of nanoparticle-protein interactions in nanomedicine and amyloid diseases • To train next-generation bio-nano scientists and engineers • To facilitate domestic and international collaboration and exchange
The thermodynamic cycle for subunit folding leading to the formation of the folded abmonomers starting from the unfolded α- and β-subunits (αU, βU).
Particle properties and the biological environment influence particle targeting in complex biological media.
Peptide aggregation and stabilisation in human pancreatic islets.
CBNS Annual Report 2017 19
R e s ear c h
Collaborating Organisations/Groups: Professor David Haddleton and Professor Greg Challis (University of Warwick), Professor Kenneth Dawson (University College Dublin), Professor Morgan Alexander (University of Nottingham), Professor Raffaelle Mezzenga (ETH Zurich), Professor Feng Ding (Clemson University), Dr Darren Creek (Monash), Dr Paul Wilson (UQ), Professor Sijie Lin (Tongji University), Professor Paul Curmi and Professor Lars Ittner (UNSW), Professor Frances Separovic and Dr Esteban Gurzov (Melbourne), Professor Killugudi Swaminatha Iyer (University of Western Australia), Professor Fiona Wood (Royal Perth Hospital Burns Unit)
SENSORS AND DIAGNOSTIC FOR MANAGING BLOODSTREAM INFECTIONS Leaders: Dr Simon Corrie, Professor Justin Gooding Co-Leaders: Dr Fabio Lisi, Dr Christian Fercher, Ms Vidhi Kesarwani, Mr Kye Robinson, Mr Jiaul Islam Collaborating Organisations/Groups: Professor Stephen Mahler and Associate Professor Kris Thurecht (UQ), Professor Pall Thordarson (UNSW)
The project Bloodstream infections (BSIs) are a major cause of morbidity and mortality world-wide, and a key contributing factor is the lack of appropriate diagnostic tests and devices to direct treatment at the early stage. People undergoing medical treatments that leave them immunosuppressed (e.g. chemotherapy, bone marrow transplants, HIV treatment) are at highest risk of fatalities related to systemic infections. Furthermore, empirical use of antibiotics has led to the development of antibiotic resistance, leading to a shrinking number of effective drugs. The most common causes of BSIs are bacterial agents, followed by fungal and viral agents, respectively. However, fungal infections are associated with the highest mortality (often > 50%), and viral infections are commonly associated with secondary bacterial infections, hence all three groups are important. Here, we aim to design sensors that allow early detection and monitoring of bloodstream infections, with special emphasis on designing systems that can be used to inform treatment decisions.
The big question
?
Can we develop new concepts and technologies for early detection and monitoring of bloodstream infections which can be used to guide anti-microbial treatment?
The benefit of this research • CBNS researchers will develop new sensors and monitoring tools that can be used to guide potentially lifesaving treatment decisions. In a research context, we will push the boundaries in terms of what is currently possible – especially in the areas of detecting extremely small concentrations of sepsis biomarkers in body fluids and also moving from exclusive in vitro detection towards in vivo sensing.
Our goals This project has two clear goals, related to in vitro and in vivo biosensing: • Re-purposing glucose meters as ultra-sensitive immunosensors for in vitro monitoring of host immune response to infections • Inventing new implantable nanoparticle-based microbial sensors for real-time early detection monitoring of BSI in high-risk patients
3D illustration showing a biofilm formed in vivo containing antibioticresistant bacteria. Once microbial biofilms are established, they are significantly less susceptible to antibiotics. Furthermore, most BSIs originate from biofilms formed on medical devices or anatomical sites.
Sepsis; bacteria in blood. 3D illustration showing rod-shaped bacteria in blood surrounded by red and white blood cells.
20 CBNS Annual Report 2017
IMPROVED MOLECULAR IMAGING AGENTS Leaders: Professor Andrew Whittaker, Professor Tom Davis Co-Leaders: Dr Jeroen Goos, Dr Ruirui Qiao, Dr Cheng Zhang, Dr Changkui Fu, Dr Simon Puttick Collaborating Organisations/Groups: Dr Ivan Greguric (ANSTO), Professor Jason Lewis (Memorial Sloan Kettering Cancer Center), Professor Thomas Nann (MacDiarmid Institute), Professor Craig Hawker (University of California), Dr Sophie Laurent (Université de Mons), Professor Debra Bernhardt (UQ), Professor Stephen Rose (CSIRO), Professor Guangjun Nie (National Center for Nanoscience and Technology of China), Professor Afang Zhang (Shanghai University), Professor Zushun Xu (Hubei University)
We aim to improve the resolution and accuracy of molecular imaging at different physiological sites and to exploit nanotechnology for specific diagnosis and theranostic applications.
The big questions
Our goals • This signature project tackles the three big problems in this field. The initial goal is to develop brighter imaging agents through smart molecular design, to allow early and more accurate detection of disease. Secondly, the imaging agents will be designed to report to the clinical scientist on the state of the disease, by responding to changes in physiology (pH, ionic strength, temperature, etc.) and the presence of specific markers of disease. Finally, each imaging modality (MRI, PET, CT) has advantages and deficiencies compared with each other. For example, PET is an extremely sensitive imaging modality, whilst MRI provides much superior spatial resolution. We are developing novel multimodal agents which can be imaged by more than one of the major imaging methods, to take advantage of the respective advantages of each modality.
?
Can we monitor pathophysiological changes non-invasively by combining molecular imaging with bioresponsive nanoparticles?
?
Can we exploit nanotechnology to increase the signal-tonoise ratio of existing molecular imaging probes?
?
Can we develop novel tools for multimodality imaging by combining different imaging probes in a single molecular imaging agent?
The benefits of this research • Molecular imaging, the visualisation of the location and biochemistry of tissue in whole organisms, is revolutionising modern medicine. Imaging modalities such as MRI, CT and PET enable the clinical scientist to provide more accurate patient diagnosis and monitoring the progress of therapy. All these imaging methods require administration of a molecular imaging agent, a nanoparticle or small molecule which enhances local image intensity or reports on the local health of tissue. • The major challenges in the field are related to sensitivity of the imaging agents and the type of information available from the scans. High sensitivity is critical for detection of the early stages of disease and for detection of diffuse pathologies or the margins of diseased tissue. For example, contrastenhance MRI is used to delineate the margins of tumours, including brain tumours and to guide the surgeon in the design of appropriate resection protocols. Such information is critical in determining long-term survival rates of cancer patients. Brighter imaging agents have the potential to improve discrimination between diseased and healthy tissue and to consequently improve the outcome of surgical intervention. • The clinical scientist also will benefit from agents which report on the biology of the tissue, for example the presence of specific surface markers indicative of particular disease types and the presence of hypoxic tissue which is more resistant to radiation therapy. Newly-developed molecular imaging agents are able to provide such information within a spatially resolved image, opening up new possibilities for more precise therapies.
Superposition of PET/CT images of a mouse with a brain tumour xenograft, after injection with a 64Cu labelled antibody.
PET/CT showing the distribution of a functional star polymer (S. Puttick/M.R. Whittaker), showing uptake in the bone marrow.
Snapshots of MD simulation of bovine serum albumin interacting with oligomeric polymer acrylic acid taken at the end of 20 ns of MD simulation.
CBNS Annual Report 2017 21
R e s ear c h
The project
Cross-Centre Activities: Computational and systems biology Systems biology and modelling in bio-nanoscience Leader: Professor Edmund Crampin (Melbourne) CBNS Chief Investigators involved: Professor Frank Caruso (Melbourne), Professor Stephen Kent (Melbourne), Professor Tom Davis (Monash), Dr Angus Johnston (Monash), Associate Professor Kris Thurecht (UQ) A major aim of the CBNS is to develop an understanding of, and thereby the ability to control, the interface between nanoscale materials and biological systems. Rational design of nanomaterials with specific, known biointeractions would enable applications of bio-nanotechnology in the clinic, through the ability to predict how the body will respond when exposed to a particular nanomaterial. This remains a major unmet challenge for the field. Understanding which characteristics and properties of nanomaterials give rise to which biological responses would enable a framework for engineering design of nanomaterials with desired and predictable biological interactions. While this ambition remains a long way off, an important initial challenge is the development of standards and approaches which will allow us to compare data from different empirical investigations. We are pursuing a number of different projects across the Centre to address this major challenge for bio-nanoscience. Three key projects that are underway in 2017 in this direction are the development of standards for consistent data collection and the annotation of nanoparticle properties as well as the methodology for comparison of nano-bio properties for nanoparticles – currently a major gap in the field. Furthermore, the application of these ideas to nanoparticle-whole blood assays to
Figure 1: Accelerating scientific discovery and translational research at the intersection of chemistry, materials science, engineering and biomedicine through convergent science. Reproduced from: Mattias Björnmalm; Matthew Faria; Frank Caruso; J. Am. Chem. Soc. 2016, 138, 13449-13456. DOI: 10.1021/jacs.6b08673. Copyright © 2016 American Chemical Society
develop predictive models of nanoparticle interaction with fresh blood cells. As part of this ‘convergent science’ approach, we are developing strategies for consistent data collection and
annotation and computational approaches for modelling of data generated in the Centre to better understand, and hence predict, how specific properties of nanoscale materials lead to specific biological responses.
Developing standards and methodology for comparison of nanoparticles Currently, it is difficult to reliably compare data generated across different experimental platforms. Combining data across different experiments would allow us to analyse merged datasets
22 CBNS Annual Report 2017
in order to identify underlying patterns, which would reveal the properties of nano-materials that dictate their biological interactions. We are developing standards for recording
and reporting such experiments as well as mathematical modelling approaches for merging data from different experimental assays, in order to further this approach.
In vitro assays are currently the basis for understanding the interactions between particles and biological systems. Commonly, these assays consider nanoparticles held in suspension in the fluid above a surface containing cells. A confounding variable for interpreting the results of such assays is the difference between the concentration of particles initially administered and the amount of the nanomaterial which actually reaches the cells. We have shown that a modelling approach to account for variation due to sedimentation and diffusion of nanoparticles can remove inconsistencies in data arising from such assays so that the cell association properties of different nanoparticle-cell combinations can more easily be compared.
Figure 2: Controlling for the variable association of advanced particle systems due to the effect of sedimentation and diffusion. (a) Scheme of the preparation of core-shell hybrid particles (SC/MS@PMA) and hollow hydrogel (PMA) capsules. (b) Experimental design of upright, inverted and vertical orientations to investigate cell association of particles. (c) Scheme of computational modelling to analyse particle sedimentation and diffusion as well as orientation-dependent cell association of these particles. Reproduced from Jiwei Cui; Matthew Faria; Mattias BjÜrnmalm; Yi Ju; Tomoya Suma; Sylvia T. Gunawan; Joseph J. Richardson; Hamed Heidari; Sara Bals; Edmund J. Crampin; Frank Caruso; Langmuir 2016, 32, 12394-12402. DOI: 10.1021/acs. langmuir.6b01634 Copyright Š 2016 American Chemical Society
Human blood-nanoparticle interaction assay The human blood-nanoparticle interaction assay provides a very useful testing ground for these ideas of standardisation and model-based data analysis for the Centre as well as being an important application area for the use of nanoparticles for vaccine delivery. The challenge is to understand what determines the distribution of uptake of nanoparticles between different blood cell types in whole blood. Preliminary work has focused on making sure that results are reproducible and assessing and controlling sources of variability which may otherwise mask important factors.
The range of nanoparticle technologies available in the CBNS provides the opportunity to perform high throughput assays across a wide range of particle sizes, charge, surface chemistry and
so forth, in order to generate a data set that may help to reveal which properties influence the observed cellular distributions when incubated in whole blood.
An example of the human blood-nano-particle-interaction assay being used to examine the biological effects of nanoparticle charge. (Ref: Glass, ACS Macro Lett 2017)
Key goals for 2018 1 Expand measurement and model-based analysis of the interaction of nanomaterials with blood, and with immune cells in whole blood, across a range of nanoparticles with varying size, charge and surface chemistry available through the Centre.
2 Determine the influence of the distribution of particle sizes on cell association in in vitro experiments of nanoparticle-cell interaction.
CBNS Annual Report 2017 23
R e s ear c h
A mathematical modelling framework to control for sedimentation and diffusion in particle-cell interaction assays
Cross-Centre Activities: Interactions of nano-materials and immune cells Immunity and bio-nanoscience Leader: Professor Stephen Kent (Melbourne) CBNS Chief Investigators involved: Professor Frank Caruso (Melbourne), Professor Edmund Crampin (Melbourne), Professor Tom Davis (Monash), Dr Angus Johnston (Monash), Associate Professor Kris Thurecht (UQ), Dr Simon Corrie (Monash) A diverse range of immune cells play critical roles in both the desired actions of nanoparticles and the clearance of nanoparticles in a wide range of biological systems. The complexity of immune cells present in tissues and fluids presents a major challenge in un-ravelling important interactions between nano-materials and biological systems. Further, nano-materials can be engineered with a range of properties (including but not limited to size, shape, charge, flexibility, surface materials, functionalisation with antibodies and the presence of protein coronas derived from host proteins). All these characteristics will influence association, uptake and the biological impact of materials on immune cells. Combinations of nanoparticle
characteristics (such as varying size, shape and/or charge simultaneously) are likely to have influence on biological interactions in important ways, but that this may be difficult to predict in advance. An enormous strength (likely unparalleled globally) of the CBNS is the wide range of particle chemistries and expertise across the Chief Investigators and nodes. This allows opportunities to directly compare particle designs and chemistries for their influence on immune cell interactions. The CBNS has produced several major advances in understanding how one single parameter of particles that vary in one parameter vary can influence in their association with, and biological impact on, function in across many human immune cell types.
We have exploited a model whereby we culture nanomaterials with healthy human blood. A major advantage of this model is that it mimics natural conditions and uses primary cells rather than cell lines. In this manner, we have recently demonstrated the influence of antibodyfunctionalisation1, surface charge2, the surface polymer architecture3 and reactive surface chemistry4 in directly human immune cell association and activation. A challenge for the CBNS moving forward will to be the study of immune cell interactions with using matrices of nano-particle characteristics and to translate this work into cellular interactions in immune organs such as lymph nodes in mouse systems.
Using human blood assay to predict in vivo behaviour of nanoparticles In vitro assays using immune cell-derived cell lines in culture media are currently a common tool to predict nanoparticle interactions with the immune system. However, these tests do not fully represent the physiological interactions of nanoparticles with primary cells in the more complex environment of fresh blood and therefore difficult to predict nanoparticle distribution to reticuloendothelial system organs in vivo. The human blood-nanoparticle interaction assay provides a useful basis to fill the gap between the in vitro cell line-based assay and the in vivo findings. It provides the detailed information of nanoparticle uptake by different blood cell types in whole blood. In this work, three types of polymeric nanoparticles were assessed for their cell associations in human blood and it showed different results from the in vitro cell line-based assay. Subsequent in vivo study also revealed that there was consistency between human blood assay and nanoparticle biodistribution. This preliminary work demonstrates a new avenue for investigating the biological behaviours of polymer nanoparticles using human blood assay.
24 CBNS Annual Report 2017
Figure 1. Global analysis of star nanoparticle association with white blood cells. To examine the global change in nanoparticle association with all white blood cell subsets, we performed a viSNE analysis (Cytobank) on the flow cytometry data of 5 donors at 37°C after concatenating all samples. Each dot represents a single cell and spatially distinct clusters represent cell subsets based on the combination of cell surface markers they express. Clustering is based on the t- Distributed Stochastic Neighbor Embedding (t-SNE) algorithm. (a) Reference plot indicating the cellular identity of viSNE clusters. Colours represent the identity of cell subsets based on conventional manual gating strategies. (b) Global cell association with Cy5-labelled nanoparticles. Individual cells are coloured based on their intensity of association with Cy5-labelled nanoparticles, revealing global association changes between PDS and control stars.
Charge has a marked influence on hyperbranched polymer nanoparticle association in whole human blood
R e s ear c h
In this study, we synthesise charge-varied hyperbranched polymers (HBPs) and demonstrate surface charge as a key parameter directing their association with specific human blood cell types. Using fresh human blood, we investigate the association of 5 nm HBPs with six white blood cell populations in their natural milieu by flow cytometry. While most cell types associate with cationic HBPs at 4°C, at 37°C phagocytic cells display similar (monocyte, dendritic cell) or greater (granulocyte) association with anionic HBPs compared to cationic HBPs. Neutral HBPs display remarkable stealth properties. Notably, these chargeassociation patterns are not solely defined by the plasma protein corona and are material and/or size dependent. As HBPs progress toward clinical use as imaging and drug delivery agents, the ability to engineer HBPs with defined biological properties is increasingly important. This knowledge can be used in the rational design of HBPs for more effective delivery to desired cell targets.
Figure 2. Production and characterisation of HBPs. (A) Schematic of HBPs produced with different end groups (R), which results in particles of similar composition and size but varied charges. (B) The three differentially charged HBPs were incubated for 1 h in fresh whole human blood or “washed blood” that had plasma replaced by PBS across six centrifugation steps. Cells were phenotyped using fluorescent monoclonal antibodies before cell association was examined by flow cytometry.
Key goals for 2018 1 Expand measurement and model-based analysis of the interaction of nanomaterials with blood, and with immune cells in whole blood, across a range of nanoparticles with varying size, charge and surface chemistry available through the Centre (performed in concert with computational biology/modelling investigators).
2 Develop informative models of how nanomaterials interact with immune cells in lymph nodes and other immune organ systems.
References: 1. Glass, J. J., Yuen, D., Rae, J., Johnston, A. P., Parton, R. G., Kent, S. J., & De Rose, R. (2016). Human immune cell targeting of protein nanoparticles– caveospheres. Nanoscale, 8(15), 8255-8265. 2. Glass, J. J., Chen, L., Alcantara, S., Crampin, E. J., Thurecht, K. J., De Rose, R., & Kent, S. J. (2017). Charge Has a Marked Influence on Hyperbranched Polymer Nanoparticle Association in Whole Human Blood. ACS Macro Letters, 6, 586-592. 3. Mann, S. K., Dufour, A., Glass, J. J., De Rose, R., Kent, S. J., Such, G. K., & Johnston, A. P. R. (2016). Tuning the properties of pH responsive nanoparticles to control cellular interactions in vitro and ex vivo. Polymer Chemistry, 7(38), 6015-6024. 4. Glass, J. J., Li, Y., De Rose, R., Johnston, A. P., Czuba, E. I., Khor, S. Y., & Kent, S. J. (2017). Thiol-Reactive Star Polymers Display Enhanced Association with Distinct Human Blood Components. ACS Applied Materials & Interfaces, 9(14), 12182-12194.
CBNS Annual Report 2017 25
Strategic Projects In addition to the core research undertaken in the ten signature projects and the Centre-wide research detailed in the previous pages, the CBNS provides funding for activities that meet the strategic objective of the CBNS to increase collaboration whilst extending the research capabilities. Strategic Projects are assessed by all Chief Investigators and are supported by a dedicated fund. The strategic funding is managed centrally and all collaborating organisations contribute part of their ARC funding each year. When assessing proposals for strategic funding the CBNS Executive Committee consider whether the projects: • Involve collaboration between at least two CIs, or members of their research groups • Involve collaboration between at least two nodes • Introduce skills, expertise or activities not presently available within the Centre
26 CBNS Annual Report 2017
• Have a duration no longer than two years (although after two years, successful projects can apply for additional funding to continue the project) • Address at least one non-research KPI (such as media, public or industry engagement, visitors, training etc.) • Not exceed an annual cost of $100,000 In addition to small amounts of funding supporting student attendance at workshops, two major projects were funded in 2017. They are detailed in the following section.
Open Data Fit Leader: Professor Pall Thordarson (UNSW)
The Open Data Fit project1 is creating a portfolio of websites that bring together tools and information of relevance
to the CBNS as well as the wider international research community. The project focuses on what we call small-scale data, i.e. the small data sets that are the bread-and-butter of research in bio-nanoscience research, ranging from kinetic measurements (kinetics) and small-angle scattering curves (nanoparticle characterisation) to cell viability measurements (IC50 for drug treatments). Currently, there are no universal tools that encourage scientists to share small-scale data effectively, not even when the results are finally published. Small-scale data from well-designed and well-executed experiments that are part of unsuccessful or unfinished research programs are in most cases never shared with the wider community at all, becoming what is
called dark data,2 languishing forever in the (digital) archives of individual laboratories around the world. The goal of the Open Data Fit is, therefore, to shine a light on smallscale dark data and transform the way scientists share small-scale datasets. To this end, we designed the Open Data Fit project to assist researchers with their everyday work while at the same time capturing the raw data for effective sharing. The opendatafit (http://opendatafit.org) web portal (tools) we are building will achieve this by allowing the end-user scientist to upload their data and then perform data fit (analysis) on these datasets, while at the same time capturing the raw data, the analysis method and the data analysis results simultaneously in an open-access database. The end-user experience is explained further in this youtube video: https://www.youtube. com/watch?v=Gc3f85Hhclw
With CBNS support, we built and successfully launched our pilot website supramolecular.org in 2015. This website provides tools for end-users to determine binding constants from NMR, UV-Vis
or fluorescence titration data. In the 31 months since this website was launched, it had over 19,000 visits with the average session lasting 3 minutes, showing a high level of engagement from end-users. Moreover, the website has been cited 32 times in the literature (Scopus). Significantly, Sir Fraser Stoddart, Nobel Prize Winner in Chemistry in 2016, agreed to become the Patron of this project. In 2017, our focus was on planning the expansion of the opendatafit platform. This expansion will be underpinned by a new robust but expandable framework that we started building in 2017. With support from the School of Chemistry at UNSW, an early version of this new framework was used to create an
In the 31 months since this website was launched, it had over 19,000 visits with the average session lasting 3 minutes, showing a high level of engagement from end-users. educational module to teach statistics in undergraduate Analytical Chemistry courses. This educational module was successfully used by over 150 students for practice, assignments, laboratory experiment recording and exams. The project has now secured nearly $150,000 in funding for 2018 to continue with the expansion of the opendatafit platform. This funding will be used to complete work on the new framework and then launch modules to analyse rate constants (kinetics), IC50 and flow cytometry data. 1. D. B. Hibbert & P. Thordarson, The death of the Job plot, transparency, open science and online tools, uncertainty estimation methods and other developments in supramolecular chemistry data analysis Chemical Communications 2016, 12792-12805. 2. M. BjĂśrnmalm, M. Faria & F. Caruso, Increasing the Impact of Materials in and beyond Bio-Nano Science J. Am. Chem. Soc., 2016, 138, 1344913456.
CBNS Annual Report 2017 27
R e s ear c h
Co-Leaders: Professor Tom Davis (Monash), Professor Ben Boyd (Monash), Professor Edmund Crampin (Melbourne), Dr Simon Corrie (Monash), Professor Maria Kavallaris (UNSW)
JTCC: visualising bio-imaging and data in 3D virtual reality (VR) Leaders: Associate Professor John McGhee (UNSW), Professor Tom Davis (Monash) Co-Leaders: Dr Andrew Lilja (UNSW), Mr John Bailey (UNSW), Mr Campbell Strong (UNSW) As described in the Signature Project section, this ARC Centre of Excellence project explores how design-led 3D VR immersive techniques can be used to visualise the dynamic processes within a cancer cell. In 2017, we started phase 2 of the strategic project. In this phase, we intend to continue the user testing of the VR content with both student and scientific communities. The support of both the Centre and UNSW will have a far-reaching impact on the project continued success. The table below outlines a $771,710 contribution from CBNS to fund one postdoc, a programmer and the travel between the centre node for a period of three years. Income Source
2017
2018
2017 Progress
Sub-projects:
Across the three projects within the JTCC Phase 2, we have focused our resources in 2017 on developing a more efficient 3D VR data software pipeline. The core of this software tool development was to allow the UNSW VR team to import scientific data directly from the CoE’s imaging modalities such as MRI, CT and Microscopy. This tool was completed in late December 2017 and will allow a more sustainable and efficient computer graphics pipeline for VR content development.
Project 1: Visualising Cells Using High-resolution Cell Tomography, this project is an immersive exploration of cellular compartments and protein structures based on new tomography data provided by UQ. This project is driven by volumetric representations of data. In 2017, this project has progressed to the data acquisition stage at the UQ Node.
2019
2020 Total
CBNS
160,306 251,898 267,570 91,936 771,710
UNSW
82,803 137,249 145,085 54,618 419,755
Total
243,109 389,147 412,655 146,554 1,191,465
Project 2: Microtubules and dynamics This project aims to utilise the immersive nature of VR to visualise complex cellular trafficking in 3-dimensions using the latest advances in dynamic cellular imaging. In 2017, this project has progressed to the data acquisition stage on the Light Sheet Lattice microscope at the UNSW Node. Project 3: In vivo nanoparticles This project aims to visualise CT and PET data to identify the precise number and location of particles following in vivo administration. Data sets used to register biological barriers and organs (e.g. liver, spleen, blood vessels etc.) will be included in the visualisation to allow for specific user-driven compartmental analysis of nanoparticle distribution. In 2017, this project has progressed from PET CT data acquisition at the UQ Node through to a prototype VR mouse model with nanoparticles. Published work 2017: Johnston AP R; Rae J; Ariotti N; Bailey B; Lija A; Webb R; Ferguson C; Maher S; Davis TP; Webb RI; McGhee J; Parton RG, 2017, ‘Journey to the centre of the cell: Virtual reality immersion into scientific data’, Traffic, http://dx.doi.org/ 10.1111/tra.12538 Press: ABC News 19 Dec 2017. Virtual reality lets scientists walk around inside cancer cells, set to revolutionise medicine. By medical reporter Sophie Scott. https://goo.gl/FJyEVA
28 CBNS Annual Report 2017
Key goals for 2018 1 Establish new computer graphics pipeline tools for enhanced forms of VR 3D visualisation on HMDs.
3 Design and build meaningful and embodied interfaces that allow multi-user immersive 3D VR data interaction.
R e s ear c h
2 Develop an education and scientific discovery VR platform for improved interaction with nanoscience laboratory data.
Visualisation of in vivo nanoparticle distribution in virtual reality. Interactive heads-up displays allow the user to navigate through the complex data set. Image credit: John McGhee, Andrew Lilja, Campbell Strong, Kris Thurecht
Multi-user virtual reality concept: exploring in vivo nanoparticle data simultaneously across multiple sites. Image credit: John McGhee, Andrew Lilja, John Bailey, Kris Thurecht
CBNS Annual Report 2017 29
Engagement 30 CBNS Annual Report 2017
e n gag e m e nt
Engagement CBNS Annual Report 2017 31
Collaborations and Partnerships CBNS researchers have a long history of collaboration with other universities, research centres, industry and medical organisations. These collaborations take a wide variety of forms – from formal relationships such as Linkage Projects or contract research, to informal and ad hoc collaborations.
Intellectual Property and Commercialisation Policy The CBNS IP and Commercialisation Committee (IPCC) provides advice for IP management to CBNS Chief Investigators. The IPCC comprises the Centre Executive (Director, Deputy Director and Manager), plus the Business Development Manager from the Administering Organisation (Monash). In discussing IP from collaborating organisations the IPCC co-opts the Business Development Manager (or equivalent) from that organisation.
Intellectual Property The CBNS does not own project intellectual property (PIP) resulting from CBNS activities. Project intellectual property is owned by the (administering, collaborating or partner) organisation making the major inventive contribution to the IP. Whilst a single organisation assumes control of PIP, in the cases of cross-institutional participation in PIP generation, beneficial interest in PIP is determined by relative contributions to IP generation based on cash and in-kind contributions to that project (cash is weighted by a factor of 2). The CBNS maintains an Intellectual Property Register, which includes
up to date details of CBNS IP and each organisation’s background IP. It includes: • the owners of each item of background and CBNS IP and the proportion of ownership; • any and all third party interests in background and CBNS IP; and • any patents or patent applications relating to CBNS IP.
Commercialisation The organisation owning the PIP supports protection and commercialisation through its IP commercialisation group and meets the cost of protection.
CBNS commercial partners provide real world advice to Centre Chief Investigators but also provide a potential path-to-market and a defined route to impact. As such, industry partners have the right of first refusal to a license to exploit project IP on terms to be agreed. In relation to the commercialisation of PIP, all parties negotiate in good faith to agree on a Commercialisation Lead and the terms of any Commercialisation. The Commercialisation Lead has the right to sublicense PIP in the interests of all parties and the CBNS, without restricting the use of the PIP for research, teaching and scholastic endeavours.
Patent applications, invention disclosures and selected commercial activities Node Type
Date
Inventors/Researchers involved
Monash National phase patent filings (US, 12 Feb 2017 Australian, Japan, Europe, China)
Christopher Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
PCT application
23 Feb 2017
Nigel Bunnett
PCT application
19 May 2017
Nigel Bunnett, Stephen Vanner
Option agreement 13 Jun 2017
Christopher Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
Licence agreement 1 Aug 2017
Christopher Porter, Jamie Simpson, Natalie Trevaskis, Tim Quach, Sifei Han, Luojuan Hu
Invention disclosure
26 Oct 2017
Jonathan Baell, Thomas Davis, Jeroen Goos, Jason Lewis
Provisional application
26 Oct 2017
Christopher Porter
Invention disclosure
2 Nov 2017
Ben Boyd, Kapilkumar Vithani, Vincent Jannin
Provisional application
11 Nov 2017
Ben Boyd
Provisional application
20 Dec 2017
Luigi Aurelio, Nigel Bunnett, Bernard Flynn, Giang Le
UNSW
PCT application
1 Mar 2017
Justin Gooding
UQ US complete application (published) 2 Feb 2017
James Thackeray, Meiliana Siauw, Peter Trefonas, Idriss Blakey, Andrew Whittaker
US complete application (published) 9 Feb 2017
James Thackeray, Ke Du, Peter Trefonas, Idriss Blakey, Andrew Whittaker
US complete application (published) 9 Feb 2017
James Thackeray, Ke Du, Peter Trefonas, Idriss Blakey, Andrew Whittaker
UniSA
Australian provisional application
1 Feb 2017
Benjamin Thierry, Marnie Winter
US complete application (published)
15 Jun 2017
Clive Prestidge, Spomenka Simovic
Australian provisional application
24 Aug 2017
Nicky Thomas, Katharina Richter, Clive Prestidge
32 CBNS Annual Report 2017
CBNS researchers have a range of collaborations with commercial organisations. These relationships are typically led by one of our Chief Investigators and link with Australian and international biotech experts. The collaborations provide an opportunity for bio-nano research to be translated into product development and, ultimately, application and use. Examples include: • Joint PhD studentship at the EPSRC Centre for Doctoral Training in Advanced Therapeutics and Nanomedicines with CBNS CI Associate Professor Kris Thurecht (UQ) and Drs Paul Gellert and Marianne Ashford from AstraZeneca. This studentship has a total value of £100,000 ($AUD178,000) over 4 years. • Target delivery technology for cancer – A collaboration between CBNS CI Professor Chris Porter (Monash) and the company Starpharma. The work will evaluate the use of antibody conjugated DEP® conjugates to enhance concentration of drug at the disease site, improving activity and reducing off-target toxicity. • Antibodies for broad protection against influenza B – CBNS CI Professor Stephen Kent and Dr Adam Wheatley (both Melbourne) were awarded funding from Sanofi-Pasteur for a University of Melbourne-Sanofi Pasteur proof-of-concept initiative.
• Improving Head and Neck Cancer staging with nanoparticles – CBNS CI Professor Benjamin Thierry (UniSA) is leading the development of an intraoperative cancer staging technology through Ferronova Ltd, a spin-off company of UniSA. Pilot clinical trialling is scheduled in late 2018. • Sun exposure technology – Luminosity Innovations is developing a chemical sensor to help better manage exposure to the sun’s radiation. The foundation technology was invented by CBNS CI Professor Justin Gooding (UNSW). Professor Gooding and CBNS CI Professor Maria Kavallaris (UNSW) received direct funding from the company Inventia and licensed IP to them. Further details on the range of industry and commercial engagements of the CBNS can be found on our website: https://www.cbns.org.au/outreach/ industrial-and-commercial-engagement/
Health and medical sector engagement CBNS researchers have a range of links with organisations in the health and medical sector. These relationships are typically led by one of our Chief Investigators and link with hospitals and medical research institutes. The collaborations provide an opportunity for bio-nano research to be undertaken in collaboration with medical researchers and practitioners, informed by end user needs.
• “SPI-CLOPS” (Surface Polymer Imprinted Closed Loop Optical Patient Sensors) for Dose Detection and Prevention of Cancer Resistance – a joint project with the EPSRC Cyclops Network. This included a visit by CBNS CI Associate Professor Kris Thurecht (UQ) to Nottingham in April 2017. • Novel formulations of nanoparticles in gels to facilitate controlled release – CBNS CI Professor Clive Prestidge (UniSA) in collaboration with Professor PeterJohn Wormald from the University of Adelaide and Associate Professor Sarah Vreugde from the Basil Hetzel Institute have secured a THRF (The Hospital Research Foundation) Development Grant to provide relief for patients undergoing back surgery. • Smart “Nano Tracer” for improved preoperative staging with MRI – CBNS CI Professor Benjamin Thierry (UniSA) has been awarded with Dr Andrew Foreman (Royal Adelaide Hospital) a conjoint grant from the Garnett Passe and Rodney Williams Memorial Foundation. Further details on the range of industry and commercial engagements of the CBNS can be found on our website: https://www.cbns.org.au/outreach/ health-and-medical-sector-engagement/
CBNS Annual Report 2017 33
e n gag e m e nt
Industry and commercial engagement
Collaboration with partner organisations The CBNS engagement with our partner organisations varies as research activities gain in focus. In 2017, there has been a research visit to Australia from Partner Investigator Professor Jason Lewis from the Memorial Sloan Kettering Cancer Center (MSKCC) to Melbourne. Dr Jan Grimm from MSKCC also visited Australia and met with researchers at UNSW. Australian CBNS researchers have travelled to our local and overseas partners to undertake collaborative activities: PhD candidate Emily Pilkington (Monash) spent 6 month at our partner organisation Warwick University (UK) from April to October 2017. Emily is part of the Monash Warwick Alliance joint PhD program. This program brings together the University of Warwick and Monash University, offering funding for 30 students to study under research leaders addressing the research challenges that the Alliance is tackling. During her visit, Emily worked in Dr Paul Wilson’s research group in the Department of Chemistry at Warwick University and we learnt about how her overseas experience has helped her research project. A focus of Emily’s research is investigating the biological identity of IAPP amyloids, which form large fibrils and plaques through a toxic aggregation process implicated in the pathology of type-2 diabetes (T2D). At Warwick University, she designed a completely new technique to isolate and identify serum proteins binding to amyloid fibrils – called the ‘amyloid-protein corona’ – which will provide new insight into how the protein-coated surface of these amyloids might participate in high-risk pathologies associated with T2D. Emily’s aim is to receive more information on how the amyloid-protein corona might impact T2D and other amyloid-related diseases, such as Alzheimer’s and Parkinson’s disease, and how this might advise the design of effective treatments.
34 CBNS Annual Report 2017
CBNS members Ms Emily Pilkington (left) and Ms May Lai (right).
Emily found her time at Warwick University to be extremely valuable. Not only did she appreciate the opportunity to use the department’s high-quality resources but she also embraced the challenge to step out of her comfort zone and adapt to a new working environment. Apart from learning new techniques, the most sustainable outcome of her visit was learning how to find ways to use a collaborative force for her research. Working in a different lab environment within an unfamiliar cultural setting required Emily to interact and network with her new colleagues. She believes it was vital for her to get this kind of exposure to appreciate the positive effects collaborating and networking had on her PhD research.
“I learned that dreams can be achievable”, Emily states. Besides, the 9-hour time difference allowed her to accelerate her research: By the time she had finished her work and sent the data to Australia,
“Engineer yourself to be the best PhD candidate you can be!” her Monash colleagues started into a new day which almost fast-tracked her work turnaround time. “Engineer yourself to be the best PhD candidate you can be!” – this study visit as part of her joint PhD program most certainly broadened her research network and as a consequence, encouraged her to get the most out of her PhD. There was also time for a bit of fun – Emily enjoyed weekend trips across Europe to attend concerts and cultural events.
Spin-Offs CBNS researchers not only collaborate successfully with other universities and research centres. They are also successful in founding companies as a result of their prosperous research and inventions. These are some of the CBNS-related spin-off companies.
Ferronova ltd Pty
In 2011, CBNS CI Professor Mark Kendall from UQ founded Vaxxas, a venture capital funded technology start-up company developing technology that originated from Professor Kendall’s research group at the Australian Institute of Bioengineering & Nanotechnology at UQ. The company focuses on enhancing the performance of existing and next-generation vaccines through the development and commercialisation of the company’s novel vaccine delivery technology – the Nanopatch™. Its aim is to commercialise the Nanopatch with $15 million investment, followed by $25 million in 2015, to clinically advance the Nanopatch as a product. The Nanopatch technology has been licensed to US-based pharmaceutical company Merck and Co.
Ferronova has received financial investment from TechinSA and Powerhouse Ventures Pty Ltd to develop a clinical technology towards clinical trialling for head and neck cancer in collaboration with the Royal Adelaide Hospital. The first-in-human pilot trial is scheduled for the first semester of 2018.
Luminosity Innovations Luminosity Innovations was established in 2017 after CBNS CI and Luminosity Innovations’ Managing Director Professor Justin Gooding from UNSW invented the foundation technology for chemical sensors to help better manage the exposure to the sun’s radiation. The technology was selected by Luminosity Innovations from a large number of projects due to its technical and commercial feasibility. Luminosity Innovations is working towards delivering both their short term development objectives and the compelling longer term public health impact that this technology promises to deliver.
The Nanopatch™ approach consists of an array of thousands of vaccine coated micro projections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch’s micro projections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. Vaxxas aims to partner with vaccine companies who are seeking a differentiated, high performance, cost-effective and safe vaccine delivery platform. Parisa Sowti Khiabani. Photo: Grant Turner/Mediakoo
CBNS Annual Report 2017 35
e n gag e m e nt
Vaxxas
Ferronova ltd Pty is a South Australian based medical devices company emerging from technologies developed at the Future Industries Institute by CBNS CI Professor Benjamin Thierry in collaboration with Professor Richard Tilley at Victoria University (now at UNSW). Ferronova’s aim is to improve outcomes for patients with cancer by broadening the application of sentinel node biopsy: a potentially life-saving surgical procedure with widespread application currently limited by sub-standard detection technologies. Ferronova’s novel magnetic-sensing probe and magnetic nanoparticulate tracers delivers pinpoint accuracy to determine sentinel node location, even when nodes are very close to the primary tumour.
CBNS Experience One of the advantages for CBNS PhD students is the opportunity to gain valuable research experience outside of their home institute and to work with national and international experts in their field. CBNS offers its PhD students the opportunity to visit other labs and present their research at external conferences and events. In this section, three PhD students and two alumni share their experience from 2017.
PhD Students Showcase on how research can have real-life impact Third year PhD student, Manish Sriram, had the chance as one of four postgraduate students from UNSW to attend the Global Fellows Programme in Germany on “Cities of the Future”. This initiative was organised by the Global Alliance of Technological Universities to help students from all disciplines develop the professional, research and collaborative skills needed to create solutions for the challenges facing cities of the future. As part of the Global Tech network, UNSW could nominate doctoral students to attend the workshop. The event took place in Burghausen, Germany from 17 to 21 July and counted students from the Technical University of Munich (TUM), Imperial College London and other Global Alliance of Technological Universities as delegates. During this summer school, the students met with the Mayor of Burghausen and city planners to pitch their ideas for improving the management of issues of expanding urban populations such as infrastructure and healthcare. “I was interested in participating in the program because it seemed like a great opportunity to both develop my professional skills and also because it has the potential for real-life impact,” says Manish. He is working with CBNS CI Professor Justin Gooding (UNSW) on the development of digital biosensors to improve disease detection.
36 CBNS Annual Report 2017
Deliver just the right amount of information at national and international conferences Dewan Akhter is in the third year of her PhD candidature, with supervisor Associate Professor Kris Thurecht, at the University of Queensland. Dewan shared with us her PhD student experience, and in particular the opportunities that she was able to undertake in 2017, through her affiliation with the CBNS. In 2017, Dewan was fortunate to present her research and represent the CBNS at four conferences (one international and three national). One of the highlights was that she was invited to present her research at three of the four conferences. Visiting Osaka, Japan in May 2017 for the International Conference and Exhibition on Nanomedicine and Drug Delivery was a great experience as Dewan gave an oral presentation on “Oral delivery of folate targeted micelle for colorectal cancer” to an international expert audience within her research discipline. Dewan noted that as a PhD student in the CBNS, she has had the opportunity to attend many conferences and present her research and has found this experience to be quite impressive. Preparing abstracts, posters and presentations that clearly define her research project and delivering just the right amount of information to engage the audience, has been an area that she has enjoyed refining over the years.
Early on in her PhD candidature, Dewan acknowledges “delivering a presentation to a largely unknown audience can be quite intimidating for a junior researcher. However over the years, the faces of the conference delegates have become more familiar and through conversations with other researchers in the bio-nano community, I have gathered ideas which add more value to my own research”. Support from her supervisors, postdocs and fellow students in her lab and UQ node have created a great research training environment.
Dewan comments “My supervisors and lab members give me lots of encouragement and the confidence to go further in my research and are always there to provide technical expertise”. In addition to the research training acquired in the lab, Dewan has also participated in CBNS-run workshops which help to build various skills and capabilities for its members. In November 2017, Dewan attended the Cell Imaging Workshop for Nanomedicine held at UNSW and found the sessions to be extremely valuable for her research project. Dewan is looking forward to completing her PhD in 2018 and working in the area of Pharmaceutical research.
Alumni
Embracing the opportunity to be part of a research collaboration program
Dr Joshua Glass, The University of Melbourne
PhD candidate Ibrahim Javed (Monash) visited Tongji University (Shanghai, China) over a period of six weeks in August/September 2017. CBNS and Tongji University are collaborating research partners and Ibrahim had the chance to use their zebrafish facility under the supervision of Dr Sijie Lin. Dr Lin is Professor and Principal Investigator at Lin Lab. Ibrahim said he greatly appreciated the opportunity to further his research at Tongji University. Working at the zebrafish facility enhanced his research capabilities of employing zebrafish as a high-throughput platform for studying the in vivo bio-nano interaction of nanomaterials he synthesised at CBNS. Ibrahim’s main focus is the synthesis of nanostructures and their interfacing with biological components like proteins, amyloids and other biomacromolecules for pharmaceutical and diagnostic applications. At the Lin Lab, Ibrahim developed the zebrafish as a model to study the toxicity of proteins that are involved in Alzheimer’s and type-2 diabetes (T2D). His future research dimensions will explore the zebrafish for the rational design of nanomedicine against protein misfolding and aggregation diseases. Ibrahim recommends embracing the opportunity to be part of a research collaboration program. “I enjoyed spending time in an energetic and vibrant city such as Shanghai where different backgrounds meet creating an exciting mix of cultures”, Ibrahim said. “You could feel this mix especially in the variety of food you can get anywhere and everywhere in the city.” The only thing he really missed during his visit was the mild weather in Melbourne and of course, the people at CBNS and MIPS.
Josh conducted his PhD research under the supervision of CBNS CI Professor Stephen Kent (Melbourne) and CBNS researcher Dr Robert De Rose (Monash) in the HIV Vaccines Laboratory at the University of Melbourne. Josh is fascinated by the drug development process, from the earliest design stages through to further commercial development. This led to Josh spending time in various drug development laboratories in a research capacity. These laboratories included the Experimental Therapeutics group at the Children’s Cancer Institute of Australia, the Oncology Research Unit, UNSW, and the Antibody Engineering Lab, Garvan Institute for Medical Research. Although Josh had little exposure to nanotechnology or immunology prior to joining the CBNS, he was drawn to a highly collaborative CBNS project that aimed to investigate the medical potential of nanotechnology by studying the biological behaviour of nanoparticles in human blood. “The CBNS enabled complex problems to be tackled by crossdisciplinary and highly collaborative teams”, Josh stated. Over three years, Josh and his CBNS colleagues investigated the influence of antibody functionalisation, charge, surface chemistry and polymer architecture on biological outcomes. This resulted in six journal publications (with more on the way) and presentations at conferences and meetings across Australia, Japan, France, England and Spain. Josh has now returned to Sydney where he has accepted an Associate management consulting role with the Boston Consulting Group. This new appointment will see Josh apply his problem-solving skills in cross-disciplinary teams to tackle critical problems facing government, society and some of the world’s largest organisations.
Dr Jeroen Goos, Monash University As a postdoc in Professor Tom Davis’ lab at Monash University, Jeroen worked on the development of nanoparticles for molecular imaging for two years. Jeroen appreciated that by being part of the CBNS, he was able to perform his research at several top institutes, not only across Australia but also overseas in the United States. As such, he spent time in Sydney, Brisbane and New York, where he worked at various state-of-theart research facilities and collaborated with leading groups in the field of molecular nano-imaging.
“I am very thankful to the CBNS for these great experiences and for giving me the opportunity to work with all the wonderful people I have met during the two years”, Jeroen said. Currently, he is continuing his research in the lab of Professor Jason Lewis at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York, an international partner of CBNS. He is working on the preclinical evaluation of the nanoparticles he has made in Australia, plus on several new molecular imaging projects. MSKCC has held a firm position as one of the top two cancer institutes worldwide for 28 years in a row and is famous for its streamlined (pre)clinical pipeline that enables quick translation of research from bench to bedside. Working in an environment that is optimised for conducting fast, high-quality cancer research, Jeroen hopes to see his research being implemented in cancer diagnosis and treatment within the near future.
CBNS Annual Report 2017 37
e n gag e m e nt
PhD Students
Events Events provide an excellent opportunity to share important research, form new collaborations and strengthen existing ones. The CBNS delivered another series of successful events during 2017. Here are some of the highlights.
CBNS Annual Research Workshop In 2017, more than 100 members of the CBNS came together at the Sunshine Coast from 25 to 27 October for our annual research workshop. As always, the workshop was an excellent opportunity for members to learn about the latest research taking place in the different nodes. In this stimulating environment, CBNS members took the chance to network, identify new collaborations and strengthen existing ones. Researchers of all levels from across our five nodes were present, along with research administration staff. The Sunshine Coast venue provided an inspirational environment for lively discussion around showcasing our research and emerging opportunities for collaboration across the Centre. We continued to build on the strong sense of community among CBNS members and communicated the overall CBNS strategic vision. Each CBNS node presented updates on their current work and discussed future collaboration opportunities. Furthermore, delegates got the chance to hear about the latest developments within the CBNS Signature Projects while learning how to become more mindful in their daily work and lives as guest speaker Associate Professor Craig Hassed gave a talk about “Applied Mindfulness”. The workshop also included recognition of members for the most significant publication and best poster presentation of 2017 as well as the presentation of the 2017 CBNS Student Travel Awards. A joint meeting of the CBNS Education Committee and the Outreach SubCommittee facilitated discussions and feedback for events, training and activities that could take place during 2018. Both committees’ programs and activities during 2017 were positively received by members at the workshop. This has resulted in a range of beneficial activities that not only build the capacity of CBNS members but also provide a platform to demonstrate the Centre’s important work to the public.
38 CBNS Annual Report 2017
Visiting Professor Wolfgang Parak talking with students
The CBNS was once again the co-host of the Australian Centre for Nanomedicine’s International Nanomedicine Conference with UNSW. The conference has been held annually at Coogee in New South Wales for eight years. The conference brings together Australian nanomedicine researchers from medicine, chemistry, engineering and sociology with international experts. A feature each year is the opening plenary talk delivered by the CBNS Visiting Professor. In 2017, Professor Wolfgang Parak from the Philipps University of Marburg, Germany presented on the Influence of physicochemical properties of particles on their ability for active targeting. In addition to the talks and poster sessions, the conference is a confluence of national and international expertise and most CBNS researchers attended. There is such a critical mass at the conference that the CBNS Scientific Advisory Board meets during this event, with expert input and advice from the plenary speakers each year.
2017 Visiting Professor: Wolfgang Parak Our annual Visiting Professor program brings outstanding international scientists to Australia to advance bio-nano science. In 2017, Professor Wolfgang Parak, Professor of Experimental Physics from the Philipps University of Marburg, Germany and Head of the Biofunctional Nanomaterials Unit at CIC biomaGUNE, San Sebastian in Spain, visited Australia. He has significantly contributed to the development of new surface chemistries of inorganic nanoparticles and towards the characterisation of their physicochemical properties. In particular, the development of an amphiphilic polymer coating that is now used by many different groups worldwide. Professor Parak visited Australia from 28 June to 5 July 2017. During this time, he visited four of the five CBNS nodes where he delivered research seminars and met with the CBNS CIs, Early Career Researchers (ECRs) and students. As part of the Visiting Professor program, Professor Parak attended the International Nanomedicine Conference and gave the opening plenary talk and also participated in the CBNS Scientific Advisory Board. The Visiting Professor in 2018 will be Warren Chan, Distinguished Professor and ACS Nano Editor from the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, Canada.
ARC Joint Workshop for ECRs: ACES and CBNS On 10 October 2017, CBNS held an ARC joint workshop together with the ARC Centre of Excellence for Electromaterials Science (ACES) targeting ECRs. Its aim was to bring together these two ARC Centres of Excellence and identify potential collaborative links amongst students and ECRs. Senior Research Fellows and students gave insight into their research experience with CBNS’ latest research activities such as delivery systems, vaccines or imaging technologies as well as sensors and diagnostics. ACES presentations included topics like electrofluids and diagnostics, synthetic energy systems or synthetic biosystems along with soft robotic and 3D electromaterials. Moreover, the joint workshop focused on issues such as ethics, policy and new ways of public engagement. The commonalities between the two centres within their research activities and this joint workshop provided an excellent platform for students and ECRs to form collaborative links and broaden their national and international research networks.
CBNS Annual Report 2017 39
e n gag e m e nt
International Nanomedicine Conference
Education Committee The Education Committee is chaired by CBNS CI Professor Maria Kavallaris (UNSW). The committee is formed of members from across all nodes with each node being represented by a postdoctorate researcher and PhD candidate. The Education Committee’s objective is to identify the training and capacity building requirements of the members of the Centre. In a collaborative, inclusive and transparent manner, the committee designs, promotes, delivers and evaluates an annual series of education-based events.
2017 Education Committee events:
The CBNS Education Committee met monthly during 2017 to assess the training and education needs of the Centre.
Open House Melbourne On 29 July 2017, CBNS participated in the Open House Melbourne event and opened Parkville’s doors to the interested public. The event was jointly organised and coordinated with the Outreach Sub-Committee. The tour ‘The Past, Present and Future of Pharmacy’ gave an insight into the history of the buildings/architecture including artistic features and historical artefacts. Student ambassadors and research staff gave an overview of Pharmacy practice and education in the faculty with a focus on Monash’s contemporary teaching spaces and its world-class Laboratory Facilities (such as the Helen Macpherson Smith Trust Lab, the Drug Discovery Biology Lab, the Imaging Facility and the Nanomedicine Lab).
Animal Imaging Workshop The Animal Imaging Workshop was a co-sponsored collaboration between the CBNS and the Centre for Advanced Imaging (CAI). The full-day imaging workshop held at UQ was organised by CBNS CI Associate Professor Kris Thurecht and CBNS postdoc Dr Zach Houston and utilised the special expertise of Dr Gary Cowin for PET-MRI, Dr Karine Mardon for PET-CT and Nicholas Westra van Holthe and Anna Gemmel from CAI for MSOT. The event covered all aspects that are important to designing a small animal imaging experiment from theory to practical demonstrations. The workshop covered Optical Imaging, Multi-Spectral Optoacoustic Tomography (MSOT), Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT).
40 CBNS Annual Report 2017
Event title
Date Node
CBNS Workshop: IP, patents, copyright and trademarks
2 June
Monash
The Strategic Academic: a workshop with Shelda Debowski
21 July
Monash
Open House Melbourne
29 July
Monash
Animal Imaging Workshop 2017 – Introduction to Animal Imaging (Stream 1)
28 September UQ
Animal Imaging Workshop 2017 – Advanced Imaging and Analysis (Stream 2)
28 September UQ
Cell Imaging Workshop for nanomedicine
17 November
UNSW
Furthermore, CBNS researchers and students hosted tours which enabled visitors to understand the “Molecular” Architecture of a cell, as they participated in a 3D VR Journey Inside the Cell.
Open House visitors
Cell Imaging Workshop for nanomedicine The Cell Imaging workshop for nanomedicine was a one-day workshop that focused on cell-based confocal imaging for nanomedical applications. It was organised by Dr Frieda Mansfeld from UNSW. The convenors Dr Alex Macmillan and Dr Michael Carnell took participants through the whole process of experimental planning and dye selection as well as image acquisition to image analysis using FiJi software. It also focused on determining fluorescence intensity and co-localisation.
Mentoring Program After launching the CBNS mentoring program in August 2016, our focus for 2017 was to build on the experience and feedback received after the first year. Mentoring relationships support professional and personal growth of mentees through the development of new skills, finding new approaches to old problems, identifying areas for professional growth and accessing a wider professional network. The CBNS-led mentoring program is a formal mentoring arrangement and is designed for ECRs and Mid Career Researchers (MCRs). The mentormentee relationship may last through the progression of the mentees current postdoctoral research project. Through the development and progression of the mentorship, the interaction can either focus on a particular challenge or concern or on broad career questions. The agenda is led by the mentee – the mentor is there to facilitate, not to influence decisions. The CBNS established a small mentoring team to review the applications and to try and match each with a mentor – either from within the
CBNS or external. The CBNS Mentoring Team is supported by CBNS CIs Professor Maria Kavallaris (UNSW) and Professor Stephen Kent (Melbourne) as well as Dr Natalie Jones (Centre Manager) and Dr Charlotte Hurry (Centre Administrator). While CBNS postgraduate students do not formally participate in the mentoring program, support for students continues to be provided by resources available at each node or institution. The Centre encourages its students to interact with senior research leaders and ECRs at their local node and more broadly with CBNS members through the regular research and training opportunities provided.
e n gag e m e nt
These strategies are provided through the guidance or sponsorship offered by a mentor. Mentors are chosen and matched with mentees based upon their relevant skills, knowledge, experience or influence. Through the mentor-mentee relationship, the mentor may assist the mentees in developing future career goals and defining a framework to assist the mentee in reaching those goals. Mentoring can be beneficial in skill development, career and goal planning, developing successful networks, confidence building, developing managerial/ leadership capabilities and understanding organisational structures.
CBNS Annual Report 2017 41
Outreach Sub-Committee The CBNS Outreach Sub-Committee is a sub-committee of the CBNS Education Committee. It is chaired by CBNS CI Associate Professor Matthew Kearnes (UNSW). The committee is formed of members from across all nodes with each node being represented by a postdoctorate researcher and PhD candidate. The Sub-Committee met monthly during 2017 to assess the outreach needs of the Centre and coordinated a series of events across CBNS nodes. The Outreach Sub-Committee identifies and promotes CBNS research to the public. It achieves this through community or industry-related annual series of outreach activities, events or media liaison. This includes working with the CBNS Education Committee to ensure strong collaboration and synergies occur across both CBNS programs.
2017 Outreach Sub-Committee events: Event title
Date Node
Open House Melbourne
29 July
Science in the Cinema (as part of National Science Week) 13 August
Monash Melbourne/ Monash
Interactive Presentations (as part of National Science Week)
8, 11, 14, 16 and 17 August UniSA
The members foster a culture within the CBNS of outward communication, in particular through public representations of the research that occurs and active use of social media channels.
Biomedicine Public Lecture
17 August
UNSW
Outreach training workshop
24 October
UQ
Science in the Cinema
Over 5 days in August, eight CBNS researchers from the UniSA node gave presentations to over 160 Year-10 students. The presentations addressed ‘What happens when chemists, pharmacists, biologists, physicists and engineers get together?’. The topics included an introduction to the CBNS and bio-nano science, as well as a success story about the importance of STEM in South Australia. There were talks on the human gut and silver nanoparticles as medical treatments, the nano in everyone’s medicine and how drugs are absorbed in the human body.
After the huge success in 2016, the CBNS and the Doherty Institute hosted another session of Science in the Cinema during National Science Week on 13 August 2017. This year’s movie was the award-winning documentary Jabbed – Love, Fear and Vaccines. The screening was followed by a discussion panel and Q&A session with experts in the fields of immunology and public health. The panel explored the growing trend of vaccine hesitancy worldwide and discussed the reasons behind this phenomenon, the consequences and what could be done to improve public trust in vaccination. The panellists were: • Laureate Professor Peter Doherty – patron and namesake of the Doherty Institute, co-recipient of the Nobel Prize in Physiology or Medicine in 1996 • Dr Jenny Royle – Immunisation Paediatrician, Immunisation Service, Royal Children’s Hospital Melbourne • Associate Professor Justin Denholm – Ethicist and Medical Director, Victorian Tuberculosis Program and Principal Research Fellow, the University of Melbourne at the Peter Doherty Institute • Dr Angus Johnston – ARC Future Fellow, CBNS CI, Monash University • Jessica Kaufman – Research Officer and PhD Candidate, La Trobe University
42 CBNS Annual Report 2017
Interactive Presentations
The event was a great success teaching the students basic concepts and also showcasing some of the great research performed at the CBNS. Hopefully planting many science seeds in young brains.
Biomedical Futures: Social Scientists engaging with big questions about science The National Science Week 2017 provided an opportunity for outreach events focused on the social aspects of the Centre’s research. CBNS researchers held a major symposium and a public lecture with key stakeholders. They explored the history and context of bio-nano research, critical issues at the intersection of care and choice, regulatory issues, the ownership and control of data as well as critical appraisal of biomedical promises. Professor Jenny Reardon from UCSC made an outstanding keynote lecture titled Just Biomedical Research based on her most recent book The Postgenomic Condition – a play on Arendt’s Human Condition. Professor Reardon powerfully argued that simplistic narratives of cures and miracle drugs obscure harder questions about not only the meaning of genomic data but also how and by whom decisions about who lives and dies should be made. A panel responded, consisting of Dr Orin Chisholm (UNSW), Professor Emma Kowal (Deakin University) and Sharif Bagnulo (NSW Rural Doctors Network).
The lecture was broadcast on ABC Radio National’s Big Ideas program (www.abc.net.au/radionational/ programs/bigideas/just-genomics/ 8838350).
Science Friction: The man in a dress: who were the real luddites? In September, CBNS researchers from UNSW and Monash – including Professor Pall Thordarson (UNSW), Associate Professor Matthew Kearnes
(UNSW), Dr Angus Johnston (Monash), Dr Declan Kuch (UNSW) and Dr Robert Utama (UNSW) were featured in an episode of the ABC Radio National program Science Friction. The episode, which covered a range of issues associated with the public response to new technologies, focused on the unique collaboration between physical and social scientists in exploring the social aspects of bio-nano research and the ways in this approach represents new ways of approaching the social impacts of technology.
CBNS Annual Report 2017 43
e n gag e m e nt
Science meets society: nanomedicine researchers at UNSW have agreed to have social scientists embedded in their lab (UNSW)
CBNS Awards During the CBNS annual research workshop from 25 to 27 October 2017, we recognised members for the most significant publication of 2017 and best poster presentation at the workshop. Furthermore, one student from each node was presented with the 2017 CBNS Student Travel Award. Congratulations once again to the following awardees:
2017 CBNS Student Travel Awards:
Ms Quynh Mai (Monash)
Most significant CBNS paper of 2017 (Director’s Choice) Most significant CBNS paper of 2017 (Postdoc)
Dr Changkui Fu (UQ) Polymeric 19F MRI agents responsive to reactive oxygen species (Polym. Chem., 2017, 8, 4585-4595)
Professor Rob Parton (UQ), Dr Angus Johnston (Monash), Dr John McGhee (UNSW), Mr John Bailey (UNSW) Journey to the centre of the cell: Virtual reality immersion into scientific data (Traffic, 2017, 1-6 http://onlinelibrary.wiley.com/ doi/10.1111/tra.12538/full)
Mr Manish Sriram (UNSW)
Ms Danzi Song (Melbourne)
Ms Nicole van der Burg (UQ)
Ms Ludivine Delon (UniSA)
For a comprehensive list of awards, memberships and grant successes, see pages 59-61. Most significant CBNS paper of 2017 (Student)
Best poster presentation of 2017
Ms Danzi Song (Melbourne)
Ms Mai Vu (Monash)
Templated Polymer Replica Nanoparticles to Facilitate Assessment of MaterialDependent Pharmacokinetics and Biodistribution (ACS Appl. Mater. Interfaces, 2017, 9 (39), pp 33683–33694)
Synthetic Vascular and Tumour Networks: Novel Models to Understand Biological Interactions of Nanoparticles under Dynamic Flow Conditions
44 CBNS Annual Report 2017
Media Coverage Media coverage of the CBNS provides the public with important insights into the kinds of research being undertaken at the Centre and its contribution to tackling vitally important advances in the understanding and treatment of human diseases. This coverage also gives Centre members a key opportunity to contribute to public debates on science and to facilitate increased understanding of the importance of scientific advances. We continued our strong media presence during 2017, with 83 newspaper or magazine articles, 11 radio interviews and 5 television appearances.
83
newspaper or magazine articles
11
radio appearances
5
television appearances
e n gag e m e nt
A particularly strong story that was picked up by multiple outlets was the work being led by CBNS Partner Investigator Professor Nigel Bunnett from Columbia University and CBNS CI Professor Chris Porter from Monash University. They discovered why previous attempts to develop new pain drugs have floundered by unravelling the molecular workings of a “receptor� protein long implicated in chronic pain. The team found in tests that targeting medication to pain receptors in the centre of cells, rather than the surface, offers more effective and longer lasting pain relief. The study centred on inflammatory and non-inflammatory pain common to many diseases and conditions. This work was highlighted both in The Australian and on SBS news in June (see https://www.sbs.com.au/news/ article/2017/06/01/relief-sight-painresearchers-announce-breakthrough).
Professor Chris Porter
Professor Nigel Bunnett
CBNS Annual Report 2017 45
46 CBNS Annual Report 2017
g ove r nan c e
Governance CBNS Annual Report 2017 47
Governance and Management The Governance Board has an independent advisory role to the Centre Director and Executive Committee. The Board provides guidance on governance, strategy, delivery of key performance indicators and stakeholder engagement. The Scientific Advisory Board provides strategic scientific insight and commercial direction to the Centre. The CBNS Executive meet regularly to discuss the research program, operational matters and Centre finances.
Governance Board
Scientific Advisory Board
Chaired by Professor Peter Doherty
Chaired by Professor Alan Rowan
Director
CBNS Executive
Professor Tom Davis
Director, Deputy Director, Manager
Deputy Director Professor Frank Caruso
National Education Committee
Outreach Sub-Committee Chaired by Associate Professor Matthew Kearnes
Chaired by Professor Maria Kavallaris
Research Program: Research Themes and Signature Projects
Monash node
Melbourne node
UQ node
Professor Tom Davis Node Leader
Professor Frank Caruso Node Leader
Professor Mark Kendall Node Leader
UniSA node
Strategic Fund
UNSW node
Professor Benjamin Thierry Professor Justin Gooding Node Leader Node Leader
Governance Board Members of the CBNS Governance Board are all research leaders and governance experts in scientific, research-based organisations. The Board monitors progress towards delivery of Key Performance Indicators and approves research, operational and financial plans. The Governance Board met twice in 2017: on 23 March 2017 and on 21 August 2017. Professor Peter C Doherty
A graduate of the University of Queensland School of Veterinary Science, Peter Doherty shared the 1996 Nobel Medicine Prize for his immunology research and was the 1997 Australian of the Year. Since then, he has gone in to bat for evidence-based reality, relating to areas as diverse as childhood vaccination, global
hunger and anthropogenic climate change. So far he has published 5 “lay” books on science with the latest, “The Knowledge Wars”, suggesting how those who don’t know much (or anything) about science can “interrogate” both the scientific evidence and those who claim to be scientists for themselves.
Professor Calum J Drummond
materials, including biomedical and energy storage applications. Professor Drummond joined RMIT University in 2014 from CSIRO where he was Group Executive for Manufacturing, Materials and Minerals comprising 1300 researchers and research support staff. Earlier he was seconded from CSIRO to be the inaugural Vice President Research at CAP-XX, an Intel portfolio company that developed supercapacitors for consumer electronic products.
Professor Drummond is currently Deputy ViceChancellor Research and Innovation and a Vice President at RMIT University, playing a leadership role in the development of discovery and practice-based research and in building and enhancing capability in research and innovation across the University. He is also an active research professor and has published over 200 papers and patents in the area of advanced
48 CBNS Annual Report 2017
Professor Michelle Haber is Executive Director of Children’s Cancer Institute and Head of the Institute’s Experimental Therapeutics Program. She is internationally recognised for her world-class research into the treatment of neuroblastoma and acute lymphoblastic leukaemia in children. Her project team are working towards more effective treatments for individual childhood cancers by identifying molecular targets that drive the growth and development of cancer in children, developing new drugs to inhibit the action of these targets, and combining existing and new drug treatments into novel therapeutic approaches that can be rapidly translated into national and international clinical trials. She has received numerous awards for her research, particularly in terms of translating her research findings into the clinic, including the 2014
Ms Maureen O’Keefe
Ms O’Keefe was appointed as Chief Executive Officer of the Australian College of Optometry in March 2013, an organisation providing public health eye care, tertiary clinical teaching and education, and research to preserve sight and prevent blindness. She spent the previous seven years as Chief Operating Officer at the Walter and Eliza Hall Institute of Medical Research and prior to that held several senior executive roles at the University of Melbourne. Ms O’Keefe is a graduate of the Australian Institute of Company Directors, the Williamson Community Leadership Program and an Executive Education Program at Massachusetts Institute of Technology, Cambridge.
Dr Warwick Tong
Dr Tong is currently the CEO of the Cancer Therapeutics Cooperative Research Centre headquartered in Melbourne. In 2013 he led the CRC through a successful extension application receiving another six years of funding until 2020. Formerly a director of Primecare Medical Ltd (NZ) and MedInnovate Ltd (UK) he is currently a member of the Advisory Board for Cortex Health. He has spent more than 20 years in executive management in drug
Professor Gordon Wallace
Professor Wallace is currently the Executive Research Director of the Australian Research Council Centre of Excellence for Electromaterials Science and the Director of the Australian National Fabrication Facility, Materials Node. Professor Wallace is a Fellow of the Australian Academy of Science, Australian Academy of Technological Sciences and Engineering (ATSE), Institute of Physics, Royal Australian Chemical Institute (RACI) and the Royal Society of NSW. He is a corresponding member of the Academy of Science in Bologna. On 26 January 2017, he was appointed as an Officer of the Order of Australia. Furthermore, he received Wollongong’s award for Innovation in 2017, served as Wollongong’s Australia Day Ambassador and was named NSW Scientist of the Year 2017. He received the Eureka Prize for Leadership in Science and Innovation in 2016. In 2015, he was appointed to the Prime Ministers Knowledge Nation.
Cancer Institute NSW Premier’s Award for Outstanding Cancer Researcher of the Year and in 2015 was appointed an inaugural Fellow of the Australian Academy of Health and Medical Sciences. She was one of three Finalists for the 2017 CSIRO Eureka Prize for Leadership in Innovation and Science. Professor Haber has a long and continuous record of peer-reviewed grant funding and an excellent track record with more than 175 journal publications. She is currently leading the Zero Childhood Cancer national child cancer personalised medicine program, which will enable all newly-diagnosed, high-risk childhood cancer patients in Australia, and all children who relapse following treatment, to have their therapy tailored to the specific genetic and biological characteristics of their individual tumour. The national clinical trial for this program was opened in September 2017.
Ms O’Keefe has spent her career in higher education, research and health organisations and has more than fifteen years’ experience in senior executive roles. She is a Board member of Vision2020 Australia, the BioMelbourne Network and the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology Governance Board. Previously, Ms O’Keefe was a member of the Council of the Victorian Cancer Agency for 6 years, a Ministerial appointment, including two years as a member of the VCA Clinical Trials Working Group and more recently a Ministerial appointment on the Victorian Department of Health’s Clinical Trail Research Consultative Council.
development and commercial roles in both the major pharmaceutical and biotech industry. After graduating as Senior Scholar in Medicine from Auckland University and working in General Practice Dr Tong joined Glaxo in NZ as Medical Director and subsequently worked in Singapore and London, in regional and global business development and commercial roles for Glaxo. Prior to coming to Melbourne, Warwick spent five years in Boston as SVP, Development, for Surface Logix Inc.
Professor Wallace is involved in the design and discovery of new materials for use in Energy and Health. In the Health area this involves using new materials to develop biocommunications from the molecular to skeletal domains in order to improve human performance. In the Energy area this involves use of new materials to transform and to store energy, including novel wearable and implantable energy systems for the use in Medical technologies. In order to facilitate the creation of functional devices from fundamental discoveries he has pioneered the development of 3D additive fabrication (including 3D printing) using advanced materials. He is committed to fundamental research and the translation of fundamental discoveries into practical applications. He is a passionate communicator, dedicated to explaining scientific advances to all in the community from the lay person to the specialist.
CBNS Annual Report 2017 49
g ove r nan c e
Professor Michelle Haber
Scientific Advisory Board The Scientific Advisory Board (SAB) has an independent mentoring and advisory role, providing strategic insight and commercial direction to the Centre. The SAB plays a key role in advising the Centre on the development of the strategic and commercialisation plans. The Board advises on patent versus publication strategy, and commercialisation and spin-out strategy as required. They assist in identifying intellectual property partnering and licensing opportunities and organisations with which the CBNS can ally. In 2017, the board members were refreshed. The SAB held a meeting on 4 July 2017. In addition to the core members of the SAB, there are temporary national and international members, including the CBNS Visiting Professor, who provide variation to the scientific mix of the SAB.
Professor Alan Rowan
Professor Alan Rowan has performed his research at the interface of chemistry and biology with seminal and pioneering work on processive catalysis and functional self-assembly. His latest scientific achievement has been the development of the first truly biomimetic hydrogel which mimics the mechanic and functional properties of the extracellular membrane. This scientific breakthrough is already now being developed commercially for wound dressing, drug therapeutic and cell growth, and has further established Professor Rowan as a truly innovative scientist, working toward understanding at the molecular level the functional of hierarchical materials and catalysis. Professor Rowan’s considerable scientific curiosity has resulted in him working in many areas, ranging from magnetic materials, single enzyme catalysis,
supramolecular catalysis through to nanometer-sized solar cells and photonic materials. In the last ten years, he developed the concept of processive catalysis, mimicking the natural exo- and endonucleases and demonstrated that a macrocyclic catalyst can thread onto and move along a polymer substrate in a highly efficient process. In January 2016, Professor Rowan joined the University of Queensland as the Director of the Australian Institute of Bioengineering and Nanotechnology. He previously led a research group at Radboud University’s Institute of Molecules and Materials, one of Europe’s leading research centres for the nanosciences. He was awarded an ARC Australian Laureate Fellowship to continue his work on novel biomimetic and dynamic materials.
Dr David Owen
Dr Owen is the Vice President of Research at Starpharma and has extensive experience in medicinal chemistry and biochemistry, and in managing teams focused on commercially directed drug discovery. He has held several positions in the biotech industry including Mimotopes, Cerylid and Glykoz and gathered extensive international experience in biotechnology and pharmaceutical research and development. Since
joining Starpharma Dr Owen has driven the drug delivery programs by developing and executing a number of successful proof-of-concept studies. The results from these studies have led to a number of commercial partnerships such as Stiefel a GSK company, Lilly and AstraZeneca, as well as driving Starpharma’s own internal drug delivery program focused on an improved dendrimer-docetaxel formulation.
Dr Julio Ribeiro
Dr Ribeiro completed his PhD in Medicine at UNSW in 1998. He then moved from academia to start a business carried at Sigma-Aldrich Pty. Ltd., Australia and NZ, where he has many executive roles, including technical support manager, sales manager and manager of a fine chemical division (SAFC ) in Australia and NZ. In 2006, Dr Ribeiro founded Inventia Pty Ltd, a fine chemical and biotechnology company. As Managing Director, Dr Ribeiro oversees R&D projects from conceptualisation to delivery. This includes the conception of projects, contracting scientists, daily operations and writing final reports based on scientists’ results. In its short period of existence, Inventia has
50 CBNS Annual Report 2017
attracted several R&D contracts. In 2012, Dr Ribeiro created Inventia Genetic Technologies Pty Ltd (IGT). A subsidiary of Inventia Pty Ltd. IGT is now Australian leading provider of bovine IVF for the beef farmers in QLD. IGT has been conducting several research projects in the field of bovine IVF with the objective of increasing the pregnancy rate; facilitate oocytes and embryo transport and development of new bovine IVF media. In 2012 Dr Ribeiro started the 3D Bioprinting project in partnership with UNSW that resulted in the creating of Inventia Life Science Pty Ltd that was created in 2013 to commercialise the 3D Bioprinting technology.
Professor Fariba Dehghani
Professor Dehghani is the Director of ARC Food Processing Training Centre and the director of Centre for Excellence for Advanced Food Enginomics at the University of Sydney, an Associate member of IChemE and a member of ARC College of Experts. She has been selected by Engineers Australia as one of the top 50 Engineers for innovation in research in 2016. She is a reputed researcher who has been instrumental in building an interdisciplinary research environment that stimulates the interface and intersect of engineering, science, business, medicine, pharmacy and agriculture. Her international team of researchers and industry partners have worked together to provide pragmatic, cost-effective and environmentally sustainable solutions to a diverse range of issues, with the aim of improving lives. Professor Dehghani’s research has made significant contributions to the design of advanced and environmentally friendly techniques for processing
materials; the extraction of high value and active compounds from natural resources for the treatment and prevention of chronic diseases such as infection and cardiovascular disease; and the synthesis of materials for musculoskeletal tissue repairs. Her research is highly regarded, not only in academia but by industry. She has established long-term collaborations with the food and biotech private sectors and acquired substantive funding from national and international competitive grant applications. She has published more than 250 papers and is co-inventor on 13 patents, including nine with potential end users. She has mentored more than 45 postgraduates, more than 100 honours/master researchers and several successful entrepreneurs. Her research led to the establishment of a start-up Company, Trimph Pty Ltd, in 2015 by receiving more than $2 M fund from a private investor and government. The product form this company has recently received approval from the TGA for the clinical application.
Professor Jagat R Kanwar
His research combines Immunology with state of the art and cutting-edge techniques in Molecular Biology, Biochemistry, Nanobiotechnology and visualisation to investigate the pathways in which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue-based coculture models for cancers, microbial infections; autoimmune diseases; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed by his group. Kanwar’s main research objective is to understand and target the mechanisms involved at the molecular and subcellular level which gives us an edge over the prevalent targeting techniques. He carries out both academic and commercial research projects and develops new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems. His recent research focus is on locked nucleic acid (LNA) LNA-modified aptamers conjugated “double targeted nano-bullet nanocapsules” with natural antitumour proteins which specifically target cancer cells.
2017 temporary members Professor Wolfgang Parak
Professor Wolfgang Parak is Professor of Experimental Physics at the PhilippsUniversity of Marburg, Germany, Head of the Biofunctional Nanomaterials Unit at CIC biomaGUNE, San Sebastian, Spain and Associate Editor of ACS Nano. He has significantly contributed to the development of new surface chemistries of inorganic nanoparticles and towards the characterisation of their physicochemical properties.
Professor Justin Gooding
Professor Justin Gooding is a Fellow of the Australian Academy of Science and is currently an ARC Australian Laureate Fellow and the co-director of the Australian Centre for NanoMedicine. He is also editor-in-chief of the journal ACS Sensors. At UNSW, Professor Gooding leads a team of researchers interested in surface modification and nanotechnology for biosensors, biomaterials, electron transfer and medical applications.
Professor Michelle S. Bradbury
Professor Michelle S. Bradbury is currently a Professor of Radiology at the Gerstner Sloan Kettering Graduate School and Weill Medical College of Cornell University and holds a Joint Appointment in the Molecular Pharmacology Program at Sloan Kettering Institute. Her work has focused on the co-development and translation of tumour-selective, ultrasmall particle-based imaging tools (C dots) to the clinic for surgical and other medical oncology applications.
CBNS Annual Report 2017 51
g ove r nan c e
Professor Jagat R Kanwar is the Head and Team Leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Professor Kanwar has an international reputation and expertise in investigating fundamental and applied molecular signalling aspects of the pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He has more than 150 research publications in high impact factor and peer-reviewed international journals, 27 book chapters and 3 edited books. Prof Kanwar’s research has generated several patents/PCTs with more than five licensed patents for commercialisation to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral and systemic drug delivery of a range of natural bioactive and biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting survivin, HIF-1α and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders.
52 CBNS Annual Report 2017
CBNS Annual Report 2017 53
p e r fo r man c e
Performance
54 CBNS Annual Report 2017
Mid-term Review On Wednesday 30 August 2017, the ARC conducted a site visit to Monash Institute of Pharmaceutical Sciences (MIPS) for the Centre’s mid-term review.
The mid-term review marks our progress towards the Centre’s research and engagement goals, since its establishment in 2014. The review assessed the Centre’s performance against the Terms of Reference, which are based on the objectives of the ARC Centres of Excellence scheme as outlined in the Funding Rules and the Centre’s own objectives as outlined in the Proposal. The ARC site visit was structured around informal discussions between the Review Panel and representative members of the Centre such as the Centre Director and Deputy Director, CIs and PIs, Centre staff and students as well as members of the Advisory Board. Furthermore, selected stakeholders and key personnel of the Administering
Organisation including the Vice-Provost (Research) formed part of the team that supported the mid-term review process. The ARC Review Panel was comprised of: • Dr Fiona Cameron, Executive Director (Biological Sciences and Biotechnology), ARC – Chair • Professor Keith Nugent, La Trobe University • Professor Paul Stoddart, Swinburne University of Technology The site visit included a tour of the research facilities, where we showcased the top 2017 publications from across the nodes demonstrating the successful collaborative research at the Centre. We also utilised this occasion to demonstrate the Centre’s strategic research investment such as the designled 3D VR immersive techniques to visualise the processes within a cell. Members of the Review Panel were given the opportunity to wear 3D VR headsets and embark on a journey into a cell. This new technology allows multiple scientists to see inside a human cell at the same time, giving researchers
a three-dimensional tool to improve doctor interaction and help analyse how cancer drugs work. See page 12 for more details on this project. We are delighted to announce that the CBNS has satisfactorily met the objectives of the ARC Centres of Excellence scheme. We can proudly state that our own previously defined aims and objectives were also met. Monash University and the Centre will therefore receive the remaining current allocation of ARC Centre funding to 30 December 2020. The Review Report arising from the site visit was very positive and the Centre is working towards addressing the recommendations from the Review Panel. A very big thank you to everyone for their support in preparing for the site visit and to all CBNS members who participated in the discussions with the ARC Review Panel. Your contributions were much appreciated. We look forward to more successful research, collaboration and engagement in the upcoming three years.
p e r fo r man c e
The ARC undertakes rigorous and comprehensive external reviews of ARC Centres of Excellence to ensure that research progress is satisfactory, the Centres are meeting the ARC’s expectations in relation to operations and national focus and to provide feedback to the Centres on their performance.
CBNS Annual Report 2017 55
Performance and KPIs The CBNS achievements are evaluated by the Australian Research Council on an annual basis with a formal review in the third year (2017, see page 55 for more information). CBNS performance is assessed against key performance indicators that were set at the commencement of the Centre. These cover the traditional research metrics of outputs like journal publications and conference presentations. There are also metrics that cover the interdisciplinarity of CBNS research, new research partnerships, measures of esteem, public awareness and student and ECR mentoring. The CBNS is progressing well and has exceeded almost all of the targets for 2017. The KPIs for 2017 are summarised in this infographic. It shows the targets for each of the KPI areas as well as our actual achievements.
Research findings: Number of research outputs: Patents (filed), target: 0
actual: 8
Book chapters [book] target: 0
Journal publications, target: 50
actual: 5 Refereed conference proceedings target: 15 actual: 4
actual: 228 Quality of research outputs: Publications impact factor >10 target: 7 actual: 24 % journals articles impact factor >2 target: 50%
actual: 93%
New research fellowships
Membership on editorial boards,
target: 2 actual:
target: 6
13
Number and nature of commentaries about the Centre’s achievements
Number of invited talks/papers/ keynote lectures given at major international meetings, target: 30 Media releases target: 7
Articles, target: 4
actual: 99
target: 10
actual: 19
56 CBNS Annual Report 2017
Postgraduates/postdocs working on cross node or interdisciplinary projects target: 6
actual: 60
actual: 24
Collaboration and interdisciplinarity:
Research outputs featuring co-authorship between nodes
actual: 57
actual: 105
Miscellaneous: Video material produced and publicised each year on the website target: >10mins
actual: 31mins 47s
Research training and professional education:
Number of professional training courses for staff and postgraduate students attended target: 10
actual: 32
Number of Centre attendees at all training/ development courses offered by the Centre target: 25 actual:
Number of new postgrads working on core CBNS research target: 8
Number of postgrad completions, by students working on core CBNS research, target: 10
actual: 22
actual: 24
Number of students mentored target: 40 actual: 175 Number of mentoring programs offered by the Centre target: 6 actual: 5
290
Number of new postdocs recruited to the CBNS working on core CBNS research target: 4
actual: 20
Number of new Honours students working on core CBNS research target: 12
actual: 7
Number of ECRs (within five years of completing PhD) working on core CBNS research target: 12 actual:
77
International, national and regional links and networks: Examples of relevant interdisciplinary research supported by the Centre:
Number of international visitors and visiting fellows target: 15
Number of national and international workshops held/ organised by the Centre, target: 2
Number of visits to overseas laboratories and facilities target: 30
actual: 81
actual: 9
actual: 40
Publications that result from CoE interdisciplinary research target: 3 actual: 38 Operational interdisciplinary projects in the research program target: 2 actual: 93
Number of government, industry and business community briefings target: 5
actual: 25
Number of website hits (page views) target: 20,000
actual: 50,128
Number and nature of public awareness/ outreach programs target: 10
Number of talks given by Centre staff open to the public, target: 10
actual: 23
actual: 88
CBNS Annual Report 2017 57
p e r fo r man c e
End-user links:
Financial Report 2017 Income and Expenditure Income
In Kind contributions 2017 ($)
Institution
2017 ($)
ARC Grant Income (indexed)
4,020,701
Monash University
1,276,381
Collaborating organisation contribution
1,502,606
University of Melbourne
1,144,738
Total income
5,523,307
University of New South Wales
740,000
Expenditure
2017 ($)
University of Queensland
707,429
Salaries 3,686,069
University of South Australia
772,955
Equipment 165,863
Australian Synchrotron
Consumables and maintenance
Australian Nuclear Science and Technology Organisation 92,800
1,170,189
Travela 371,754 Scholarships and Student support
433,352
Administration 26,995 Otherb 169,116 Total expenditure
6,023,338
Carry forward
5,168,643
1,180,224
Sungkyunkwan University
45,000
University of Wisconsin-Madison
15,000
University of Warwick
62,000
University of Nottingham
60,000
Imperial College London
5,000
Memorial Sloan-Kettering Cancer Center
65,000
Carry forward adjustment 286,884
University College Dublin
Balance 4,955,496
University of California, Santa Barbara
26,000
a includes accommodation and conference expenses b includes media consultant, website development, training courses c upon reconciliation of previous reports, the carry forward has been adjusted to report on income amounts incorrectly reported in prior years.
Columbia University Medical Center
69,810
c
Cash contributions Institution
2017 ($)
Monash University
376,000
University of Melbourne
333,019
University of New South Wales
323,252
University of Queensland
290,952
University of South Australia
179,383
Total 1,502,606
58 CBNS Annual Report 2017
5,000
Total 6,267,337
Awards, Memberships and Grant Success During 2017, members at all levels were recognised for their contribution to the Centre, as well as their hard work and dedication to science and pushing the boundaries of understanding in the area of bio-nanoscience. This section includes some of the highlights. See page 60 and 61 for a comprehensive list.
Highlights
Leadership in Innovation in NSW CBNS CI Professor Maria Kavallaris (UNSW) won a 2017 NSW Premier’s Prize for Science and Engineering in October this year. Professor Kavallaris won the ‘Leadership in Innovation in NSW’ Prize for a career encompassing the discovery of clinically important mechanisms of cancer drug resistance and the development of less toxic cancer therapies using nanotechnology. The NSW Premier’s Prizes for Science and Engineering recognise outstanding researchers in science and engineering for cuttingedge work that has led to economic, environmental, health, social or technological benefits for New South Wales. Fellow of The Australian Academy of Technological Sciences and Engineering (ATSE) In October 2017, Professor Mark Kendall, CBNS CI and Node Leader (UQ), was elected a Fellow of The Australian Academy of Technological Sciences and Engineering. Professor Kendall is one of 25 Fellows to be elected this year.
Australian Museum Eureka Prize Professor Justin Gooding, CBNS CI and Node Leader (UNSW), was presented with the 2017 University of Technology Sydney Eureka Prize for Outstanding Mentor of Young Researchers during the Australian Museum Eureka Prizes 2017 at Sydney Town Hall in August. Through a program of individualised mentorship, Professor Gooding has trained and developed an all-new breed of research leader in bionanotechnology and nanomedicine. ARC Future Fellowship Dr John Quinn (Monash) was awarded the 2017 ARC Future Fellowship in June this year. Dr Quinn is harnessing nanomaterials to stimulate specific sub-cellular processes that could potentially be used to deliver signalling molecules for agricultural, pharmaceutical and veterinary applications. ARC Industrial Transformation Training Centre CBNS CI Associate Professor Kris Thurecht (UQ) is part of the new ARC Training Centre for Innovation in Biomedical Imaging Technology. This Centre expects to train 20 industryready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to develop ‘smart’ probes and ‘smart’ scanning, harnessing the digital revolution for better, cost effective diagnostic imaging and improved health outcomes.
NHMRC Program Grant CBNS Deputy Director Frank Caruso (Melbourne) and CBNS CI Professor Stephen Kent (Melbourne) received a major NHMRC Program Grant for their collaborative project “Addressing the Major Challenges in HIV Vaccine and Cure Research”. The grant will support a five-year program to tackle priority areas in HIV prevention, management and cure discovery. Garnett Passe and Rodney Williams Memorial Foundation (GPRWMF) CBNS CI and Node Leader Professor Benjamin Thierry (UniSA) has been awarded a conjoint grant from the Garnett Passe and Rodney Williams Memorial Foundation. The GPRWMF offers a suite of Awards and Grants to scientists and clinical practitioners in otolaryngology, head & neck surgery, to support career pathways and promote the development of related products and technologies.
p e r fo r man c e
Fellow of The Australian National Academy of Science CBNS Director Professor Tom Davis (Monash) was elected a Fellow of The Australian National Academy of Science. Professor Davis was one of 21 distinguished scientists announced on 22 May 2017 as new Fellows. His scientific contributions have embraced polymerisation kinetics, nanostructured films, nanoparticles, protein conjugates, nanoparticle enhanced bio-imaging, gene delivery and targeted therapeutics.
CBNS Annual Report 2017 59
Awards
Editor of Journals
Grant Success
Professor Frank Caruso (Melbourne) Langmuir Lectureship Award, American Chemical Society
Professor Justin Gooding (UNSW) Inaugural Editor-in-Chief of the American Chemical Society Journal, ACS Sensors
During 2017, over $55M in additional funding was secured to further support research being undertaken at the Centre. This funding reinforces the collaborative nature and expertise of CBNS researchers. Details of grant successes are as follows:
Professor Tom Davis (Monash) Fellow of The Australian National Academy of Science
Member of Editorial Boards Professor Justin Gooding (UNSW) ACS journal Bioconjugate Chemistry
MDPI journal Nanomaterials
ARC grants The following CBNS researchers secured over $13M in combined grant funding with eight ARC grants: Industrial Transformation Training Centre, Discovery Project and Linkage Infrastructure, Equipment and Facilities.
Wiley journal Electroanalysis
Professor Ben Boyd (Monash)
Wiley-VCH journal Chemistry – A European Journal
Professor Frank Caruso (Melbourne)
Wiley-VCH journal ChemElectroChem
Professor Tom Davis (Monash)
University of Technology Sydney Eureka Prize for Outstanding Mentor of Young Researchers
Professor Chris Porter (Monash) Journal of Pharmaceutical Sciences
Dr Angus Johnston (Monash)
UNSW Innovation award in Enterprise award in engagement
Journal of Pharmacy and Pharmacology
Professor Rob Parton (UQ)
Molecular Pharmaceutics
Professor Chris Porter (Monash)
Pharmaceutical Research
Professor Pall Thordarson (UNSW)
Professor Justin Gooding (UNSW) Bertram Dillon Steel Lectureship from University of Queensland School of Chemistry Katsumi Niki Prize in Bioelectrochemistry from the International Society of Electrochemistry Special Commendation, Australian Council for Graduate Research Award for Excellence in Promoting Industry Engagement in Graduate Research
Professor Maria Kavallaris (UNSW) 2017 NSW Premier’s Prize for Science and Engineering Dr Yiming Ma (UQ) Eudragit Award Professor Chris Porter (Monash) 2017 Australasian Pharmaceutical Science Association medallist (APSA) Professor Clive Prestidge (UniSA) Director of the Australian Controlled Release Society Co-Director of the Australian Bioactive Compounds Centre Dr. Md. Arifur Rahim 2017 Reviewer Excellence Award Dr Yi (David) Yu (Melbourne) 2017 Chemistry of Materials Reviewer Award
Elected Fellows Professor Mark Kendall (UQ) Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE) Professor Pall Thordarson (UNSW) Fellow of the Royal Society of Chemistry (RSC)
Elsevier journal Sensors and Actuators B Royal Society of Chemistry journal Chemical Sciences MDPI journal Biosensors
Professor Clive Prestidge (UniSA) Journal of Liposome Research (International advisory board) Mesoporous Biomaterials (International advisory board) AAPS Open Professor Benjamin Thierry (UniSA) Plos One Scientific Reports
Committee and other memberships Professor Frank Caruso (Melbourne) Distinguished Academic Awards Committee – The University of Melbourne Lloyd Rees Lecture Awards Committee – Australian Academy of Science Research Advisory Committee, Institute for Future Environments – Queensland Institute of Technology Scientific Advisory Board, LEO Center for Cutaneous Drug Delivery – University of Copenhagen
Professor Stephen Kent (UNSW)
Associate Professor Kris Thurecht (UQ) Professor Andrew Whittaker (UQ)
Australian Competitive Grants Register (ACGR) grants The following CBNS researchers secured $31M in combined grant funding with nine National Health and Medical Research Council (NHMRC) grants: Project Grant and Program Grant. Funding was also awarded from the Garnett Passe and Rodney Williams Memorial Foundation. Professor Frank Caruso (Melbourne) Professor Edmund Crampin (Melbourne) Professor Stephen Kent (Melbourne) Professor Rob Parton (UQ) Dr John Quinn (Monash) Dr Hang Ta (UQ) Professor Benjamin Thierry (UniSA)
Public sector grants Over $2M through five separate public sector grants were secured by the following CBNS researchers:
Working Party on Australia-Germany Polymer Interactions – AustraliaGermany Advisory Group
Professor Justin Gooding (UNSW)
Ms Linda Hong (Monash) Young Scientist Committee for the Controlled Release Society
Professor Benjamin Thierry (UniSA)
Dr Yi Ju (Melbourne) Chinese Association of Professionals and Scholars, Australia
60 CBNS Annual Report 2017
Professor Edmund Crampin (Melbourne)
Professor Chris Porter (Monash) Professor Clive Prestidge (UniSA) Professor Pall Thordarson (UNSW)
Professor Ben Boyd (Monash) Dr Angus Johnston (Monash) Professor Stephen Kent (Melbourne) Professor Maria Kavallaris (UNSW) Professor Chris Porter (Monash) Professor Clive Prestidge (UniSA) Professor Benjamin Thierry (UniSA) Dr Adam Wheatley (Melbourne)
Other grants The following CBNS researchers secured over $3M in combined funding with twenty additional grants: Dr Mattias Björnmalm (former postdoc at Melbourne, now at Imperial College London) Professor Ben Boyd (Monash) Professor Frank Caruso (Melbourne) Dr Simon Corrie (Monash) Professor Edmund Crampin (Melbourne) Professor Maria Kavallaris (UNSW) Professor Stephen Kent (Melbourne) Ms Emily Pilkington (Monash) Professor Benjamin Thierry (UniSA) Associate Professor Kris Thurecht (UQ) Dr Orazio Vittorio (UNSW)
National Health and Medical Research Council (NHMRC) Fellowships The following CBNS researchers secured over $3M through NHMRC Fellowships: Professor Frank Caruso (Melbourne) NHMRC Senior Principal Research Fellowship – Advancing Nanomedicine through Particle Technology Dr Jacob Coffey (former PhD student and postdoc at the AIBN, UQ) NHMRC CJ Martin Biomedical Fellowship – Administering oral vaccines and modulating gastrointestinal immunity using a new physical device Dr Angus Johnston (Monash) NHMRC Career Development Fellowship – Improving Drug Delivery Using Nanotechnology Professor Stephen Kent (Melbourne) NHMRC Senior Principal Research Fellowship – Improved HIV and Influenza Vaccines Associate Professor Kris Thurecht (UQ) NHMRC Career Development Fellowship – Next generation imaging to bridge the knowledge gap in nanomedicine
ARC Fellowships The following CBNS researchers secured over $1.2M through ARC Fellowships: Dr Nghia Truong Phuoc (Monash) ARC Discovery Early Career Researcher Award (DECRA) Dr John Quinn (Monash) ARC Future Fellowship
Fellowships The following CBNS researchers secured over $370,000 through additional Fellowships: Dr Daniel Yuen (Monash) STEM+ Business Fellowship Dr Leo Noi (Monash) STEM+ Business Fellowship Ms Christina Cortez-Jugo (Melbourne) Melbourne Research Fellowship (Career Interruption)
Student Awards Tara Alvarez (Monash) Runner up prize for poster presentation/3-minute presentation at the International Nanomedicine Conference Stefan Bader (Olivia Newton-John Cancer Research Institute, Monash) First prize for poster presentation/ 3-minute presentation at the International Nanomedicine Conference Poster Prize ‘Best Honours/1st year poster presentation – runner up’ at the Comprehensive Cancer Student Symposium 2017 Poster Prize ‘Highly-commended in the First Year PhD/Equivalent Poster Presentation Award’ at the 8th Annual ASMR VIC Student Research Symposium Joanne Du (Monash) 2017 Poster Award Winner at the Australasian Colloids and Interface Society (ACIS2017, Coffs Harbour) 2017 Australian Nanotechnology Network conference bursary (ACIS2017, Coffs Harbour) Paulina Ramírez García (Monash) Best Presentation Award at the ASCEPT Neuropharmacology and Drug Discovery ECR Symposium Joshua Glass (Melbourne) Seqiris (a CSL company) PhD Oration Award (runner up) for his PhD Completion seminar entitled “The interface of nanotechnology and the human immune system”. Song Yang Khor (Monash) Best Oral Presentation by a PhD Student award at PolymerVic 2017
CBNS Annual Report 2017 61
p e r fo r man c e
Industry grants The following CBNS researchers secured over $4.2M in combined funding with ten industry grants:
CBNS Personnel Chief Investigators Professor Tom Davis ARC Australian Laureate Fellow, CBNS Director and Node Leader, Delivery Systems, Imaging Technologies Monash University
Associate Professor Matthew Kearnes ARC Future Fellow, Social Dimensions of Bio-Nano Science and Technology University of New South Wales
Professor Frank Caruso ARC Australian Laureate Fellow, CBNS Deputy Director and Node Leader, Delivery Systems, Imaging Technologies, Vaccines University of Melbourne
Professor Mark Kendall CBNS Node Leader, Vaccines University of Queensland
Professor Justin Gooding CBNS Node Leader, Sensors and Diagnostics University of New South Wales
Professor Stephen Kent Vaccines, Delivery Systems University of Melbourne
Professor Nicolas Voelcker CBNS Node Leader, Delivery Systems, Sensors and Diagnostics University of South Australia Effective until 14 February 2017 Dr Angus Johnston ARC Future Fellow, Delivery Systems, Vaccines Monash University
Professor Christopher Porter Vaccines, Delivery Systems Monash University
Professor Benjamin Boyd ARC Future Fellow, Delivery Systems, Sensors and Diagnostics, Vaccines Monash University
Professor Andrew Whittaker ARC Australian Professorial Fellow, Imaging Technologies University of Queensland
Professor Maria Kavallaris Delivery Systems, Sensors and Diagnostics University of New South Wales
Professor Edmund Crampin Systems Biology and Computational Modelling, Delivery Systems University of Melbourne
62 CBNS Annual Report 2017
Professor Rob Parton Delivery Systems, Vaccines University of Queensland
Professor Pall Thordarson ARC Future Fellow, Delivery Systems, Imaging Technologies University of New South Wales Associate Professor Kris Thurecht ARC Future Fellow, Delivery Systems, Imaging Technologies, Vaccines University of Queensland Dr Simon Corrie ARC DECRA Fellow, Sensors and Diagnostics University of Queensland
Associate Professor John McGhee Visualisation University of New South Wales
Dr Beatriz Prieto-Simรณn Sensors and Diagnostics University of South Australia Effective until 14 February 2017
Professor Clive Prestidge Nanomedicine, Drug Formulation and Delivery University of South Australia Effective from 14 February 2017 Professor Benjamin Thierry CBNS Node Leader, Biodiagnostic Technologies University of South Australia Effective from 14 February 2017
Partner Investigators
Professor Cameron Alexander Head of Division of Drug Delivery and Tissue Engineering, Faculty of Science University of Nottingham, UK
Professor Nigel Bunnett Delivery Systems Columbia University Medical Center, USA
Professor Kenneth Dawson Director of the Centre for BioNano Interactions, Chair of Physical Chemistry University College Dublin, Ireland
Dr Ivan Greguric Head of Radiochemistry Australian Nuclear Science and Technology Organisation, Australia Professor David Haddleton Head of Inorganic and Materials Section, Department of Chemistry University of Warwick, UK
Professor Craig Hawker Director of the California Nanosystems Institute, Dow Materials Institute, Co-Director of the Materials Research Lab University of California, Santa Barbara, USA
Professor Doo Sung Lee Director Theranostic Macromolecules Research Center, Dean of College of Engineering Sungkyunkwan University, South Korea Professor Jason Lewis Vice Chair for Research, Chief of the Radiochemistry and Imaging Sciences Service Memorial Sloan Kettering Cancer Center, USA Professor Molly Stevens Research Director for Biomedical Material Sciences, Institute of Biomedical Engineering Imperial College London, UK
p e r fo r man c e
Professor Nicholas Abbott John T. and Magdalen L. Sobota Professor, Hilldale Professor, and Director, Materials Research and Engineering Center, Chemical and Biological Engineering University of Wisconsin, Madison, USA
CBNS Annual Report 2017 63
Research staff Postdoctoral and other research staff Dr Maria Alba-Martin Researcher University of South Australia Dr Lakmali Atapattu Research Officer University of New South Wales Dr Padmavathy Bakthavathsalam Trust-India Fellow University of New South Wales Dr Michele Bastiani Researcher The University of Queensland Dr Nadja Bertleff-Zieschang Postdoctoral Researcher Melbourne University Dr Quinn Besford Postdoctoral Researcher Melbourne University Dr Mattias Björnmalm Postdoctoral Researcher Melbourne University Dr Simone Bonaccorsi Scientia PhD University of New South Wales Dr Zhen Cai Researcher University of South Australia Dr Meritxell Canals Research Fellow Monash University Dr Simona Carbone Research Fellow Monash University Dr Chia-Chi Chen Researcher University of South Australia Dr Pavel Cherepanov Postdoctoral Fellow Melbourne University Dr Jacob Coffey Research Fellow The University of Queensland Dr Christina Cortez-Jugo Postdoctoral Researcher Melbourne University Dr Aidan Cousins Researcher University of South Australia Dr Michael Crichton Researcher The University of Queensland Dr Peter Cudmore Postdoctoral Researcher Melbourne University
64 CBNS Annual Report 2017
Dr Robert De Rose Research Fellow Monash University
Dr Luojuan Hu Research Fellow Monash University
Dr Adam Martin Researcher University of New South Wales
Dr Alexandra Depelsenaire Postdoctoral Researcher – ECR The University of Queensland
Dr Pie Huda Postdoctoral Fellow The University of Queensland
Dr Joshua McCarroll Research Fellow/Project Leader University of New South Wales
Dr Francesca Ercole Research Fellow Monash University
Dr Zil e Huma Research Fellow Monash University
Dr Lars Esser Postdoctoral Researcher Monash University
Dr Daniel Hurley Postdoctoral Researcher Melbourne University
Dr Andrew McGrath Postdoctoral Researcher – ECR University of New South Wales
Dr Christian Fercher Research Fellow The University of Queensland
Dr Paul Joyce Research Associate University of South Australia
Dr Germain Fernando Senior Research Fellow The University of Queensland
Dr Yi (David) Ju Postdoctoral Researcher Melbourne University
Dr Christian Fersher Postdoctoral Researcher UQ
Dr Aleksandr Kakinen Postdoctoral Research Fellow Monash University
Dr Christopher Fife Research Officer University of New South Wales
Dr Pu-Chun Ke Senior Research Fellow Monash University
Dr Nicholas Fletcher Postdoctoral Fellow The University of Queensland
Dr Kristian Kempe NHMRC – ARC Dementia Research Development Fellow Monash University
Dr Changkui Fu Research Fellow The University of Queensland Dr Adrian Fuchs Researcher The University of Queensland Dr Vinicius Goncales Research Fellow University of New South Wales Dr Jeroen Goos Researcher Monash University Dr Bin Guan Research Associate University of South Australia Dr Yi Guo Researcher The University of Queensland Dr Hanna Gustafsson Research Associate University of South Australia Dr Johan Gustafsson Research Associate University of South Australia Dr Thomas Hall Senior Research Fellow The University of Queensland Dr Sifei Han Research Fellow Monash University Dr Zachary Houston Research Fellow The University of Queensland
Dr Samantha Kristufek Postdoctoral Researcher Melbourne University Dr Declan Kuch Researcher University of New South Wales Dr David Ladd Postdoctoral Research Fellow Melbourne University Dr Alistair Laos Postdoctoral Researcher University of New South Wales Dr Jianhua Li Postdoctoral Researcher Melbourne University Dr Yuhuan Li Postdoctoral Researcher Monash University Dr Andrew Lilja Researcher University of New South Wales Dr Fabio Lisi Postdoctoral Researcher – ECR University of New South Wales Dr Qingtao (Jason) Liu Research Fellow Monash University Dr Friederike Mansfeld Senior Researcher University of New South Wales
Dr Dharmini Mehta Research Fellow Monash University Dr Georgia Miller Researcher University of New South Wales Dr Ernesto Moles Research Officer University of New South Wales Dr Ka Fung (Leo) Noi Research Fellow Monash University Dr Anna Oszmiana Research Associate University of South Australia Dr Stephen Parker Postdoctoral Researcher – ECR University of New South Wales Dr Maryam Parviz Postdoctoral Researcher University of New South Wales Dr Zhao Peishen Research Fellow Monash University Dr Hui Peng Researcher The University of Queensland Dr Nghia Truong Phuoc Research Fellow Monash University Dr Daniel Poole Research Fellow Monash University Dr Sela Pouha Researcher University of New South Wales Dr Simon Puttick Research Fellow in Molecular Imaging The University of Queensland Dr Ruirui Qiao Research Fellow Monash University Dr Tim Quach Research Fellow Monash University Dr John Quinn Senior Research Fellow Monash University
Dr Md Arifur Rahim Postdoctoral Researcher Melbourne University
Dr Robert Utama Research Fellow University of New South Wales
Dr Wei (Joyce) Zhao Research Fellow The University of Queensland
Dr Bin Guan Research Associate University of South Australia
Dr Shasha Rao Research Associate – ECR University of South Australia
Dr Nicholas Veldhuis Research Fellow Monash University
Dr Hanna Gustafsson Research Associate University of South Australia
Dr Joseph Richardson Postdoctoral Researcher Melbourne University
Dr Orazio Vittorio Research Fellow/Project Leader University of New South Wales
Dr Yuanhui Zheng UNSW Vice Chancellor’s Postdoctoral Research Fellow University of New South Wales
Dr Iman Roohani NHMRC Fellow University of New South Wales Dr Priyank Shenoy Research Fellow Monash University Dr Alexander Soeriyadi Research Associate (NHMRC Early Career Fellow) University of New South Wales Dr Parisa Sowti Postdoctoral Researcher University of New South Wales Dr Johnston Stuart Postdoctoral Researcher Melbourne University Dr Adrian Sulistio Research Fellow Monash University/Polyactiva Dr Hang Ta Researcher The University of Queensland Dr Angel Tan Research Fellow Monash University Dr Roya Tavallaie Research Fellow University of New South Wales Dr Wee Siang Teo Researcher University of New South Wales Dr Nicky Thomas Research Associate (NHMRC Research Fellow) University of South Australia
Dr Ting Yi Wang Postdoctoral Researcher Melbourne University Dr Wenqian Wang Postdoctoral Researcher University of New South Wales Dr Adam Wheatley Postdoctoral Researcher Melbourne University Dr Michael Whittaker Senior Research Fellow Monash University Dr Marnie Winter Postdoctoral Researcher/ PhD student University of South Australia Dr Jonathan Wojciechowski Postdoctoral Researcher University of New South Wales Dr Chin (Ken) Wong Postdoctoral Researcher University of New South Wales Dr Chih-Tsung Yang Postdoctoral Researcher/ PhD student University of South Australia
Ms Christiana (Christie) Agyei-Yeboah Research Assistant The University of Queensland Ms Sheilajen (Vinca) Alcantara Research Assistant Melbourne University Ms Katie Ardipradja Research Associate Monash University Dr Lakmali Atapattu Research Officer University of New South Wales Mr Benjamin John Bailey Research Assistant University of New South Wales Ms Juliette Bignard Research Staff Monash University Mr Zhe Chen Research Assistant Monash University Mr Roey Elnathan Adjunct Research Fellow University of South Australia
Dr Ying Yang Postdoctoral Researcher University of New South Wales
Ms Robyn Esterbauer Research Assistant Melbourne University
Dr Daniel Yuen Research Fellow Monash University
Ms Orlagh Feeney Research Associate Monash University
Dr Gyeongwon Yun Postdoctoral Fellow Melbourne University
Mr Charles Ferguson Immunoem Facility Manager The University of Queensland
Dr Cheng Zhang Postdoctoral Research Fellow The University of Queensland
Ms Victoria Gernedl Research Trainee University of New South Wales
Dr Robert Healey Research Assistant University of New South Wales Dr Paul Joyce Research Associate University of South Australia Ms Hannah Kelly Research Assistant Melbourne University Ms Kathleen Kimpton Senior Research Assistant University of New South Wales Ms May Lai Research Assistant Monash University Ms Marion Le Grand Research Fellow University of New South Wales Mr Christopher Lumb Research Assistant Monash University Ms Ayaat Mahmoud Research Assistant Monash University Mr Nick Martel Research Assistant The University of Queensland Dr Susan Nixon Lab Manager The University of Queensland Ms Rose-Marie Olsson Senior Research Assistant University of New South Wales Dr Anna Oszmiana Research Associate University of South Australia Ms Amelia Parker Research Officer University of New South Wales
p e r fo r man c e
Dr Katharina Richter Research Associate University of South Australia
Research Support Staff
Dr Johan Gustafsson Research Associate University of South Australia
CBNS Annual Report 2017 65
Mr Karl Peressin Research Assistant University of South Australia Dr Joshua Peterson Lab Manager University of New South Wales Mr James Rae Research Assistant The University of Queensland Mr Jeffri Retamal Santibanez Research Assistant Monash University Dr Katharina Richter Research Associate University of South Australia Ms Ayame Saito Research Assistant Monash University Mrs Sona Samuels Research Assistant University of New South Wales Ms Danielle Senschyn Research Assistant Monash University Mr Sougata Sinha Research Associate University of South Australia Ms Jenny Tran Research Assistant Melbourne University Ms Efremova Varvara Research Assistant University of New South Wales Mr James Wilmot Research Assistant University of New South Wales Mr Jin Zhang Research Assistant The University of Queensland
Students PhD students Mr Hazem Abdelmaksoud University of South Australia Ms Dewan Ahkter The University of Queensland Mr Md Mahbub Alam The University of Queensland Ms Yassamin Albayaty University of South Australia Mr Nicholas Alcaraz Monash University Mr Mohammadreza Alizadeh Ghodsi University of South Australia Ms Fida’a Alshawawreh University of New South Wales Ms Tara Alvarez Monash University
66 CBNS Annual Report 2017
Ms Fernanda Ana-Sosa-Batiz Melbourne University
Mr Jesse Di Cello Monash University
Mr WooRam Jung The University of Queensland
Mr Adit Ardana The University of Queensland
Mr Eric Du University of New South Wales
Ms Mohadesseh Kahram University of New South Wales
Mr Yosef Arman University of New South Wales
Ms Joanne Du Monash University
Ms Hannah Kelly Melbourne University
Mr Arunpandian Balaji The University of Queensland
Ms Genevieve Duche University of New South Wales
Ms Vidhishri Kesarwani Monash University
Mr Gregory Bass Melbourne University
Ms Gayathri Ediriweera The University of Queensland
Mr Song Yang Khor Monash University
Dr Nathan Boase The University of Queensland
Ms Mona Elsemary University of South Australia
Ms Ana Klisuric University of South Australia
Mr Achal Bhatt University of South Australia
Mr Sanjun Fan University of New South Wales
Ms Ruby Kochappan Monash University
Mr Brandon Binnie The University of Queensland
Mr Matthew Faria Melbourne University
Ms Given Lee Monash University
Mr Mehran Bolourian Kashi University of New South Wales
Ms Ava Faridi Monash University
Mr Hong Seng (Nick) Lee The University of Queensland
Ms Caterina Brighi The University of Queensland
Ms Helen Forgham University of New South Wales
Ms Tang Li Monash University
Mr Daniel Brundel Monash University
Ms Anna Gemmell The University of Queensland
Ms Jianxin Lily Lian University of New South Wales
Ms Enyuan Cao Monash University
Mr Joshua Glass Melbourne University
Mr Gan Lin Melbourne University
Mr Lachlan Carter University of New South Wales
Mr James Grace Monash University
Mr Zhixing Lin Melbourne University
Dr David Chang University of New South Wales
Ms Gracia Gracia Monash University
Mr Yi Liu Melbourne University
Mr Patrick Chang University of South Australia
Mr Zhaobin Guo University of South Australia
Ms Sarah Lloyd Melbourne University
Mr Ao Chen The University of Queensland
Mr Fei Han University of New South Wales
Ms Joanne Ly Monash University
Mr Hsiang-Sheng Chen University of New South Wales
Ms Yiyuan Han Melbourne University
Mr Yutian Ma Melbourne University
Ms Liyu Chen The University of Queensland
Mr Md. Musfizur Hassan University of New South Wales
Ms Zerong Ma University of New South Wales
Ms Rinku Chhasatia University of South Australia
Ms Linda Hong Monash University
Ms Saji Maghrebi University of South Australia
Ms Evon Chong Monash University
Mr Douglas Howard University of South Australia
Ms Quynh Mai Monash University
Mr Joshua Conner Monash University
Ms Yingjie Hu Melbourne University
Ms Sharmin Maitry University of New South Wales
Ms Ewa Czuba Melbourne University
Mr Gabriel Huynh Monash University
Ms Tahlia Meola University of South Australia
Ms Qiong (Ada) Dai Melbourne University
Ms Susan Ireland University of New South Wales
Ms Valentina Milanova University of South Australia
Mr Nam Dao Monash University
Mr Jiaul Islam Monash University
Ms Georgia Miller University of New South Wales
Mr Abbas Darestani Farahani University of New South Wales
Mr Ibrahim Javed Monash University
Mr Alexander Moersdorf Monash University
Ms Ludivine Delon University of South Australia
Mr Zhengyang Jia University of South Australia
Mrs Shebbrin Moonshi The University of Queensland
Ms Tahnee Dening University of South Australia
Mr Yi (David) Ju Melbourne University
Mr Walter Muskovic University of New South Wales
Mr Hweeing Ng The University of Queensland
Ms Jiaying Song Melbourne University
Ms Sul (Elly) Yu Monash University
Mr Joshua Rennick Monash University
Ms Duyen Nguyen University of New South Wales
Mr Manish Sriram University of New South Wales
Mr Thilagavathi Yuvaraj University of South Australia
Mr Zacharia Schuurs The University of Queensland
Ms Vy Nguyen University of South Australia
Mr Campbell Strong University of New South Wales
Ms Leila Zarei University of New South Wales
Ms Cindy Xiao Monash University
Mr Ka Fung (Leo) Noi Melbourne University
Mr Ian Styles Monash University
Mr Wenjie Zhang Melbourne University
Administrative staff
Mr Peter O’Mara University of New South Wales
Mr Tomoya Suma Melbourne University
Ms Manchen Zhao University of New South Wales
Mr Shuaijun Pan Melbourne University
Ms. Xiaohan Sun Monash University
Ms Yongmei Zhao The University of Queensland
Ms Raheleh Pardekhorram University of New South Wales
Ms Estelle Suys Monash University
Mr Jiang Zhen The University of Queensland
Ms Amanda Pearce The University of Queensland
Mr Vincent Tan University of New South Wales
Mr Qizhi Zhong Melbourne University
Ms Thuy Pham University of South Australia
Ms Wenxian Tang University of New South Wales
Ms Xiaotong Zhou Monash University
Ms Emily Pilkington Monash University
Ms Chelsea Thorn University of South Australia
Ms Aadarash Zia Monash University
Ms Ranjana Piya University of New South Wales
Ms Kristel Tjandra University of New South Wales
Ms Kelly Zong University of New South Wales
Mr Bijan Po University of New South Wales
Ms Nicole van der Burg The University of Queensland
Master students
Ms Yijiao Qu Melbourne University
Ms Florida Voli University of New South Wales
Mr Pradeep Rajasekhar Monash University
Ms Julia Walker Monash University
Ms Paulina Ramirez Garcia Monash University
Mr Miaoyi (Marvin) Wang Monash University
Dr Gishan Ratnayake The University of Queensland
Mr Hareth Wassiti Monash University
Mr Meysam Rezaeishahmirzadi University of South Australia
Mr Jonathan Wei The University of Queensland
Mr Tobias Klein Monash University Mr Mathis Majorel Monash University Ms Siobhan O’Brien The University of Queensland Ms Ngoc Mai Vu Monash University
Honours students Ms Aria Ahmed-Cox University of New South Wales
Mr Kye Robinson Monash University
Mr Nicholas Westra van Holthe The University of Queensland
Ms Bilquis Romana University of South Australia
Mr Jonathan Wojciechowski University of New South Wales
Mr Ashwin Dravid IITB (India)
Mr Hasan Sayeed University of South Australia
Ms Adelene Wong Monash University
Mr Edward Henderson Monash University
Mr Abu Sadat Md. Sayem Rahman University of New South Wales
Mr Chin (Ken) Wong University of New South Wales
Mr Michael Lawler University of New South Wales
Mr Stephen Wood Monash University
Mr Joshua Luong Monash University
Ms Leah Wright University of South Australia
Ms Holly McEwen University of New South Wales
Mr Yanfang Wu University of New South Wales
Ms Emilia Morris University of South Australia
Dr Chih-Tsung Yang University of South Australia
Mr Mubtasim Murshed Monash University
Mr Ken Yong Monash University
Mr Alexander Rashleigh University of New South Wales
Ms Hayley Schultz University of South Australia Mrs Laura Selby Monash University Mr Saimon Silva University of New South Wales Mr Joshua Simpson The University of Queensland Ms Danzi Song Melbourne University
Ms Kalista Clout-Holding Monash University
Ms Samantha Ellis Executive Assistant to Professor Maria Kavallaris – since October 2017 University of New South Wales Ms Carla Gerbo Research Administrator The University of Queensland Dr Charlotte Hurry Centre Administrator – since April 2017 Monash University Dr Natalie Jones Centre Manager Monash University Dr Maryline Chee Kimling Administration – since July 2017 Melbourne University Ms Anne Meyer Senior Coordinator Communications and Events – since October 2017 Monash University Mr Jason Murphy Senior Coordinator Communications and Events – until June 2017 Monash University Mr Marc Riemer Administration – until March 2017 Melbourne University Ms Jesu Schlogl Executive Assistant to Professor Maria Kavallaris – until January 2017 University of New South Wales Mrs Katrina Sewell Centre Administrator and Personal Assistant to Professor Tom Davis – until March 2017 Monash University Ms Shelley Steart Senior Coordinator Communications and Events – from June until October 2017 Monash University
CBNS Annual Report 2017 67
p e r fo r man c e
Mr Samuel Richardson The University of Queensland
Ms Alessia Weiss Melbourne University
Ms Nadine Kalverkamp Monash University
Ms Claudia Demech Executive Assistant to Professor Maria Kavallaris – until July 2017 University of New South Wales
Visitors to the CBNS The CBNS has hosted a diverse range of visitors from academia and industry during 2017. CBNS visitors have presented seminars and met with research staff and students to establish collaborations and to investigate potential commercialisation opportunities.
Visitors from national organisations
Visitors from international organisations
Associate Professor Lisa Butler University of Adelaide, Australia
Dr Alessia Amodo University of Rome Tor Vergata, Italy
Dr Douglas Campbell Mimomic International Ltd, Australia
Dr Eric Anslyn University of Texas at Austin, USA
Dr Melinda Dean Australian Red Cross Blood Service, Australia
Associate Professor Kristel Bergstrom Uppsala University, Sweden
Ms Bruna Ferrante Universidade Federal de SĂŁo Paulo, Brazil Associate Professor Albert Folch University of Washington, USA Dr Daohan Ge Jiangsu University, China Professor Nathan Gianneschi North Western University, USA
Professor Havazelet Bianco-Peled Technion-Israel Ins Technology, Israel
Associate Professor Jan Grimm Memorial Sloan Kettering Cancer Center, USA
Professor Peter Hudson AVIPEP, Australia
Ms Juliette Bignard INL – Lyon Institute of Nanotechnology, France
Ms Rui Guo Hunan University, China
Professor Emma Kowal Deakin, Australia
Dr Niya Bowers Gates Foundation, USA
Professor Yanchun Han Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, China
Associate Professor Joanne Macdonald University of the Sunshine Coast, Australia
Dr Zhen Cai NanFang Hospital, Republic of China
Mr Yuuki Hata Tokyo Institute of Technology, Japan
Dr Brian McNamee Tarnagulla Ventures, Australia
Professor Yongming Chen Sun-Yat Sen University, China
Professor Junpo He Fudan University, China
Dr Trent Munro AMGEN, Australia
Dr Benoit Couturaud Warwick University, United Kingdom
Dr Christine Heerup The University of Copenhagen, Denmark
Dr Catherine Owczarek CSL Ltd, Australia
Professor Dongmei Cui Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, China
Professor Stephen Hill University of Nottingham, UK
Professor Fariba Dehghani University of Sydney, Australia
Professor Robert Ramsey Peter McCallum Cancer Centre, Australia Professor Helen Rizos Macquarie University, Australia Dr Evan Shave Patheon Biologics, Australia Professor Erica Wanless University of Newcastle, Australia Dr Majid Warkiani UNSW, Australia
Dr Krishna K Darodaran University of Iceland, Iceland Professor Benjamin G Davis Oxford University, UK Dr Aranzazu del Campo Max Planck Institute for Polymer Research, Germany Professor Jenny Dressman Goethe University, Germany
Dr Shinichiro Iwamoto National Institute of Advanced Industrial Science, Japan Professor Xingyu Jiang NCNST, Chinese Academy of Sciences, China Professor Ming-Dou Ker National Chiao Tung University, Taiwan Mr Hiroaki Kitagawa Gifu Univeristy, Japan Mr Tobias Klein University of Bayreuth, Germany Dr Miia Kovalainen University of Easter Finland, Finland Dr Chia-Fone Le Buddhist Tzu Chi General Hospital, Taiwan Professor Jason S. Lewis Memorial Sloan Kettering Cancer Center, USA Ms Shanshan Li Sichuan University, China Professor Yaping Li Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China
Professor Yaping Li from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China
68 CBNS Annual Report 2017
Dr Po-Kang Lin Taipei Veterans General Hospital, Taiwan
Johannes Reynisson University of Auckland, New Zealand
Dr Sander J Wezenberg University of Groningen, The Netherlands
Professor Xiaobing Lyu Dalian University of Technology, China
Mr Tijs Robinson PowerHouse Ventures, New Zealand
Mr William Whitehouse Imperial College London, UK
Mr Mathis Majorel School of Engineering, CPE Lyon, France
Professor Linqi Shi Nankai University, China
Professor Chung-Yu Wu National Chiao Tung University, Taiwan
Dr Ravin Narain University of Alberta, Canada
Professor Bradley Smith Notre Dame University, USA
Professor Zongquan Wu Hefei University of Technology, China
Professor Guangjun Nie NCNST, Chinese Academy of Sciences, China
Dr Claudia Sperling Leibniz Institute for Polymer Research, Germany
Professor Xuming Xie Tsinghua University, China
Professor David O’Connor University of Wisconsin, USA
Ms Sarah Streck University Otago, New Zealand
Dr Sherry Wu University of Texas, M.D. Anderson Cancer Center (MDACC), USA
Associate Professor Shelby O’Connor University of Wisconsin, USA
Professor Junqi Sun Jilin University, China
Professor Feng Yan Soochow University, China
Professor Wolfgang Parak University of Marburg, Germany
Dr Andrew Surman University of Glasgow, UK
Professor Fred Ye Nanjing University, China
Professor Kinam Park Purdue Uni, USA
Ms Kelcilene Teodoro Costa Universidade Federal de São Carlos, Brazil
Dr Tianlei Ying Fudan University, China
Dr Amanda Pearce Nottingham University, United Kingdom
Professor Andreas Walther Freiburg University, Germany
Professor Haijun Yu Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China
Professor Xinhua Wan Peking University, China
Professor Afang Zhang Shanghai University, China
Dr Anna Wang Harvard University, USA
Ms Fan Zhang Xi’an Jiaotong University, China
Professor Barbara Prainsack King’s College London, UK
Mr Sai-Shyr Wang Taipei Economic and Cultrual Office, Taiwan
Professor Jie Zhang Peking University, China
Professor Jenny Reardon University of California, Santa Cruz, USA
Professor Yajun Wang Fudan University, China
Associate Professor Josh Reineke South Dakota State University, USA
Professor Andrew Webster University of York, UK
Dr Suang-Jing Pong Taipei Economic and Cultrual Office, Taiwan
Professor Zhengbiao Zhang Soochow University, China Professor Yongfeng Zhou Shanghai Jiao Tong University, China Associate Professor Khalid Zia Government College University, Pakistan
p e r fo r man c e
Ms Saskia Peters Delft University of Technology, The Netherlands
Professor Jason Lewis from the Memorial Sloan Kettering Cancer Center, USA
CBNS Annual Report 2017 69
Publications Books and book chapters Corrie S.R., Kendall M.A.F., Transdermal Drug Delivery, in Drug Delivery and Targeting: Fundamentals and Applications, 2 ed, 2017, 215-229. CE140100036 (2015) Depelsenaire A.C.I., Young P., Kendall M.A.F., Muller D., 2017, Introduction to vaccines and vaccination, in Vaccine Development, pp 47-62, Elsevier Kearnes M., Declan K., Marks M., Miller G., Russell W., Stephenson N., Chapter 3.2: Public Engagement, in The Future of Precision Medicine in Australia. Report for the Australian Council of Learned Academies, pp. 59-64 Kent, S.J., 2017, Eradication and cure of HIV, in Infectious Diseases, 4 ed, pp 931–935, Elsevier, London, UK Kent S.J., 2017, HIV Vaccine Approaches, in eLS, John Wiley & Sons, Ltd., Chichester, UK
Conference Proceedings Kuch D., Data Ownership in Precision Medicine, paper to Biomedical Futures Symposium, UNSW Law School, August Miller G., Asking the Tail to Wag the Dog: What’s at Stake in the Push to Commercialise Australian Science, paper to Everything is Connected conference, Canberra, October Miller G., Biomedical Futures in the Making: Research Policy as Industry Policy, paper to Biomedical Futures Symposium: Precision Medicine and Beyond, UNSW Law School, August Cheng X., McVey B.F.P., Robinson A.B., Longatte G., O’Mara P.B., Tan V.T.G., Thordarson P., Tilley R.D., Gaus K., Gooding J.J., Colloidal silicon quantum dots: From preparation to the modification of self-assembled monolayers for bioimaging and sensing applications, paper to Progress in Biomedical Optics and Imaging – Proceedings of SPIE, http://dx.doi. org/10.1117/12.2249592
Journal articles Abdelmaksoud H.H., Guinan T.M., Voelcker N.H., Fabrication of Nanostructured Mesoporous Germanium for Application in Laser Desorption Ionization 70 CBNS Annual Report 2017
Mass Spectrometry, ACS Applied Materials and Interfaces, 2017, 9, 5092-5099 Alam M.M., Peng H., Jack K.S., Hill D.J.T., Whittaker A.K., Reactivity Ratios and Sequence Distribution Characterization by Quantitative 13C NMR for RAFT Synthesis of StyreneAcrylonitrile Copolymers, Journal of Polymer Science, Part A: Polymer Chemistry, 2017, 55, 919-927 Alcaraz N., Liu Q., Hanssen E., Johnston A.P.R., Boyd B. J.,, Clickable Cubosomes for Antibody-free Drug Targeting and Imaging Applications, Bioconjugate Chemistry, 2017 Al-Shereiqi A.S., Boyd B.J., Saito K., Photo-Switchable SelfAssemblies Based on ThymineContaining Bolaamphiphiles, ChemPlusChem, 2017, 82, 1135-1144 Ana-Sosa-Batiz F., Johnston A.P.R., Hogarth P.M., Wines B.D., Barr I., Wheatley A.K., Kent S.J., Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults, Vaccine, 2017, 35, 6451-6458 Anastasaki A., Oschmann B., Willenbacher J., Melker A., Van Son M.H.C., Truong N.P., Schulze M.W., Discekici E.H., McGrath A.J., Davis T.P., Bates C.M., Hawker C.J., One-Pot Synthesis of ABCDE Multiblock Copolymers with Hydrophobic, Hydrophilic, and Semi-Fluorinated Segments, Angewandte Chemie – International Edition, 2017, 56, 14483-14487 Ardana A., Whittaker A.K., Thurecht K.J., Synthesis and post-polymerisation ligations of PEG-based hyperbranched polymers for RNA conjugation via reversible disulfide linkage, Macromolecular Research, 2017, 25, 599-614 Barker E.C., Martin A.D., Garvey C.J., Goh C.Y., Jones F., Mocerino M., Skelton B.W., Ogden M.I., Becker T., Thermal annealing behaviour and gel to crystal transition of a low molecular weight hydrogelator, Soft Matter, 2017, 13, 1006-1011 Bertleff-Zieschang N., Rahim Md.A., Ju Y., Braunger J.A., Suma T., Dai Y., Pan S., Cavalieri F., Caruso F., Biofunctional metal-phenolic films from dietary flavonoids, Chemical
Communications, 2017, 53, 1068-1071 Besford Q.A., Wojnilowicz M., Suma T., Bertleff-Zieschang N., Caruso F., Cavalieri F., Lactosylated Glycogen Nanoparticles for Targeting Prostate Cancer Cells, ACS Applied Materials and Interfaces, 2017, 9, 16869-16879 Birru W.A., Warren D.B., Han S., Benameur H., Porter C.J.H., Pouton C.W., Chalmers D.K., Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion, Molecular Pharmaceutics, 2017, 14, 580-592 Birru W.A., Warren D.B., Headey S.J., Benameur H., Porter C.J.H., Pouton C.W., Chalmers D.K., Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids, Molecular Pharmaceutics, 2017, 14, 566-579 Björnmalm M., Cui J., BertleffZieschang N., Song D., Faria M., Rahim M. A., Caruso, F., Nanoengineering Particles through Template Assembly, Chemistry of Materials, 2017, 29, 289-306 Björnmalm M., Thurecht K.J., Michael M., Scott A.M., Caruso F., Bridging Bio-Nano Science and Cancer Nanomedicine, ACS Nano, 2017, 11, 9594-9613 Braunger J.A., Björnmalm M., Isles N.A., Cui J., Henderson T.M.A., O’Connor A.J., Caruso F., Interactions between circulating nanoengineered polymer particles and extracellular matrix components in vitro, Biomaterials Science, 2017, 5, 267-273 Chakraborty R., Chandra J., Cui S., Tolley L., Cooper M.A., Kendall M., Frazer I.H., CD8+ lineage dendritic cells determine adaptive immune responses to inflammasome activation upon sterile skin injury, Experimental Dermatology, 2017 Chan L.J., Feeney O.M., Leong N.J., McLeod V.M., Porter C.J.H., Williams C.C., Kaminskas L.M., An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration, Biomacromolecules, 2017, 18, 2866-2875
Chen A., Peng H., Blakey I., Whittaker A.K., Biocidal polymers: A mechanistic overview, Polymer Reviews, 2017, 57, 276-310 Chen L., Simpson J.D., Fuchs A.V., Rolfe B.E., Thurecht K.J., Effects of surface charge of hyperbranced polymers on cytotoxicity, dynamic cellular uptake and localization, hemotoxicity and pharmacokinetics in mice, Molecular Pharmaceutics, 2017 Chen X., Cortez-Jugo C., Choi G.H., Björnmalm M., Dai Y., Yoo P.J., Caruso F., Patterned Poly(dopamine) Films for Enhanced Cell Adhesion, Bioconjugate chemistry, 2017, 28, 75-80 Cheng X., McVey B.F.P., Robinson A.B., Longatte G., O’Mara P.B., Tan V.T.G., Thordarson P., Tilley R.D., Gaus K., Gooding J.J., Colloidal silicon quantum dots: From preparation to the modification of self-assembled monolayers for bioimaging and sensing applications, Progress in Biomedical Optics and Imaging – Proceedings of SPIE, 2017, 10078 Cheng X., McVey B.F.P., Robinson A.B., Longatte G., O’Mara P.B., Tan V.T.G., Thordarson P., Tilley R.D., Gaus K., Gooding J.J., Protease sensing using nontoxic silicon quantum dots, Journal of Biomedical Optics, 2017, 22 Chhasatia R., Sweetman M.J., Harding F.J., Waibel M., Kay T., Thomas H., Loudovaris T., Voelcker N.H., Non-invasive, in vitro analysis of islet insulin production enabled by an optical porous silicon biosensor, Biosensors and Bioelectronics, 2017, 91, 515-522 Choudhury M.H., Ciampi S., Lu X., Kashi M.B., Zhao C., Gooding J.J., Spatially confined electrochemical activity at a non-patterned semiconductor electrode, Electrochimica Acta, 2017, 242, 240-246 Cifuentes-Rius A., Boase N.R.B., Font I., Coronas N., Ramos-Perez V., Thurecht K.J., Borrós S., In Vivo Fate of Carbon Nanotubes with Different Physicochemical Properties for Gene Delivery Applications, ACS Applied Materials and Interfaces, 2017, 9, 11461-11471
Cifuentes-Rius A., Ivask A., Sporleder E., Kaur I., Assan Y., Rao S., Warther D., Prestidge C.A., Durand J.-O., Voelcker N.H., Dual-Action Cancer Therapy with Targeted Porous Silicon Nanovectors, Small, 2017, 13 Cirillo G., Curcio M., Spizzirri U.G., Vittorio O., Tucci P., Picci N., Iemma F., Hampel S., Nicoletta F.P., Carbon nanotubes hybrid hydrogels for electrically tunable release of Curcumin, European Polymer Journal, 2017, 90, 1-12 Clulow A., Parrow A., Hawley A., Khan J., Pham A., Larsson P., Bergström C., Boyd B.J., Characterisation of solubilising nanoaggregates present in different versions of simulated intestinal fluid, Journal of Physical Chemistry B, 2017 Clulow A.J., Salim M., Hawley A., Boyd B.J., A closer look at the behaviour of milk lipids during digestion, Chemistry and Physics of Lipids, 2017 Collins J., Wallis S.J., Simula A., Whittaker M.R., McIntosh M.P., Wilson P., Davis T.P., Haddleton D.M., Kempe K., Comb Poly(Oligo(2-Ethyl2-Oxazoline)Methacrylate)Peptide Conjugates Prepared by Aqueous Cu(0)-Mediated Polymerization and Reductive Amination, Macromolecular Rapid Communications, 2017, 38 Cork J., Whittaker A.K., Cooper-White J.J., Grøndahl L., Electrospinning and mechanical properties of P(TMC-co-LLA) elastomers, Journal of Materials Chemistry B, 2017, 5, 22632272 Cromer D., Pinkevych M., Rasmussen T.A., Lewin S.R., Kent S.J., Davenport M.P., Modelling of anti-latency treatment in HIV; What is the optimal duration of antiretroviral-free HIV remission?, Journal of Virology, 2017, 91 Crum M.F., Trevaskis N.L., Pouton C.W., Porter C.J.H., Transient supersaturation supports drug absorption from lipid-based formulations for short periods of time, but ongoing solubilization is required for longer absorption periods, Molecular Pharmaceutics, 2017, 14, 394-405
Dai Q., Guo J., Yan Y., Ang C.-S., Bertleff-Zieschang N., Caruso F., Cell-Conditioned Protein Coronas on Engineered Particles Influence Immune Responses, Biomacromolecules, 2017, 18, 431-439 Dai Y., Guo J., Wang T.-Y., Ju Y., Mitchell A.J., Bonnard T., Cui J., Richardson J.J., Hagemeyer C.E., Alt K., Caruso F., Self-Assembled Nanoparticles from Phenolic Derivatives for Cancer Therapy, Advanced Healthcare Materials, 2017, 6 Daryl Ariawan A., Webb J.E.A., Howe E.N.W., Gale P.A., Thordarson P., Hunter L., Cyclic peptide unguisin A is an anion receptor with high affinity for phosphate and pyrophosphate, Organic and Biomolecular Chemistry, 2017, 15, 2962-2967 Delalat B., Harding F., Gundsambuu B., De-JuanPardo E.M., Wunner F.M., Wille M.-L., Jasieniak M., Malatesta K.A.L., Griesser H.J., Simula A., Hutmacher D.W., Voelcker N.H., Barry S.C., 3D printed lattices as an activation and expansion platform for T cell therapy, Biomaterials, 2017, 140, 58-68 Discekici E.H., Anastasaki A., Kaminker R., Willenbacher J., Truong N.P., Fleischmann C., Oschmann B., Lunn D.J., Read De Alaniz J., Davis T.P., Bates C.M., Hawker C.J., Light-Mediated Atom Transfer Radical Polymerization of Semi-Fluorinated (Meth) acrylates: Facile Access to Functional Materials, Journal of the American Chemical Society, 2017, 139, 5939-5945 Dong, Y.-D., Tchung, E., Nowell, C., Kaga, S., Leong, N., Mehta, D., Kaminskas, L. M., Boyd, B. J., Microfluidic preparation of drugloaded PEGylated liposomes, and the impact of liposome size on tumour retention and penetration, Journal of Liposome Research, 2017 Dos Santos Neto A.G., de Sousa C.S., da Silva Freires A., Silva S.M., Zanin H., Damos F.S., de Cássia Silva Luz R., Electrochemical sensor for detection of imipramine antidepressant at low potential based on oxidized carbon nanotubes, ferrocenecarboxylic acid, and cyclodextrin: application in psychotropic drugs and urine samples, Journal of Solid State Electrochemistry, 2017, 1-10 Du E.Y., Martin A.D., Heu C., Thordarson P., The Use of Hydrogels as Biomimetic
Materials for 3D Cell Cultures, Australian Journal of Chemistry, 2017, 70, 1-8 Dumont C., Czuba E., Chen M., Villadangos J.A., Johnston A.P.R., Mintern J.D., DNA-based probes for flow cytometry analysis of endocytosis and recycling, Traffic, 2017, 18, 242-249 Ejima H., Richardson J.J., Caruso F., Metal–phenolic networks as a versatile platform to engineer nanomaterials and biointerfaces, Nano Today, 2017, 12, 136-148 Engelis N.G., Anastasaki A., Nurumbetov G., Truong N.P., Nikolaou V., Shegiwal A., Whittaker M.R., Davis T.P., Haddleton D.M., Sequencecontrolled methacrylic multiblock copolymers via sulfur-free RAFT emulsion polymerization, Nature Chemistry, 2017, 9, 171-178 Ercole F., Whittaker M.R., Halls M.L., Boyd B.J., Davis T.P., Quinn J.F., Garlic-inspired trisulfide linkers for thiolstimulated H2S release, Chemical Communications, 2017, 53, 8030-8033 Fife C.M., Sagnella S.M., Teo W.S., Po’Uha S.T., Byrne F.L., Yeap Y.Y.C., Ng D.C.H., Davis T.P., McCarroll J.A., Kavallaris M., Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration, Oncogene, 2017, 36, 501-511 Fong W.-K., Sánchez-Ferrer A., Ortelli F.G., Sun W., Boyd B.J., Mezzenga R., Dynamic formation of nanostructured particles from vesicles via invertase hydrolysis for on-demand delivery, RSC Advances, 2017, 7, 4368-4377 Footman C., De Jongh P.A.J.M., Tanaka J., Peltier R., Kempe K., Davis T.P., Wilson P., Thiolreactive (co)polymer scaffolds comprising organic arsenical acrylamides, Chemical Communications, 2017, 53, 8447-8450 Fu C., Herbst S., Zhang C., Whittaker A.K., Polymeric 19F MRI agents responsive to reactive oxygen species, Polymer Chemistry, 2017, 8, 4585-4595 Fu C., Yi. D., Deng C., Wang X., Zhang J., Tang Y., Caruso F., Wang, Y., A Partially Graphitic Mesoporous Carbon Membrane with Three-Dimensionally Networked Nanotunnels for Ultrasensitive Electrochemical Detection, Chemistry of Materials, 2017, 29, 5286-5293
Fuchs A.V., Bapat A.P., Cowin G.J., Thurecht K.J., Switchable 19F MRI polymer theranostics: Towards: in situ quantifiable drug release, Polymer Chemistry, 2017, 8, 5157-5166 Fuchs A.V., Thurecht K.J., Stability of trithiocarbonate RAFT agents containing both a cyano and a carboxylic acid functional group, ACS Macro Letters, 2017, 6, 287-291 Gause K.T., Wheatley A.K., Cui J., Yan Y., Kent S.J., Caruso F., Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery, ACS Nano, 2017, 11, 54-68 Gavin P.D., El-Tamimy M., Keah H.H., Boyd B.J., Tocopheryl phosphate mixture (TPM) as a novel lipid-based transdermal drug delivery carrier: formulation and evaluation, Drug Delivery and Translational Research, 2017, 7, 53-65 Gawthrop P.T., Crampin E.J., Energy-based analysis of biomolecular pathways, Proceedings of the Royal Society A, 2017, 473 Gawthrop P.T., Siekmann I., Kameneva T., Saha S., Ibbotson M.R., Crampin E.J., Bond graph modelling of chemoelectrical energy transduction, IET Systems Biology, 2017, 11, 127-138 Ge X., Kakinen A., Gurzov E.N., Yang W., Pang L., Pilkington E.H., Govindan-Nedumpully P., Chen P., Separovic F., Davis T.P., Ke P.C., Ding F., Zinc-coordination and C-peptide complexation: A potential mechanism for the endogenous inhibition of IAPP aggregation, Chemical Communications, 2017, 53, 9394-9397 Ghai R., Du X., Wang H., Dong J., Ferguson C., Brown A.J., Parton R.G., Wu J-W., Yang H., ORP5 and ORP8 bind phosphatidylinositol-4, 5- biphosphate (PtdIns(4,5) P2) and regulate its level at the plasma membrane, Nature Communications, 2017, 8, 757-771 Glass J.J., Chen L., Alcantara S., Crampin E.J., Thurecht K.J., De Rose R., Kent S.J., Charge Has a Marked Influence on Hyperbranched Polymer Nanoparticle Association in Whole Human Blood, ACS Macro Letters, 2017, 6, 586-592 Glass J.J., Li Y., De Rose R., Johnston A.P.R., Czuba E.I., Khor S.Y., Quinn J.F., Whittaker M.R., Davis T.P., Kent S.J.,
CBNS Annual Report 2017 71
p e r fo r man c e
Cifuentes-Rius A., Ivask A., Das S., Penya-Auladell N., Fabregas L., Fletcher N.L., Houston Z.H., Thurecht K.J., Voelcker N.H., Gold nanoclustermediated cellular death under electromagnetic radiation, ACS Applied Materials and Interfaces, 2017, 9, 41159-41167
Thiol-Reactive Star Polymers Display Enhanced Association with Distinct Human Blood Components, ACS Applied Materials and Interfaces, 2017, 9, 12182-12194 Gooding J.J., Gonçales V.R., Recent advances in the molecular level modification of electrodes for bioelectrochemistry, Current Opinion in Electrochemistry, 2017, 5, 203-210 Grace J.L., Alcaraz N., Truong N.P., Davis T.P., Boyd B.J., Quinn J.F., Whittaker M.R., Lipidated polymers for the stabilization of cubosomes: Nanostructured drug delivery vehicles, Chemical Communications, 2017, 53, 10552-10555 Grace J.L., Elliott A.G., Huang J.X., Schneider E.K., Truong N.P., Cooper M.A., Li J., Davis T.P., Quinn J.F., Velkov T., Whittaker M.R., Cationic acrylate oligomers comprising amino acid mimic moieties demonstrate improved antibacterial killing efficiency, Journal of Materials Chemistry B, 2017, 5, 531-536 Guo J., Richardson J.J., Besford Q.A., Christofferson A.J., Dai Y., Ong C.W., Tardy B.L., Liang K., Choi G.H., Cui J., Yoo P.J., Yarovsky I., Caruso F., Influence of Ionic Strength on the Deposition of Metal–Phenolic Networks, Langmuir, 2017, 33, 10616-10622 Gustafsson O.J.R., Guinan T.M., Rudd D., Kobus H., Benkendorff K., Voelcker N.H., Metabolite mapping by consecutive nanostructure and silver-assisted mass spectrometry imaging on tissue sections, Rapid Communications in Mass Spectrometry, 2017, 31, 991-1000 Gutekunst W.R., Anastasaki A., Lunn D.J., Truong N.P., Whitfield R., Jones G.R., Treat N.J., Abdilla A., Barton B.E., Clark P.G., Haddleton D.M., Davis T.P., Hawker C.J., Practical Chain-End Reduction of Polymers Obtained with ATRP, Macromolecular Chemistry and Physics, 2017, 218 Haque S., McLeod V.M., Jones S., Fung S., Whittaker M., McIntosh M., Pouton C., Owen D.J., Porter C.J.H., Kaminskas L.M., Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers, European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 408-418 Hasan S., Thoma, N., Thierry B., 72 CBNS Annual Report 2017
Prestidge C.A., Controlled and Localized Nitric Oxide Precursor Delivery From Chitosan Gels to Staphylococcus aureus Biofilms, Journal of Pharmaceutical Sciences, 2017, 106, 35563563
Robinson P.J., Escriou V., Nassini R., Materazzi S., Ge, Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief, Science Translational Medicine, 2017, 9
Healey R.D., Lebhar H., Hornung S., Thordarson P., Marquis C.P., An improved process for the production of highly purified recombinant thaumatin taggedvariants, Food Chemistry, 2017, 237, 825-832
Jia S., Du J.D., Hawley A., Fong W.-K., Graham B., Boyd B.J., Investigation of Donor-Acceptor Stenhouse Adducts as New Visible Wavelength-Responsive Switching Elements for LipidBased Liquid Crystalline Systems, Langmuir, 2017, 33, 2215-2221
Hinde E., Thammasiraphop K., Duong H.T.T., Yeow J., Karagoz B., Boyer C., Gooding J.J., Gaus K., Pair correlation microscopy reveals the role of nanoparticle shape in intracellular transport and site of drug release, Nature Nanotechnology, 2017, 12, 81-89 Hu J., Qiao R., Whittaker M.R., Quinn J.F., Davis T.P., Synthesis of star polymers by RAFT polymerization as versatile nanoparticles for biomedical applications, Australian Journal of Chemistry, 2017, 70, 1161-1170 Jarosz J., Ghosh S., Delbridge L.M.D., Petzer A., Hickey A.J.R., Crampin E.J., Hanssen E., Rajagopal V., Changes in mitochondrial morphology and organization can enhance energy supply from mitochondrial oxidative phosphorylation in diabetic cardiomyopathy, American Journal of Physiology – Cell Physiology, 2017, 312 Javed I., Sun Y., Adamcik J., Wang B., Kakinen A., Pilkington E.H., Ding F., Mezzenga R., Davis T.P., Ke P.C., Co-Fibrillization of Functional-Pathogenic Protein Fibrils with Gold Nanoparticles against Amyloidogenesis, Biomacromolecules, 2017, 18 Jegaskanda S., Vanderven H.A., Wheatley A.K., Kent S.J., Fc or not Fc; that is the question: Antibody Fcreceptor interactions are key to universal influenza vaccine design, Human Vaccines and Immunotherapeutics, 2017, 13, 1288-1296 Jenie S.N.A., Hickey S.M., Du Z., Sebben D., Brooks D.A., Voelcker N.H., Plush S.E., A europiumbased ‘off-on’ colourimetric detector of singlet oxygen, Inorganica Chimica Acta, 2017, 462, 236-240 Jensen D.D., Lieu T.M., Halls M.L., Veldhuis N.A., Imlach W.L., Mai Q.N., Poole D.P., Quach T., Aurelio L., Conner J., Herenbrink C.K., Barlow N., Simpson J.S., Scanlon M.J., Graham B., McCluskey A.,
Jiang C., Moraes Silva S., Fan S., Wu Y., Alam M.T., Liu G., Gooding J.J., Aryldiazonium salt derived mixed organic layers: From surface chemistry to their applications, Journal of Electroanalytical Chemistry, 2017, 785, 265-278 Jiang Z., Blakey I., Whittaker A.K., Aqueous solution behaviour of novel water-soluble amphiphilic copolymers with elevated hydrophobic unit content, Polymer Chemistry, 2017, 8, 4114-4123 Johnston A.P.R., Life under the Microscope: Quantifying Live Cell Interactions to Improve Nanoscale Drug Delivery, ACS Sensors, 2017, 2, 4-9 Johnston A.P.R., Rae J., Ariotti N., Bailey B., Lija A., Webb R., Ferguson C., Maher S., Davis T.P., Webb R.I., McGhee J., Parton R.G, Journey to the centre of the cell: Virtual reality immersion into scientific data, Traffic, 2017 Johnston A.P.R., Rae J., Ariotti N., Bailey B., Lija A., Webb R., Ferguson C., Maher S., Davis T.P., Webb R.I., McGhee J., Parton R.G., Journey to the centre of the cell: Virtual reality immersion into scientific data, Traffic, 2017 Joyce P., Dening T.J., Gustafsson H., Prestidge C.A., Modulating the Lipase-Mediated Bioactivity of Particle-Lipid Conjugates Through Changes in Nanostructure and Surface Chemistry, European Journal of Lipid Science and Technology, 2017, 119 Joyce P., Yasmin R., Bhatt A., Boyd B.J., Pham A., Prestidge C.A., Comparison across Three Hybrid Lipid-Based Drug Delivery Systems for Improving the Oral Absorption of the Poorly Water-Soluble Weak Base Cinnarizine, Molecular Pharmaceutics, 2017, 14, 4008-4018 Juno J.A., Bockel D., Kent S.J., Kelleher A.D., Zaunders J.J., Munier C.M.L., Cytotoxic CD4
T cells-friend or foe during viral infection?, Frontiers in Immunology, 2017, 8 Kaga S., Truong N.P., Esser L., Senyschyn, D., Sanyal A., Sanyal R., Quinn J.F, Davis T.P., Kaminskas, LM., Whittaker M.R., Influence of Size and Shape on the Biodistribution of Nanoparticles Prepared by Polymerization-Induced SelfAssembly, Biomacromolecules, 2017 Kakinen A., Adamcik J., Wang B., Ge X., Mezzenga R., Davis T.P., Ding F., Ke P.C., Nanoscale Inhibition of Polymorphic and Ambidextrous IAPP Amyloid Aggregation with Small Molecules, Nano Research, 2017 Kashi M.B., Silva S.M., Yang Y., Gonçales V.R., Parker S.G., Barfidokht A., Ciampi S., Gooding J.J., Light-activated electrochemistry without surface-bound redox species, Electrochimica Acta, 2017, 251, 250-255 Ke P.C., Lin S., Parak W. J., Davis T. P., Caruso F., A Decade of the Protein Corona, ACS Nano, 2017, 11, 11773-11776 Ke P.C., Lin S., Parak W.J., Davis T.P., Caruso F., A Decade of the Protein Corona, ACS Nano, 2017, 11 Ke P.C., Sani M.A., Ding F., Kakinen A., Javed I., Separovic F., Davis T.P., Mezzenga R., Implications of peptide assemblies in amyloid diseases, Chemical Society Reviews, 2017, 46, 6492-6531 Kempe K., Chain and Step Growth Polymerizations of Cyclic Imino Ethers: From Poly (2-oxazoline)s to Poly(ester amide)s, Macromolecular Chemistry and Physics, 2017, 218 Kempe K., Xiang S.D., Wilson P., Rahim M.A., Ju Y., Whittaker M.R., Haddleton D.M., Plebanski M., Caruso F., Davis T.P., Engineered Hydrogen-Bonded Glycopolymer Capsules and Their Interactions with Antigen Presenting Cells, ACS Applied Materials and Interfaces, 2017, 9, 6444-6452 Kent S.J., Kelleher A.D., Expanding role for type i Interferons in restricting HIV growth, Immunology and Cell Biology, 2017, 95, 417-418 Khor S.Y., Truong N.P., Quinn J.F., Whittaker M.R., Davis T.P., Polymerization-Induced Self-Assembly: The Effect of End Group and Initiator Concentration on Morphology of Nanoparticles Prepared
Kongkatigumjorn N., CortezJugo C., Czuba E., Wong A.S.M., Hodgetts R.Y., Johnston A.P.R., Such G.K., Probing Endosomal Escape Using pHlexi Nanoparticles, Macromolecular Bioscience, 2017, 17 Kratochvil S., McKay P.F., Kopycinski J.T., Bishop C., Hayes P.J., Muir L., Pinder C.L., Cizmeci D., King D., Aldon Y., Wines B.D., Mark Hogarth P., Chung A.W., Kent S.J., Held K., Geldmacher C., Dally L., Santos N.S., Cole T., Gilmour J., Fidler S., Shat, A phase 1 human immunodeficiency virus vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost vaccine regimens, Frontiers in Immunology, 2017, 8
Lee K.T., Coffey J.W., Robinson K.J., Muller D.A., Grøndahl L., Kendall M.A.F., Young P.R., Corrie S.R., Investigating the effect of substrate materials on wearable immunoassay performance, Langmuir, 2017, 33, 773-782 Lee W.S., Kent S.J., Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization?, Current Opinion in HIV & AIDS, 2017 Lee W.S., Kristensen A.B., Rasmussen T.A., Tolstrup M., Østergaard L., Søgaard O.S., Wines B.D., Mark Hogarth P., Reynaldi A., Davenport M.P., Emery S., Amin J., Cooper D.A., Kan V.L., Fox J., Gruell H., Parsons M.S., Kent S.J., Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption, Journal of Virology, 2017, 91
Krismastuti F.S.H., Dewi M.R., Prieto-Simon B., Nann T., Voelcker N.H., Disperse-andCollect Approach for the TypeSelective Detection of Matrix Metalloproteinases in Porous Silicon Resonant Microcavities, ACS Sensors, 2017, 2, 203-209
Levrier C., Rockstroh A., Gabrielli B., Kavallaris M., Lehman M., Davis R.A., Sadowski M.C., Nelson C.C., Discovery of Thalicthuberine as a Novel Antimitotic Agent from Nature that Disrupts Microtubule Dynamics and Induces Apoptosis in Prostate Cancer Cells., Cell Cycle, 2017
Ku K.-L., Grøndahl L., Dao H., Du K., Puttick S., Lai P.-L., Peng H., Chu I.-M., Whittaker A.K., In vitro degradation study of polyanhydride copolymers / surface grafted hydroxyapatite composites for bone tissue application, Polymer Degradation and Stability, 2017, 140, 136-146
Levrier C., Sadowski M.C., Rockstroh A., Gabrielli B., Kavallaris M., Lehman M., Davis R.A., Nelson C.C., 6α-Acetoxyanopterine: A novel structure class of mitotic inhibitor disrupting microtubule dynamics in prostate cancer cells, Molecular Cancer Therapeutics, 2017, 16, 3-15
Kumeria T., McInnes S.J.P., Maher S., Santos A., Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives, Expert Opinion on Drug Delivery, 2017, 14, 1407-1422
Li S., Zhang Y., Wang J., Zhao Y., Ji T., Zhao X., Ding Y., Zhao X., Zhao R., Li F., Yang X., Liu S., Liu Z., Lai J., Whittaker A.K., Anderson G.J., Wei J., Nie G., Nanoparticle-mediated local depletion of tumour-associated platelets disrupts vascular barriers and augments drug accumulation in tumours, Nature Biomedical Engineering, 2017, 1, 667-679
Kunz-Schughart L.A., Dubrovska A., Peitzsch C., Ewe A., Aigner A., Schellenburg S., Muders M.H., Hampel S., Cirillo G., Iemma F., Tietze R., Alexiou C., Stephan H., Zarschler K., Vittorio O., Kavallaris M., Parak W.J., Mädler L., Pokhrel S., Nanoparticles for radiooncology: Mission, vision, challenges, Biomaterials, 2017, 120, 155-184 Laos A.J., Dean J.C., Toa Z.S.D., Wilk K.E., Scholes G.D., Curmi P.M.G., Thordarson P., Cooperative Subunit Refolding of a Light-Harvesting Protein through a Self-Chaperone Mechanism, Angewandte Chemie – International Edition, 2017, 56, 8384-8388
Liang K., Richardson J.J., Doonan C.J., Mulet X., Ju Y., Cui J., Caruso F., Falcaro P., An Enzyme-Coated Metal– Organic Framework Shell for Synthetically Adaptive Cell Survival, Angewandte Chemie – International Edition, 2017, 56, 8510-8515 Lim J.Y., Barnett T.C., Bastiani M., McMahon K-A., Ferguson, C., Webb I.R., Parton R.G., Walker M.J., Caveolin 1 restricts Group A Streptococcus invasion of nonphagocytic host cells, Cellular Microbiology, 2017, 19
Lim Y-W., Lo H.P., Perguson C., Martel N., Giacomotto J., Gomez G.A., Yap A.S., Hall T.E., Parton R.G., Caveolae Protect Notochord Cells against Catastrophic Mechanical Failure during Development, Current Biology, 2017, 27, 1968-1981
Maartens J.H., De-Juan-Pardo E., Wunner F.M., Simula A., Voelcker N.H., Barry S.C., Hutmacher D.W., Challenges and opportunities in the manufacture and expansion of cells for therapy, Expert Opinion on Biological Therapy, 2017, 17, 1221-1233
Lin S., Mortimer M., Chen R., Kakinen A., Riviere J.E., Davis T.P., Ding F., Ke P.C., NanoEHS beyond toxicityfocusing on biocorona, Environmental Science: Nano, 2017, 4, 1433-1454
Macri C., Dumont C., Panozza S., Lahoud M.H., Caminschi I., Villadangos J.A., Johnston A.P.R., Mintern J.D., Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes, Molecular Immunology, 2017, 81, 143-150
Liu Q., Graham B., Hawley A., Dong Y.D., Boyd B.J., Novel agrochemical conjugates with self-assembling behaviour, Journal of Colloid and Interface Science, 2018, 512, 369-378 Liu Q., Hu J., Whittaker M.R., Davis T.P., Boyd B.J., Nitric oxidesensing actuators for modulating structure in lipid-based liquid crystalline drug delivery systems, Journal of Colloid and Interface Science, 2017, 508, 517-524 Lloyd S.B., Niven K.P., Kiefel B.R., Montefiori D.C., Reynaldi A., Davenport M.P., Kent S.J., Winnall W.R., Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV, Human Vaccines and Immunotherapeutics, 2017, 13, 2726-2737 Lovelace M.D., Powter E.E., Coleman P.R., Zhao Y., Parker A., Chang G.H., Lay A.J., Hunter J., McGrath A.P., Jormakka M., Bertolino P., McCaughan G., Kavallaris M., Vadas M.A., Gamble J.R., The RhoGAP protein ARHGAP18/SENEX localizes to microtubules and regulates their stability in endothelial cells, Molecular Biology of the Cell, 2017, 28, 1066-1078 Lu X., Nicovich P.R., Gaus K., Gooding J.J., Towards single molecule biosensors using super-resolution fluorescence microscopy, Biosensors and Bioelectronics, 2017, vol. 93 Lu X., Nicovich P.R., Gaus K., Gooding J.J., Towards single molecule biosensors using super-resolution fluorescence microscopy, Biosensors and Bioelectronics, 2017, 93, 1-8 Ma Y., Yamamoto Y., Nicovich P.R., Goyette J., Rossy J., Gooding J.J., Gaus K., A FRET sensor enables quantitative measurements of membrane charges in live cells, Nature Biotechnology, 2017, 35, 363-370
Madhavi V., Kulkarni A., Shete A., Lee W.S., McLean M.R., Kristensen A.B., Ghate M., Wines B.D., Hogarth P.M., Parsons M.S., Kelleher A., Cooper D.A., Amin J., Emery S., Thakar M., Kent S.J., Effect of Combination Antiretroviral Therapy on HIV1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts, Journal of Acquired Immune Deficiency Syndromes, 2017, 75, 345-353 Madhavi V., Wines B.D., Amin J., Emery S., Lopez E., Kelleher A., Center R.J., Mark Hogarth P., Chung A.W., Kent S.J., Stratov I., HIV-1 Env- and Vpuspecific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV, Journal of Virology, 2017, 91 Martin A.D., Wojciechowski J.P., Robinson A.B., Heu C., Garvey C.J., Ratcliffe J., Waddington L.J., Gardiner J., Thordarson P., Controlling self-assembly of diphenylalanine peptides at high pH using heterocyclic capping groups, Scientific Reports, 2017, 7 Mason A.F., Thordarson P., Polymersomes as Protocellular Constructs, Journal of Polymer Science, Part A: Polymer Science, 2017, 55, 3817-3825 McEvoy C.L., Trevaskis N.L., Feeney O.M., Edwards G.A. Perlman M.E., Ambler C.M., Porter C.J.H., Correlating in vitro solubilisation and supersaturation profiles of the CETP inhibitor CP-532,623 with in vivo exposure for long and medium chain lipid based formulations., Molecular Pharmaceutics, 2017, 14 McEwen H., Du, E.Y., Mata J.P., Thordarson P., Martin A.D., Tuning hydrogels through metal-based gelation triggers, Journal of Materials Chemistry B, 2017, 5, 9412-9417
CBNS Annual Report 2017 73
p e r fo r man c e
via RAFT Aqueous Emulsion Polymerization, ACS Macro Letters, 2017, 6, 1013-1019
McGrath A.J., Cheong S., Henning A.M., Gooding J.J., Tilley R.D., Size and shape evolution of highly magnetic iron nanoparticles from successive growth reactions., Chemical Communications, 2017, vol. 53 McLean M.R., Madhavi V., Wines B.D., Hogarth P.M., Chung A.W., Kent S.J., Dimeric Fcg receptor enzyme-linked immunosorbent assay to study HIV-specific antibodies: A new look into breadth of fcg receptor antibodies induced by the rv144 vaccine trial, Journal of Immunology, 2017, 199, 816-826 McVey B.F.P., O’Mara P.B., McGrath A.J., Faramus A., Yasarapudi V.B., Gonçales V.R., Tan V.T.G., Schmidt T.W., Gooding J.J., Tilley R.D., Role of Surface Capping Molecule Polarity on the Optical Properties of Solution Synthesized Germanium Nanocrystals, Langmuir, 2017, 33, 8790-8798 Meliga S.C., Coffey J.W., Crichton M.L., Flaim C., Veidt M., Kendall M.A.F., The hyperelastic and failure behaviors of skin in relation to the dynamic application of microscopic penetrators in a murine model, Acta Biomaterialia, 2017, 48, 341-356 Mills R.J., Titmarsh D.M., Koenig X., Parker B.L., Ryall J.G., QuaifeRyan G.A., Voges H.K., Hodson M.P., Ferguson C., Drowley L., lowright A.T., Needham E.J., Wang Q-D., Gregorevic P., Xin M., Thomas W.G., Parton R.G., Nielsen L.K., Launikonis B.S., Jame, Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest, Proceedings of the National Academy of Sciences of the United States of America, 2017, 114 Mollazade M., Tabarin T., Nicovich P.R., Soeriyadi A., Nieves D.J., Gooding J.J., Gaus K., Can single molecule localization microscopy be used to map closely spaced RGD nanodomains?, PloS one, 2017, 12 Moule E.C., Guinan T.M., Gustafsson O.J.R., Kobus H., Kirkbride K.P., Voelcker N.H., Silver-assisted development and imaging of fingermarks on non-porous and porous surfaces, International Journal of Mass Spectrometry, 2017 Muller D.A., Fernando G.J.P., Owens N.S., Agyei-Yeboah C., Wei J.C.J., Depelsenaire A.C.I., Forster A., Fahey P., Weldon
74 CBNS Annual Report 2017
W.C., Oberste M.S., Young P.R., Kendall M.A.F., High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses, Scientific Reports, 2017, 7 Nurumbetov G., Engelis N., Godfrey J., Hand R., Anastasaki A., Simula A., Nikolaou V., Haddleton D.M., Methacrylic block copolymers by sulfur free RAFT (SF RAFT) free radical emulsion polymerisation, Polymer Chemistry, 2017, 8, 1084-1094
Sensing of Antifibrotic Drug Action in Primary Human Cells, ACS Sensors, 2017, 2, 1482-1490 Pearce A.K., Simpson J.D., Fletcher N.L., Houston Z.H., Fuchs A.V., Russell P.J., Whittaker A.K., Thurecht K.J., Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic, Biomaterials, 2017, 141, 330-339
Oliver S., Jofri A., Thomas D.S., Vittorio O., Kavallaris M., Boyer C., Tuneable catechin functionalisation of carbohydrate polymers, Carbohydrate Polymers, 2017, 169, 480-494
Pham A.C., Gavin P., Libinaki R., Ramirez G., Boyd B.J., A new lipid excipient, phosphorylated tocopherol mixture, TPM enhances the solubilisation and oral bioavailability of poorly water soluble CoQ10 in a lipid formulation, Journal of Controlled Release, 2017, 268, 400-406
Pai J.H., Yang C.T., Hsu H.Y., Wedding B.A., Thierry B., Development of a Simplified Approach for the Fabrication of Localised Surface plasmon Resonance Sensors based on Gold Nanorods Functionalised using Mixed Polyethylene glycol Layers., Analytica Chimica Acta, 2017, 974, 87-92
Pilkington E.H., Lai M., Ge X., Stanley W.J., Wang B., Wang M., Kakinen A., Sani M.-A., Whittaker M.R., Gurzov E.N., Ding F., Quinn J.F., Davis T.P., Ke P.C., Star Polymers Reduce Islet Amyloid Polypeptide Toxicity via Accelerated Amyloid Aggregation, Biomacromolecules, 2017, 18
Pan Y., Choy K.H.C., Marriott P.J., Chai S.Y., Scanlon M.J., Porter C.J.H., Short J.L., Nicolazzo J.A., Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/ PS1 mice to cognitive deficits from low omega-3 fatty acid diets, Journal of Neurochemistry, 2018, 144, 81-92
Pilkington E.H., Xing Y., Wang B., Kakinen A., Wang M., Davis T.P., Ding F., Ke P.C., Effects of protein corona on IAPP amyloid aggregation, fibril remodelling, and cytotoxicity, Scientific Reports, 2017, 7
Parker A.L., Teo W.S., McCarroll J.A., Kavallaris M., An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance, International Journal of Molecular Sciences, 2017, 18 Parsons M.S., Lloyd S.B., Lee W.S., Kristensen A.B., Amarasena T., Center R.J., Keele B.F., Lifson J.D., La Branche C.C., Montefiori D., Wine B.D., Hogarth P.M., Swiderek K.M., Venturi V., Davenport M.P., Kent S.J., Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection, Science Translational Medicine, 2017, 9 Parviz M., Gaus K., Gooding J.J., Simultaneous impedance spectroscopy and fluorescence microscopy for the real-time monitoring of the response of cells to drugs, Chemical Science, 2017, 8, 1831-1840 Parviz M., Toshniwal P., Viola H.M., Hool L.C., Fear P.M.W., Wood F.M., Gaus K., Iyer K.S., Gooding J.J., Real-Time Bioimpedance
Pocock K., Delon L., Bala V., Rao S., Priest C., Prestidge C., Thierry B., Intestine-on-A-Chip Microfluidic Model for Efficient in Vitro Screening of Oral Chemotherapeutic Uptake, ACS Biomaterials Science and Engineering, 2017, 3, 951-959 Qiao Y., Qiao R., He Y., Shi C., Liu Y., Hao H., Su J., Zhong J., Instrumental Analytical Techniques for the Characterization of Crystals in Pharmaceutics and Foods, Crystal Growth and Design, 2017, 17, 6138-6148 Quinn J.F., Whittaker M.R., Davis T.P., Glutathione responsive polymers and their application in drug delivery systems, Polymer Chemistry, 2017, 8, 97-126 Quinn M.D.J., Wang T., Du J.D., Boyd B.J., Hawley A., Notley S.M., Graphene as a photothermal actuator for control of lipid mesophase structure, Nanoscale, 2017, 9, 341-348 Rahim M.A., Björnmalm M., Bertleff-Zieschang N., Besford Q., Mettu S., Suma T., Faria M., Caruso F., Rust-Mediated Continuous Assembly of Metal–
Phenolic Networks, Advanced Materials, 2017, 29 Rajagopal V., Bass G., Ghosh S., Walker C.G., Hanssen E.; Crampin E.J., Soeller C., Creating a Structurally Realistic Finite Element Geometric Model of a Cardiomyocyte to Study the Role of Cellular Architecture in Cardiomyocyte Systems Biology, Journal of Vizualised Experiments, 2017 Rajasekhar P., Poole D.P., Veldhuis N.A., Role of Nonneuronal TRPV4 Signaling in Inflammatory Processes, Advances in Pharmacology, 2017 Rehman M., Madni A., Shi D., Ihsan A., Tahir N., Chang K.R., Javed I., Webster T.J., Enhanced blood brain barrier permeability and glioblastoma cell targeting via thermoresponsive lipid nanoparticles, Nanoscale, 2017, 9, 15434-15440 Richter K., Facal P., Thomas N., Vandecandelaere I., Ramezanpour M., Cooksley C., Prestidge C.A., Coenye T., Wormald P.J., Vreugde S., Taking the Silver Bullet Colloidal Silver Particles for the Topical Treatment of Biofilm-Related Infections, ACS Applied Materials and Interfaces, 2017, 9, 2163121638 Richter K., Thomas N., Claeys J., McGuane J., Prestidge C.A., Coenye T., Wormald P.J., Vreugde S., A topical hydrogel with deferiprone and galliumprotoporphyrin targets bacterial iron metabolism and has antibiofilm activity, Antimicrobial Agents and Chemotherapy, 2017, 61 Richter K., Thomas N., Zhang G., Prestidge C.A., Coenye T., Wormald P.-J., Vreugde S., Deferiprone and galliumprotoporphyrin have the capacity to potentiate the activity of antibiotics in Staphylococcus aureus small colony variants, Frontiers in Cellular and Infection Microbiology, 2017, 7 Rong G., Corrie S.R., Clark H.A., In Vivo Biosensing: Progress and Perspectives, ACS Sensors, 2017, 2, 327-338 Rouse C.K., Martin A.D., Easton C.J., Thordarson P., A Peptide Amphiphile Organogelator of Polar Organic Solvents, Scientific Reports, 2017, 7 Ryan G.M., McLeod V.M., Mehta D., Kelly B.D., Stanislawski P.C., Owen D.J., Kaminskas L.M., Porter C.J.H., Lymphatic transport and lymph node targeting
Sahbaz Y., Nguyen T.-H., Ford L., McEvoy C.L., Williams H.D., Scammells P.J., Porter C.J.H., Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies, Molecular Pharmaceutics, 2017, 14, 3669-3683 Santander-Borrego M., Taran E., Shadforth M.A., Whittaker A.K., Chirila T.V., Blakey I., Hydrogels with Lotus Leaf Topography: Investigating Surface Properties and Cell Adhesion, Langmuir, 2017, 33, 485-493 Scheidegger L., FernándezRodríguez M.Á., Geisel K., Zanini M., Elnathan R., Richtering W., Isa L., Compression and deposition of microgel monolayers from fluid interfaces: Particle size effects on interface microstructure and nanolithography, Physical Chemistry Chemical Physics, 2017, 19, 8671-8680 Scott D., Gunn N.J., Yong K.J., Wimmer V.C, Veldhuis N.A., Challis L.M., Haidar M., Petrou S., Bathgate R.A.D, Griffin M.D.W, A Novel Ultra-Stable, Monomeric Green Fluorescent Protein For Direct Volumetric Imaging of Whole Organs Using CLARITY, Scientific Reports, 2018, 8, 1-15 Selby L.I., Cortez-Jugo C.M., Such G.K., Johnston A.P.R., Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2017, 9 Selva K.J., Kent S.J., Parsons M.S., Modulation of innate and adaptive cellular immunity relevant to HIV-1 vaccine design by seminal plasma, AIDS, 2017, 31, 333-342 Sivaram A.J., Wardiana A., Howard C.B., Mahler S.M., Thurecht K.J., Recent advances in the generation of antibodynanomaterial conjugates, Advanced Healthcare Materials, 2017 Song D., Cui J., Sun H., Nguyen T. H., Alcantara S., De Rose R., Kent S. J., Porter C. J. H., Caruso, F., Templated Polymer Replica Nanoparticles to Facilitate
Assessment of MaterialDependent Pharmacokinetics and Biodistribution, ACS Applied Materials & Interfaces, 2017, 9, 33683-33694
De Rose R., Kent S.J., Induction of vaginal-resident HIV-specific CD8 T cells with mucosal primeboost immunization, Mucosal Immunology, 2017
Norbornene Conjugation for Bioorthogonal Polymer CrossLinking across Tissue, Chemistry of Materials, 2017, 29, 36783685
Sulistio A., Reyes-Ortega F., D’Souza A.M., Ng S.M.Y., Valade D., Quinn J.F., Donohue A.C., Mansfeld F., Blencowe A., Qiao G., Prankerd R., Quirk S., Whittaker M.R., Davis T.P., Tait R.J., Precise control of drug loading and release of an NSAID-polymer conjugate for long term osteoarthritis intraarticular drug delivery, Journal of Materials Chemistry B, 2017, 5, 6221-6226
Tan H.X., Wheatley A.K., Esterbauer R., Jegaskanda S., Glass J.J., Masopust D., De Rose R., Kent S.J., Induction of vaginal-resident HIV-specific CD8 T cells with mucosal primeboost immunization., Mucosal Immunology, 2017
Turnbull T., Douglass M., Bezak E., Thierry B., Kempson I., An image processing application for quantitative cross-correlative microscopy for large cellpopulations. A gold nanoparticle radiosensitization study, Powder Diffraction, 2017, 32
Tan V.T.G., Nguyen D.H.T., Utama R.H., Kahram M., Ercole F., Quinn J.F., Whittaker M.R., Davis T.P., Gooding J.J., Modular photoinduced RAFT polymerised hydrogels: Via thiol-ene click chemistry for 3D cell culturing, Polymer Chemistry, 2017, 8, 6123-6133
Ung P., Clerc M., Huang H., Qiu K., Chao H., Seitz M., Boyd B., Graham B., Gasser G., Extending the Excitation Wavelength of Potential Photosensitizers via Appendage of a Kinetically Stable Terbium(III) Macrocyclic Complex for Applications in Photodynamic Therapy, Inorganic Chemistry, 2017, 56, 7960-7974
Suma T., Cui J., Müllner M., Fu S., Tran J., Noi K.F., Ju Y., Caruso F., Modulated Fragmentation of Proapoptotic Peptide Nanoparticles Regulates Cytotoxicity, Journal of the American Chemical Society, 2017, 139, 4009-4018 Sun H., Cui J., Ju Y., Chen X., Wong E.H.H., Tran J., Qiao G.G., Caruso F., Tuning the Properties of Polymer Capsules for Cellular Interactions, Bioconjugate Chemistry, 2017, 28, 18591866 Suys E.J.A., Warren D.B., Porter C.J.H., Benameur H., Pouton C.W., Chalmers D.K., Computational Models of the Intestinal Environment. 3. the Impact of Cholesterol Content and pH on Mixed Micelle Colloids, Molecular Pharmaceutics, 2017, 14, 3684-3697 Ta H.T., Li Z., Hagemeyer C.E., Cowin G., Zhang S., Palasubramaniam J., Alt K., Wang X., Peter K., Whittaker A.K., Molecular imaging of activated platelets via antibodytargeted ultra-small iron oxide nanoparticles displaying unique dual MRI contrast, Biomaterials, 2017, 134, 31-42
Tanaka J., Gleinich A.S., Zhang Q., Whitfield R., Kempe K., Haddleton D.M., Davis T.P., Perrier S., Mitchell D.A., Wilson P., Specific and Differential Binding of N-Acetylgalactosamine Glycopolymers to the Human Macrophage Galactose Lectin and Asialoglycoprotein Receptor, Biomacromolecules, 2017, 18, 1624-1633 Tardy B.L., Tan S., Dam H.H., Suma T., Guo J., Qiao G.G., Caruso F., Formation of Polyrotaxane Particles via Template Assembly, Biomacromolecules, 2017, 18, 2118-2127 Thomas A.W., Kuroishi P.K., Pérez-Madrigal M.M., Whittaker A.K., Dove A.P., Synthesis of aliphatic polycarbonates with a tuneable thermal response, Polymer Chemistry, 2017, 8, 5082-5090
Ta H.T., Truong N.P., Whittaker A.K., Davis, T.P., Peter K., The effects of particle size, shape, density and flow characteristics on particle margination to vascular walls in cardiovascular diseases, Expert Opinion on Drug Delivery, 2017, 13, 1-13
To E.E., Vlahos R., Luong R., Halls M.L., Reading P.C., King P.T., Chan C., Drummond G.R., Sobey C.G., Broughton B.R.S., Starkey M.R., Van Der Sluis R., Lewin S.R., Bozinovski S., O’Neill L.A.J., Quach T., Porter C.J.H., Brooks D.A., O’Leary J.J., Selemid, Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy, Nature Communications, 2017, 8
Ta, H.T., Li Z., Wu Y., Cowin, G., Zhang, Z.H., Yago, A., Whittaker, A.K., Xu, Z.P., Effects of magnetic field strength and particle aggregation on relaxivity of ultra-small dual contrast iron oxide nanoparticles, Materials Reseaerch Express, 2017, 4, 116105
Truong N.P., Quinn J.F., Anastasaki A., Rolland M., Vu M.N., Haddleton D.M., Whittaker M.R., Davis T.P., Surfactant-free RAFT emulsion polymerization using a novel biocompatible thermoresponsive polymer, Polymer Chemistry, 2017, 8, 1353-1363
Tan H.X., Wheatley A.K., Esterbauer R., Jegaskanda S., Glass J.J., Masopust D.,
Truong V.X., Tsang K.M., Ercole F., Forsythe J.S., Red Light Activation of Tetrazine-
Upama M.B., Elumalai N.K., Mahmud M.A., Wang D., Haque F., Gonçales V.R., Gooding J.J., Wright M., Xu C., Uddin A., Role of fullerene electron transport layer on the morphology and optoelectronic properties of perovskite solar cells, Organic Electronics: physics, materials, applications, 2017, 50, 279-289 Uppalapati D., Boyd B., TravasSejdic J., Svirskis D., Porous conducting polymer prepared through liquid crystal template for drug delivery, International Journal of Nanotechnology, 2017, 14, 422-431 Vanderven H.A., Jegaskanda S., Wheatley A.K., Kent S.J., Antibody-dependent cellular cytotoxicity and influenza virus, Current Opinion in Virology, 2017, 22, 89-96 Vanderven H.A., Jegaskanda S., Wines B.D., Hogarth P.M., Carmuglia S., Rockman S., Chung A.W., Kent S.J., Antibodydependent cellular cytotoxicity (ADCC) responses to seasonal influenza vaccination in older adults, Journal of Infectious Diseases, 2017, 217, 12-23 Vanderven H.A., Liu L., AnaSosa-Batiz F., Nguyen T.H.O., Wan Y.M., Wines B., Hogarth P.M., Tilmanis D., Reynaldi A., Parsons M.S., Hurt A.C., Davenport M.P., Kotsimbos T., Cheng A.C., Kedzierska K., Zhang X.Y., Xu J.Q., Kent S.J., Fc functional antibodies in humans with severe H7N9 and seasonal influenza, JCI Insight, 2017, 2 Vithani K., Hawley A., Jannin V., Pouton C., Boyd B.J., Inclusion of Digestible Surfactants in Solid SMEDDS Formulation Removes Lag Time and Influences the CBNS Annual Report 2017 75
p e r fo r man c e
of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site, Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2485-2494
Formation of Structured Particles During Digestion, AAPS Journal, 2017, 19, 754-764 Vittorio O., Curcio M., Cojoc M., Goya G.F., Hampel S., Iemma F., Dubrovska A., Cirillo G., Polyphenols delivery by polymeric materials: challenges in cancer treatment, Drug delivery, 2017, 24, 162-180 Vittorio O., Le Grand M., Makharza S.A., Curcio M., Tucci P., Iemma F., Nicoletta F.P., Hampel S., Cirillo G., Doxorubicin synergism and resistance reversal in human neuroblastoma BE(2)C cell lines: An in vitro study with dextrancatechin nanohybrids, European Journal of Pharmaceutics and Biopharmaceutics, 2018, 122, 176-185 Vogel Y.B., Zhang L., Darwish N., Gonçales V., Le Brun A., Gooding J.J., Molina A., Wallace G.G., Coote M., González J., Ciampi S., Reproducible flaws unveil electrostatic aspects of semiconductor electrochemistry, Nature Communication, 2017, 8, 2066 Vogel Y.B., Darwish N., Kashi M.B., Gooding J.J., Ciampi S., Hydrogen evolution during the electrodeposition of gold nanoparticles at Si(100) photoelectrodes impairs the analysis of current-time transients, Electrochimica Acta, 2017, 247, 200-206 Voges H.K., Mills R.J., Elliot D.A., Parton R.G., Porrello E.R., Hudson J.E., Development of a human cardiac organoid injury model reveals innate regenerative potential, Development, 2017, 144, 1118-1127 Von Krbek L.K.S., Schalley C.A., Thordarson P., Assessing cooperativity in supramolecular systems, Chemical Society Reviews, 2017, 46, 2622-2637 Wang B., Pilkington E.H., Sun Y., Davis T.P., Ke P.C., Ding F., Modulating protein amyloid aggregation with nanomaterials, Environmental Science: Nano, 2017, 4, 1772-1783 Wang H., Zetterlund P.B., Boyer C., Boyd B.J., Prescott S.W., Spicer P.T., Soft polyhedral particles based on cubic liquid crystalline emulsion droplets, Soft Matter, 2017, 13, 84928501 Wang M., Kakinen A., Pilkington E.H., Davis T.P., Ke P.C., Differential effects of silver and iron oxide nanoparticles on IAPP amyloid aggregation, Biomaterials Science, 2017, 5, 485-493 76 CBNS Annual Report 2017
Wang M., Siddiqui G., Gustafsson O.J.R., Käkinen A., Javed I., Voelcker N.H., Creek D.J., Ke P.C., Davis T.P., Plasma Proteome Association and Catalytic Activity of Stealth Polymer-Grafted Iron Oxide Nanoparticles, Small, 2017, 13 Wei J.C.J., Edwards G.A., Martin D.J., Huang H., Crichton M.L., Kendall M.A.F., Allometric scaling of skin thickness, elasticity, viscoelasticity to mass for micro-medical device translation: from mice, rats, rabbits, pigs to humans, Scientific Reports, 2017, 7 Williams H.D., Ford L., Lim S., Han S., Baumann J., Sullivan H., Vodak D., Igonin A., Benameur H., Pouton C.W., Scammells P.J., Porter C.J.H., Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations, Journal of Pharmaceutical Sciences, 2017 Wilson P., Ke P.C., Davis T.P., Kempe K., Poly(2-oxazoline)based micro- and nanoparticles: A review, European Polymer Journal, 2017, 88, 486-515 Wines B.D., Billings H., McLean M.R., Kent S.J., Hogarth P., Antibody functional assays as measures of Fc receptormediated immunity to HIV – New technologies and their impact on the HIV vaccine field, Current HIV Research, 2017, 15, 202-215 Wojciechowski J.P., Martin A.D., Mason A.F., Fife C.M., Sagnella S.M., Kavallaris M., Thordarson P., Choice of Capping Group in Tripeptide Hydrogels Influences Viability in the Three-Dimensional Cell Culture of Tumor Spheroids, ChemPlusChem, 2017, 82, 383-389 Wong A.S.M., Czuba E., Chen M.Z., Yuen D., Cupic K.I., Yang S., Hodgetts R.Y., Selby L.I., Johnston A.P.R., Such G.K., PHResponsive Transferrin-pHlexi particles capable of targeting cells in vitro, ACS Macro Letters, 2017, 6, 315-320 Wong C.K., Mason A.F., Stenzel M.H., Thordarson P., Formation of non-spherical polymersomes driven by hydrophobic directional aromatic perylene interactions, Nature Communications, 2017, 8 Xing Y., Pilkington E.H., Wang M., Kakinen A., Davis T.P., Ding F., Ke P.C., Lysophosphatidylcholine Modulates the Aggregation of Human Islet Amyloid Polypeptide, Physical Chemistry Chemical Physics, 2017, 19, 30627-30635
Xu C., Zhang C., Wang Y., Li L., Li L., Whittaker A.K., Controllable synthesis of a novel magnetic core-shell nanoparticle for dual-modal imaging and pH-responsive drug delivery, Nanotechnology, 2017, 28
Searles D.J., Král P., Whittaker A.K., PFPE-Based Polymeric 19F MRI Agents: A New Class of Contrast Agents with Outstanding Sensitivity, Macromolecules, 2017, 50, 5953-5963
Yang C.T., PourhassanMoghaddam M., Wu L., Bai P., Thierry B., Ultrasensitive detection of cancer prognostic miRNA biomarkers based on surface plasmon enhanced light scattering, ACS Sensors, 2017, 2, 635-640
Zhao W., Ta H.T., Zhang C., Whittaker A.K., PolymerizationInduced Self-Assembly (PISA) – Control over the Morphology of 19F-Containing Polymeric Nano-objects for Cell Uptake and Tracking, Biomacromolecules, 2017, 18, 1145-1156
Yarwood RE., Imlach W.L., Lieu T., Veldhuis N.A., Jensen D.D., Klein Herenbrink C., Aurelio L., Cai Z., Christie M.J., Poole D.P., Porter C.J.H., McLean P., Hicks G.A., Geppetti P., Halls M.L., Canals M., Bunnett N.W., Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission., Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12309-12314
Zhao Y., Houston Z.H., Simpson J.D., Chen L., Fletcher N.L., Fuchs A.V., Blakey I., Thurecht K.J., Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics, Molecular Pharmaceutics, 2017, 14, 3539-3549
Yee E.M.H., Brandl M.B., Pasquier E., Cirillo G., Kimpton K., Kavallaris M., Kumar N., Vittorio O., Dextran-Catechin inhibits angiogenesis by disrupting copper homeostasis in endothelial cells, Scientific Reports, 2017, 7 Yee E.M.H., Hook J.M., Bhadbhade M.M., Vittorio O., Kuchel R.P., Brandl M.B., Tilley R.D., Black D.S., Kumar N., Preparation, characterization and in vitro biological evaluation of (1:2) phenoxodiol-β-cyclodextrin complex, Carbohydrate Polymers, 2017, 165, 444-454
Zhu C., Schneider E.K., Nikolaou V., Klein T., Li J., Davis T.P., Whittaker M.R., Wilson P., Kempe K., Velkov T., Haddleton D.M., Hydrolyzable Poly[Poly(Ethylene Glycol) Methyl Ether Acrylate]Colistin Prodrugs through Copper-Mediated Photoinduced Living Radical Polymerization, Bioconjugate Chemistry, 2017, 28, 1916-1924 Zhu C., Schneider E.K., Wang J., Kempe K., Wilson P., Velkov T., Li J., Davis T.P., Whittaker M.R., Haddleton D.M., A traceless reversible polymeric colistin prodrug to combat multidrugresistant (MDR) gram-negative bacteria, Journal of Controlled Release, 2017, 259, 83-91
Yong J.K.J., Stevens G.W., Caruso F., Kentish S.E., The resilience of carbonic anhydrase enzyme for membrane-based carbon capture applications, International Journal of Greenhouse Gas Control, 2017, 62, 122-129
Zhu C., Zhao J., Kempe K., Wilson P., Wang J., Velkov T., Li J., Davis T.P., Whittaker M.R., Haddleton D.M., A HydrogelBased Localized Release of Colistin for Antimicrobial Treatment of Burn Wound Infection, Macromolecular Bioscience, 2017, 17
Yu S.H., Ercole F., Veldhuis N.A., Whittaker M.R., Davis T.P., Quinn J.F., Polymers with acylprotected perthiol chain termini as convenient building blocks for doubly responsive H2Sdonating nanoparticles, Polymer Chemistry, 2017, 8, 6362-6367
Zhu H., Liu A., Li D., Zhang Y., Wang X., Yang W., Gooding J.J., Liu J., Wafer-scale fabrication of a Cu/graphene double-nanocap array for surface-enhanced Raman scattering substrates, Chemical Communications, 2017, 53, 3273-3276
Zenker J., White M.D., Templin R.M.,Parton R.G., Thorn-Seshold O., Bissiere S., Plachta N., A microtubule-organizing center directing intracellular transport in the early mouse embryo, Science, 2017, 357, 925-928
Zyuzin M.V., Yan Y., Hartmann R., Gause K.T., Nazarenus M., Cui J., Caruso F., Parak W.J., Role of the Protein Corona Derived from Human Plasma in Cellular Interactions between Nanoporous Human Serum Albumin Particles and Endothelial Cells, Bioconjugate Chemistry, 2017, 28, 20622068
Zhang C., Moonshi S.S., Han Y., Puttick S., Peng H., Magoling B.J.A., Reid J.C., Bernardi S.,
This report is printed on recycled paper. The text pages comprise 100% post-consumer waste and the cover stock comprises 60% post-consumer waste.
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology Monash University, 399 Royal Parade, Parkville, Victoria, 3052, Australia Phone: +61 3 9903 9712 Email: info@cbns.org.au www.cbns.org.au